Inhibition of cytokine-induced SH2 protein in NK cells

By inhibiting cytokine-induced SH2 protein and activating NK cells, the problem of insufficient activation of NK cells in the prior art is solved, and the immune response to tumors and infections is enhanced, providing a new therapeutic strategy, reducing the side effects of chemotherapy.

CN112972492BActive Publication Date: 2024-11-08THE WALTER AND ELIZA HALL INSTITUTE OF MEDECAL RESEARCH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202110049192.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2015-12-16
Filing Date
2016-12-16
Publication Date
2024-11-08
Estimated Expiration
2036-12-16

AI Technical Summary

Technical Problem

The difficulty in effectively activate NK cells in the prior art limits the immune response to tumors and infections, especially in cancer and infection situations, the inhibitory mechanism of IL-15 signaling is unclear, resulting in limited NK cell-mediated treatment strategies.

Method used

By inhibiting cytokine-induced SH2 protein (CIS), use CIS inhibitors or CIS inhibitory NK cells, including genetically modified CIS-/-NK cells and CIS inhibitors, such as peptides, polynucleotides, polypeptides, small molecules, etc. , to compete to inhibit the binding of CIS to JAK1 and JAK3, and then activate NK cells.

Benefits of technology

Increased sensitivity and activation of NK cells to IL-15, enhanced immune responses to tumors and infections, and provided new strategies for treating NK cell-responsive disorders, reducing the destructive side effects of chemotherapeutic agents.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The present invention relates to treatment and prevention methods based on the inhibition of CIS in NK cells. In particular, the present invention relates to treating or preventing NK responsive disorders by administering CIS inhibitors or CIS-inhibitory NK cells to a subject. The present invention also relates to methods for identifying CIS inhibitors, and for determining the likelihood that a cancer will respond to treatment with CIS inhibition.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of a patent application with a priority date of December 16, 2015, application number 2016800812529, and invention name "Inhibition of cytokine-induced SH2 protein in NK cells". Technical Field

[0002] The present disclosure generally relates to the field of therapeutic agents. More specifically, the present disclosure relates to methods for preventing or treating health conditions suitable for NK cell-mediated therapy. Background Art

[0003] The role of the immune system in inhibiting tumor growth and infection is well known, and it is now believed that avoiding immune detection is an important factor in the development of cancer. For example, cytotoxic lymphocytes such as natural killer (NK) and CD8 effector T cells help anti-tumor immunity through cancer immunoediting. However, tumors and infectious agents (e.g., viruses) use a variety of mechanisms that disable these cytotoxic lymphocytes. The pleiotropic cytokine IL-15 is an important regulator of NK cell development, homeostatic regulation and activation, but its effect on NK cell activation is short-lived, which limits the effectiveness of NK cell-mediated responses in many cancers and infections. So far, people have great interest in understanding the inhibitory signals that inhibit NK cell responses, but it is still unclear how intracellular IL-15 signaling is turned off.

[0004] Therefore, there is a continuing need to discover new strategies to initiate NK cell responses to effectively treat many potential NK cell-responsive health conditions, including cancer, while avoiding the damaging side effects of most chemotherapeutic agents. Summary of the invention

[0005] The present inventors have discovered that inhibition of cytokine-induced SH2 proteins (CIS) can be used to treat a number of NK cell responsive disorders, including certain cancers and infections.

[0006] Thus, in one aspect, the invention provides a method for treating a subject having or at risk of having a NK cell responsive disorder comprising administering to the subject a CIS inhibitor.

[0007] In another aspect, the present invention provides a method for adoptive cell therapy or prevention, comprising administering CIS inhibitory NK cells to a subject suffering from an NK cell responsiveness disorder or at risk of suffering from an NK cell responsiveness disorder. In some embodiments, the CIS inhibitory NK cells are autologous. In other embodiments, the CIS inhibitory NK cells are allogeneic. In some embodiments, the CIS inhibitory NK cells are NK cells contacted with a CIS inhibitor.

[0008] In some embodiments, the CIS inhibitory NK cells are genetically modified, such as by gene editing using programmable nucleases or by gene silencing (RNA interference), to have reduced CIS expression. In some embodiments, the genetically modified CIS inhibitory NK cells are Cish - / - In some embodiments, Cish - / - NK cells are human Cish - / - NK cells.

[0009] With respect to any of the above aspects, in some embodiments, the CIS inhibitor to be administered or used to generate CIS inhibitory NK cells is a peptide, a peptide mimetic, a small molecule, a polynucleotide or a polypeptide. In some embodiments, the CIS inhibitor competitively inhibits the binding of CIS to JAK1 and / or JAK3. In some embodiments, the CIS inhibitor competitively inhibits the binding of CIS to phosphorylated JAK1 (e.g., JAK1 phosphorylated at Tyr1034) and / or phosphorylated JAK3 (e.g., JAK3 phosphorylated at Tyr980). In other embodiments, the CIS inhibitor competitively inhibits the binding of CIS to one or more of elongin B, elongin C or stagnation protein-5.

[0010] In some embodiments, where the CIS inhibitor is a peptide, the peptide is a phosphopeptide or a phosphopeptide mimetic.

[0011] In some embodiments, where the CIS inhibitor is a polypeptide, the polypeptide is an anti-CIS antibody or an antigen-binding fragment thereof.

[0012] In some embodiments, in the case where the CIS inhibitor is a polynucleotide, the polynucleotide is a dsRNA. In some embodiments, the dsRNA CIS inhibitor is a shRNA, siRNA or miRNA. In some embodiments, the polynucleotide is provided as a vector for expressing a polynucleotide CIS inhibitor. In some embodiments, the vector is a viral vector. In some embodiments, the polynucleotide CIS inhibitor encodes a dominant negative inhibitor of CIS. In some embodiments, the encoded dominant negative inhibitor comprises an amino acid sequence of CIS containing R107K substitutions. In other embodiments, the encoded dominant negative inhibitor comprises an amino acid sequence of CIS with L223A substitutions.

[0013] In some embodiments, where the CIS inhibitor is a polynucleotide, the polynucleotide is a chemically modified mRNA. In some embodiments, the chemically modified mRNA encodes a dominant negative inhibitor of CIS (e.g., CIS-R107K).

[0014] In some embodiments, where the CIS inhibitor is a small molecule, the small molecule CIS inhibitor destabilizes CIS. In some embodiments, where the small molecule CIS inhibitor acts by destabilizing CIS, the small molecule CIS inhibitor is a deubiquitinase inhibitor.

[0015] In some embodiments, any of the above methods of treatment or prevention further comprises administering IL-15 or an IL-15 agonist to the subject.

[0016] In other embodiments, any of the above treatment or prevention methods further comprises administering a B-Raf protein kinase inhibitor or a MEK protein kinase inhibitor.

[0017] In some embodiments, any of the above treatments or prevention methods further include administering an immunotherapeutic agent. Examples of such immunotherapeutics include, but are not limited to, antibodies to programmed cell death 1 receptor (PD-1), antibodies to programmed death ligand 1 (PD-L1), antibodies to cytotoxic T lymphocyte-associated protein 4 (CTLA-4), antibodies to transforming growth factor β (TGF-b), antibodies to Tactile (CD96), or combinations thereof. In some embodiments, any of the above treatments may additionally include administering a TGF-β receptor antagonist.

[0018] In some embodiments of the above-described methods of treatment or prevention, the subject has cancer or has been identified as being at risk for having cancer or an infection.

[0019] In some embodiments, in the case where the subject suffers from cancer, the cancer is characterized by the presence of a tumor. In some embodiments, in the case where the subject suffers from cancer or is at risk of suffering from cancer, the cancer is metastatic melanoma, metastatic prostate cancer, metastatic breast cancer, triple-negative breast cancer, bladder cancer, brain cancer, esophageal cancer, liver cancer, head and neck cancer, squamous cell lung cancer, non-small cell lung cancer, Merkel cell carcinoma (Merkel cell carcinoma), sarcoma, hepatocellular carcinoma, multiple myeloma, pancreatic cancer, colorectal cancer, cervical cancer, gastric cancer, kidney cancer, metastatic renal cell carcinoma, leukemia, ovarian cancer and malignant glioma. In some preferred embodiments, cancer is metastatic melanoma, metastatic prostate cancer or metastatic breast cancer. In some embodiments, in the case where the subject suffers from cancer, the subject has received allogeneic tissue transplantation related to cancer treatment.

[0020] In other embodiments, where the subject suffers from an infection or is at risk of suffering from an infection, the infection is a viral infection. In some embodiments, where the subject suffers from a viral infection, the viral infection is infection by herpes simplex virus, adenovirus, vaccinia virus, human cytomegalovirus, influenza virus, poxvirus, or papillomavirus.

[0021] In another aspect, the present invention provides a method for identifying a CIS inhibitor, comprising:

[0022] i) contacting CIS or a fragment thereof with at least one CIS binding partner in the presence of a test agent; and

[0023] ii) determining whether the test agent competes with the CIS protein binding partner for binding of CIS or a fragment thereof; and

[0024] iii) Optionally, if in step ii) the test agent exhibits competition with the CIS protein binding partner for binding to CIS or a fragment thereof, the test agent is identified as a CIS inhibitor. In some embodiments, the CIS binding partner is selected from JAK1, JAK3, IL-2Rβ, elongin B, elongin C or tardatin 5 or a fragment thereof.

[0025] In a related aspect, the invention provides a method for identifying a CIS inhibitor, comprising:

[0026] i) contacting the CIS or a fragment thereof with a test agent; and

[0027] ii) determining whether the test agent binds to CIS or a fragment thereof. In some embodiments, the method further comprises determining whether the test agent competes with a CIS PEST domain peptide or a CIS N-terminal peptide for binding to CIS or a fragment thereof. In some embodiments, the sequence of the CIS PEST domain peptide is selected from SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 32, and SEQ ID NO: 37. In some embodiments, the sequence of the N-terminal peptide is selected from SEQ ID NO: 31 and SEQ ID NO: 34.

[0028] In another related aspect, the present invention provides a method for identifying a CIS inhibitor, comprising:

[0029] i) incubating the phosphorylated JAK1 protein or its CIS binding fragment in vitro in the presence of:

[0030] (a) a trimeric complex comprising CIS or a fragment thereof, wherein the CIS or a fragment thereof comprises at least an SH2 domain and a SOCS box; elongin B; and elongin C;

[0031] (b) ubiquitination mixture; and

[0032] (c) test reagents; and

[0033] ii) determining whether the test agent inhibits CIS-induced ubiquitination of the phosphorylated JAK1 protein or fragment relative to the level of CIS-induced ubiquitination in the absence of the test agent. In some embodiments, the ubiquitination mixture comprises: tardalin 5, Rbx2, E1, E2, and free ubiquitin.

[0034] In another related aspect, the present invention provides a method for identifying a CIS inhibitor, comprising:

[0035] i) incubating in vitro a JAK1 protein or a fragment thereof comprising a JH1 kinase domain in the presence of:

[0036] (a) a trimeric complex comprising CIS or a fragment thereof, wherein the CIS or a fragment thereof comprises at least an SH2 domain and a SOCS box; elongin B; and elongin C;

[0037] (b) JAK1 kinase substrates; and

[0038] (c) test reagents; and

[0039] ii) determining whether the test agent increases phosphorylation of the JAK1 kinase substrate relative to phosphorylation of the JAK1 kinase substrate in the absence of the test agent. In some embodiments, the JAK1 kinase substrate is a STAT5 protein or a STAT5 peptide.

[0040] In another related aspect, the present invention provides a method for in silico identification of CIS inhibitors, comprising:

[0041] i) generating a three-dimensional structural model of CIS or a fragment thereof; and

[0042] ii) Computer simulation design or screening of test agents that bind to the modeled structure. In some embodiments, the three-dimensional structural model is a complex of CIS or a fragment thereof bound to JAK1 protein or its CIS binding fragment; or JAK3 protein or its CIS binding fragment.

[0043] In another related aspect, the present invention provides a method for identifying a CIS inhibitor, comprising:

[0044] i) providing a cell expressing CIS; and

[0045] ii) Determine whether the test agent reduces the CIS activity in the cell compared to cells that have not been exposed to the test agent. In some embodiments, the CIS activity to be evaluated is the inhibition of JAK1 kinase activity, the inhibition of STAT5 tyrosine phosphorylation, the downregulation of STAT5 promoter activity, or the increase of JAK1 degradation. In some embodiments, the cells used in the method are NK cells. In some embodiments, when the cells used are NK cells, step ii) includes determining the effect of the test agent on IL 15 inducible responses in NK cells. In some embodiments, IL-15 inducible responses are NK cell proliferation, interferon-γ (IFN-γ) production, intracellular granzyme expression, JAK1 tyrosine phosphorylation, JAK1 degradation, regulation of gene expression, or cytotoxicity.

[0046] In some embodiments, the test agent used in the cell-based screening method has been previously identified as a candidate CIS inhibitor in any of the other CIS inhibitor identification methods described.

[0047] In some embodiments of any of the above methods of identifying a CIS inhibitor, the test agent is a peptide, a peptidomimetic, a small molecule, a polynucleotide, or a polypeptide.

[0048] In some embodiments of any of the aforementioned methods of identifying a CIS inhibitor, the amino acid sequence of CIS or a fragment thereof comprises an amino acid sequence that is at least 80% identical to any one of SEQ ID NOs: 6-10.

[0049] In another aspect, the invention provides use of a CIS inhibitor in the manufacture of a medicament for treating or preventing a NK cell responsive disorder in a subject.

[0050] In another aspect, the present invention provides a use of CIS suppressor NK cells in the manufacture of a medicament for treating or preventing a NK cell responsive disorder in a subject.

[0051] In another aspect, the present invention provides use of a CIS inhibitor as a medicament for treating or preventing a NK cell responsive disorder in a subject.

[0052] In another aspect, the present invention provides use of CIS suppressor NK cells as a medicament for treating or preventing a NK cell responsive disorder in a subject.

[0053] In another aspect, the present invention provides a CIS inhibitor for use in treating or preventing a NK cell responsive disorder.

[0054] In yet another aspect, the present invention provides a method for determining the likelihood of a therapeutic response to CIS inhibition in a patient having a tumor, the method comprising determining the level of IL-15 in the tumor microenvironment, wherein an increase in the level of IL-15 in the tumor microenvironment relative to a threshold level of IL-15 indicates an increased likelihood of a therapeutic response.

[0055] In a related aspect, the present invention provides a method for assessing the induction of increased expression of Cish in tumor-infiltrating NK cells in a subject having a tumor, the method comprising determining the level of IL-15 in the tumor microenvironment, wherein an increase in the level of IL-15 in the tumor microenvironment relative to a threshold level of IL-15 indicates the induction of increased expression of Cish in tumor-infiltrating NK cells.

[0056] A method for increasing the response of NK cells to IL-15 is also provided, the method comprising inhibiting CIS in NK cells. In one embodiment, this method comprises administering a CIS inhibitor to a subject. In another embodiment, the method for increasing the response of NK cells to IL-15 comprises reducing the expression of CIS in NK cells. In some embodiments, the reduction of CIS expression is carried out in ex vivo NK cells. In other embodiments, the reduction of CIS expression is in vivo NK cells (e.g., in human subjects). Unless otherwise specifically stated, any embodiment herein should be considered to apply necessary modifications to any other embodiment. For example, as will be appreciated by a technician, the examples of inhibitors and health conditions for the methods of the present invention outlined above are equally applicable to the purposes and pharmaceutical compositions of the present invention.

[0057] The present invention is not to be limited in scope by the specific embodiments described herein, which are intended for purposes of illustration only. Functionally equivalent products, compositions and methods, as described herein, are clearly within the scope of the invention.

[0058] Throughout this specification, reference to an individual step, composition of matter, group of steps or group of compositions of matter shall be considered to encompass both one and a plurality (i.e., one or more) of these steps, compositions of matter, groups of steps or groups of compositions of matter, unless specifically stated otherwise or the context requires otherwise.

[0059] The invention is hereinafter described by way of the following non-limiting examples and with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0060] Figure 1 CIS-deficient NK cells showed superior proliferation, survival, and killing in response to IL-15. (a) Cultured wild-type NK cells were washed and deprived of IL-15, and then incubated with 50 ng ml -1IL-15 was incubated for the indicated time. Cells were collected and analyzed for SOCS mRNA expression by Q-PCR. (b) NK cells were treated as described in (a), lysed and analyzed for CIS protein expression by Western blotting. (c) NK cells (NK1.1 + NKp46 + TCR-β - ) and in wild type (Cish + / + ) and Cish-deficient (Cish - / - ) The counts were made in the bone marrow, liver, lung and spleen of mice. (d) Cish + / + and Cish - / - NK cells were cultured with increasing concentrations of IL-15 (5-40 ng ml -1 ) for 5 days and then analyzed by flow cytometry. The images represent 5 independent experiments. (e) Freshly isolated spleen Cish + / + and Cish - / - NK cells were cultured for 4 h in IL-15 in tissue culture plates coated with immunoglobulin control (cIg; negative control), anti-NK1.1, anti-NKp46, anti-Ly49H (confers antiviral response) antibodies, or IL-12 / IL-18 (positive control), and IFN-γ production and CD107a (LAMP-1) expression were analyzed by flow cytometry. (f) Cish + / + and Cish - / - NK cells were expanded in IL-15 and co-cultured with CHO target cells at the indicated NK:CHO (E:T; effector cell:target cell) ratios for a specified period of time. The normalized CHO cell index was determined using the xCELLigence system. (g) Cish + / + and Cish - / - NK cells were cultured in IL-15 for 7 days and RNA sequencing was performed. - / - Selected genes differentially expressed in NK cells are shown as reads per kilobase of exon per million reads (RPKM). Figure 8 and Table 1.

[0061] Figure 2 CIS negatively regulates IL-15 signaling by targeting JAK / STAT signaling. (a) Purified Cish + / + and Cish - / - NK cells and at 50 ng ml -1IL-15 was added to the cells and cultured for 21 h. Surface expression of IL-2Rβ (CD122) and IL-2Rγ (CD132) was determined by flow cytometry. Each histogram represents NK cells from a single mouse. (b) + / + and Cish - / - NK cells were purified from spleen and incubated with 50 ng ml -1 (c) Alternatively, NK cells were purified and cultured for 7-10 days, washed and allowed to rest for 4 h in the absence of IL-15, and then treated with IL-15. Cells were lysed and analyzed by Western blot with antibodies to the indicated phosphorylated (p) and total proteins. (d) A modified N-linker analog of the JAK inhibitor CYT387 was coupled to NHS-Sepharose beads and used as an affinity reagent to enrich JAK kinases from the cell lysate generated in (c). The enriched kinases were eluted, digested with trypsin and analyzed by mass spectrometry. The total JAK1 and JAK3 peptide intensities were calculated by Cish + / + and Cish - / - NK cells are shown. Mean ± SEM. **p ≤ 0.005; n = 3 biological replicates (e and f) CYT-387 enrichment identified 69 unique protein kinases, 16 of which showed significantly differential expression. Volcano plot (e) shows the quantitative pipeline analysis (Cish + / + With Cish - / - ). Red and yellow lines represent a 2-fold change in protein expression (log2 ratio of 1), while blue and green lines represent a 4-fold change (log2 ratio of 2); points are colored accordingly and represent individual proteins. –Proteins with a log10 p-value of 1.3 or greater were considered differentially abundant. Heatmap (f) shows the Log2-transformed aggregate peptide intensities (non-filled) of kinases with significant differential expression. Data from a single replicate (n=3) are shown. Green to red indicates an increase in expression level. Gene ontology analysis revealed that the enrichment of kinases involved Cish - / - Cell cycle and DNA replication in NK cells. See also Figure 8 .

[0062] Figure 3CIS binds to the JAK activation loop to inhibit JAK1 kinase activity and targets the JAK1 kinase for proteasomal degradation. (a) Isothermal calorimetry (ITC) was used to determine the affinity of hCIS-SH2-BC binding to phosphopeptides corresponding to tyrosines within the JAK1 / 3 kinase domain activation loop and the IL-2Rβ cytoplasmic domain. The results list view shows the mean ± SD of two independent experiments. ND = not detected, p = phosphorylated. (b and c) Flag-tagged JAK1 and JAK3 were expressed in 293T cells with Flag-tagged CIS, SOCS1, SOCS3 or CIS mutants, in which the SH2 domain (mSH2; R107K) or the stagnation protein-5 binding site in the SOCS box was mutated (mSB; P241A / L242A / P243A). In some examples, cells were treated with the proteasome inhibitor MG132. Cells were lysed and proteins were immunoprecipitated using anti-FLAG-beads, followed by western blotting with antibodies to detect phosphorylated (p)JAK1 and JAK3. Protein expression levels were shown in anti-FLAG blotting of whole cell lysates (bottom). (d) FLAG-tagged JAK1 and CIS were co-expressed in 293T cells and immunoprecipitated (IP) using anti-CIS (upper left) or anti-JAK1 antibodies (upper right). Western blotting with anti-FLAG antibodies revealed that specific CIS-JAK complexes were present in each case (top). Protein levels were shown in the bottom figure in anti-FLAG blotting of cell lysates. (e) Using a cell-free system, FLAG-JAK1 was incubated with ubiquitin, E1 and E2 enzymes at 37°C for a specified time in the presence (+) and absence (-) of CIS-E3 ligase complexes (CIS-SH2-BC with stagnation protein 5 and Rbx2). JAK1 ubiquitination was visualized by western blotting with antibodies to phosphorylated JAK1. (f) Kinase inhibition assays were performed using all four JAKs and the kinase domain (JH1) of CIS, SOCS1, SOCS2, or SOCS3. CIS preferentially inhibited JAK1 JH1 activity (upper panel), while SOCS1, SOCS3, and CIS inhibited JAK1 JH1 activity to varying degrees (lower panel). Data were normalized to non-CIS controls. Insert table: IC 50 Values; mean ± SEM; n = 3-5 independent experiments. (g) Schematic diagram showing a proposed model for in vitro E3 ligase ubiquitination components and CIS-mediated inhibition of JAK activity, in which CIS recruitment to the receptor complex promotes binding to active JAK1 and leads to kinase inhibition and proteasomal degradation. eloB: elongin B; C: elongin C. See also Fig. 9 .

[0063] Figure 4Loss of control of experimental lung tumor metastasis for Cish. + / + and Cish - / - Mice were intravenously injected with (a) 3×10 5 B16F10 melanoma cells or (b) 2×10 5 B16F10 melanoma cells were treated with control Ig (cIg), anti-CD8 (αCD8; CD8 T cell depletion), anti-asialoGM1 (αasGM1; NK cell depletion), or anti-IFNγ (αIFNγ; neutralization) antibodies on days -1, 0, and 6 relative to tumor inoculation. Mice were sacrificed on day 14 after tumor injection. (c) NK cell-deficient (Ncr1 Mcl1Δ / Δ ) mice were intravenously injected with 3×10 6 In vitro amplified Cish + / + or Cish - / - NK cells or PBS, 1×10 5 B16F10 melanoma cells. 24 h after tumor inoculation, mice received a second injection of 1.5 × 10 6 In vitro amplified Cish + / + or Cish - / - NK cells or PBS and were sacrificed on day 18 after tumor injection. (ac) Metastatic burden (mets) was quantified in the lung by counting colonies on the lung surface. (d) Cish + / + , Cish - / - and Ncr1 Mcl1Δ / Δ (NK-nude) mice were injected intravenously with 5×10 5 E0771mCherry + Breast cancer cells were analyzed for lung metastasis by IVIS (fluorescence emission; left) or H&E stained tissue sections (right). (e) 1×10 5 E0771 cells were implanted into Cish + / + and Cish - / - Mammary fat pads of mice were harvested and tumor size was measured over time. (f) At 400–600 mm 3 The orthotopic E0771 tumors generated in (e) were surgically removed, and spontaneous lung metastasis was determined in the lungs by IVIS 14 days later, and mCherry mRNA expression was determined by RT-PCR. (g) Cish + / + and Cish - / - Mice were intravenously injected with B16F10 lung cancer (7.5×10 5cells). Mice received control Ig or combined anti-PD-1 / anti-CTLA-4 antibodies on days 0, 3, and 6 relative to tumor inoculation. Metastatic burden was quantified by counting colonies on the lung surface after 13 days. Mean ± SEM and all data (n) are shown. Representative whole lungs (a, c, d, f) and (d) tissue sections from a single mouse are shown. Significant differences between groups were determined by (a, c, g) Mann-Whitney U test (b) Kruskal Wallis and post hoc Dunn test or (e) Mantel-Cox test. See also Fig.10 .

[0064] Figure 5 Analysis of NK, T cells, Treg, ILC2 and regulatory T cells in Cish-deficient mice. (a) Cish was cultured in IL-15 + / + or Cish - / - NK cells were lysed and Cish mRNA was analyzed by Q-PCR. Data were normalized to GAPDH mRNA expression (top). ND: not detected. Cish was cultured in the presence of IL-15 and the proteasome inhibitor MG132. + / + or Cish - / - NK cells were cultured for 4 h, then lysed, and the CIS protein in the whole cell lysate was detected by Western blotting (lower panel). + / + and Cish - / - (b) NK cells (NK1.1) in the specified organs of mice + NKp46 + TCR-β - ) and (c) T cells (NK1.1 - TCR-β + (d and e) ILC2 cells were treated with PBS or IL-2 (IL-2-JES6.1) complexed with anti-IL-2 antibody every 2 days. + / + and Cish - / - , and sacrificed after 5 or 7 days (D5, D7). Representative flow cytometry plots of ILC2 gated on CD3 / 19 / NK1.1 / B220 / Gr1 negative cells in the bone marrow. (e) Frequency of ILC2 in the bone marrow after IL-2-JES6.1 treatment. (a, c, e) Mean ± SEM n = 3 biological replicates. (f) Regulatory T cells (Treg) Cish before and 5 days after IL-2-JES6-1 treatment. + / + and Cish - / - CD4 in mouse spleen and lymph nodes +Expression of FoxP3 and CD25 on cells. Representative flow cytometry plots are shown. (g) Expansion and reduction of Tregs in spleen and lymph nodes after IL-2-JES6-1 complex treatment (mean ± SEM, n = 1-2 mice / group).

[0065] Figure 6 Loss of Socs1 and / or Socs3 does not alter IL-15 responses in NK cells. (a) Socs3 cells were treated with 4-hydroxytamoxifen (4-OHT; induces Socs3 loss) by gavage. + / + ERT2 Cre / + (Cre+), Socs1 - / - Ifnγ - / - (Socs1Δ), Socs3 fl / fl ERT2 Cre / + (Socs3Δ) and Socs1 - / - Ifnγ - / - Socs3 fl / fl ERT2 Cre / + (Socs1ΔSocs3Δ) mice were used to analyze spleen NK cells by flow cytometry 14 days later. (b) Splenic NK cells (TCR-β - NK1.1 + NKp46 + ), IL-15 (50 ng ml -1 ) for 7 days, then labeled with CFSE and transferred intravenously into lymphocytes without Rag2 - / - g C - / - receptor or IL-15 (50 ng ml -1 ) in vitro. Donor NK cells in the recipient liver were analyzed by flow cytometry five and ten days after transfer. In vitro cultures were analyzed on day 5. + / + and Cish - / - NK cell cultures were used as a reference for differential proliferation (lower right panel). (c) Cish - / - Enhanced effector function in NK cells. + / + and Cish - / - NK cells were cultured for 7 days and then co-cultured with CHO or B16F10 target cells at a 1:1 ratio. Target cell killing at 5 h was determined by relative changes in electrical impedance using the xCELLigence system. + / + and Cish - / - NK cells achieved maximal killing (defined as 100% killing) at an effector cell:target cell ratio of 9:1. + / + and Cish- / - Mice were injected intraperitoneally with RMA-m157 cells, and peritoneal NK cells were analyzed for intracellular granzyme-A and granzyme-B production by flow cytometry 18 h later. Average of two experiments + SD. n = 2 mice. MFI: mean fluorescence index.

[0066] Figure 7 For in vitro cultured and isolated Cish - / - Transcriptome analysis of freshly sorted ex vivo NK cells + / + and Cish - / - NK cells, and in the presence of IL-15 (50 ng ml -1 ) for 7 days + / + and Cish - / - NK cells were subjected to 100 bp single-end RNAseq. (a) The heat map shows Cish - / - Relative expression levels (Z-scores) of approximately the top 100 most differentially expressed genes in cells, color coding as per legend. Rows are scaled to mean 0 and sd 1. n = 2 biological replicates. (b) Figure 3 Mean difference plot of cultured NK cell data generated in , which shows the Log2 fold change relative to the mean expression. (c) Cish - / - Functional analysis of 1230 differentially expressed genes observed in NK cells. Gene ontology analysis was performed using the PANTHER classification system. The main gene network was represented by Cish - / - The percentage of total differentially expressed genes in cells is shown.

[0067] Figure 8 For Cish - / - NK cells showed increased JAK / STAT signaling and normal respiration and glycolysis. (a) Cish + / + and Cish - / - NK cells and washed away the IL-15-containing medium. Cells were lysed at multiple indicated time points after washing. The levels of phosphorylated (p) and total signaling proteins were analyzed by Western blotting with specific antibodies. (b) Cish - / - NK cell respiration and glycolysis were not disturbed. Cish + / + and Cish - / -NK cells, and the extracellular acidification rate (ACR; glycolysis) and oxygen consumption rate (OCR; mitochondrial respiration) were measured using the XF Analyzer System. Glucose (1), oligomycin (2), FCCP and pyruvate (3), and antimycin A / rotenone (4) were added at the time points indicated by the arrows. (c) Overview of the proteomics workflow used in this study. Lysates were obtained from Cish + / + and Cish - / - Cultured NK cells from mice and kinase enrichment using NHS-CYT-387 beads. In addition to a portion of the whole cell lysate (pre-kinase enrichment), the protein eluate from the CYT-387 resin was subjected to trypsin digestion and nano-LC-MS / MS. (d) Label-free quantification of global protein expression. Volcano plots show quantitative pipeline analysis from WCL (Cish + / + With Cish - / - ) after the log2 protein ratio. The red and yellow lines represent a 2-fold change in protein expression (log2 ratio of 1), while the blue and green lines represent a 4-fold change (log2 ratio of 2); points are colored accordingly and represent individual proteins. 10 Proteins with a p-value of 1.3 or greater (corresponding to a p-value ≤ 0.05) were considered differentially abundant. (e) Heat map showing the Log2-transformed aggregate peptide intensities (non-filled) of proteins with significant differential expression in (d). Data from a single biological replicate (n=3) are shown. Green to red indicates an increase in expression level.

[0068] Fig. 9 Targeting JAK and IL-2R complexes for CIS. (a) - / -Cultured NK cells of mice were lysed, mRNA was purified and analyzed by RNAseq. Average RPKM values ​​of duplicate samples (left figure). JAK1 mRNA levels were analyzed by Q-PCR (right figure). Mean ± SD, n = 3. (b) 4-12% Coomassie stained SDS-PAGE gel shows purified hCIS-SH2-BC complex, elongin B and elongin C. (c) Isothermal calorimetry (ITC) was used to determine the affinity of hCIS-SH2-BC binding to phosphopeptides corresponding to tyrosines in the activation loop of the JAK1 / 3 kinase domain and the IL-2Rβ and γ cytoplasmic domains. 300 μM phosphopeptides were titrated into 30 μM GST-CIS-SH2-BC ternary complex solutions. The ITC titration curve and a list view of some results (inset) show the mean ± SD of two independent experiments. ND = not detected, p = phosphorylation. The titration curves all fit the single-point model well. (d) Cultured wild-type NK cells were washed and starved of IL-15 for 4 h with and without the addition of the proteasome inhibitor MG132. -1 Cells were stimulated with IL-15 for the indicated times, followed by cell lysis and Western blotting with antibodies to the indicated proteins. (e) Kinase inhibition assay using the kinase domain of JAK1 (JH1) in the presence of CIS-SH2-BC, in the presence and absence of excess JAK1-Y1034 phosphopeptide competitor. The pY1034 peptide partially reduced CIS-mediated inhibition. Data were normalized to non-CIS control.

[0069] Fig.10 To protect Cish - / - NK cells are protected from experimental lung metastasis. + / + and Cish - / - Mice were intravenously injected with (a) 2×10 5 LWT1 (B-RAF mutant) melanoma or (b) 2×10 5 RM-1 prostate cancer cells. Metastatic burden in the lung was quantified 14 days later by counting colonies on the lung surface. (c and d) 1×10 5 E0771.LMB-mCherry+ cells were implanted into Cish + / + and Cish - / - The mammary fat pad of mice was surgically removed with 400-600 mm 3 and (c) were weighed after resection. Spontaneous lung metastasis was determined by measuring mCherry fluorescence by IVIS after 14 days (d). (d; vertical axis: total radiation efficiency Mean ± SEM of indicated (n) are shown. Statistical differences between groups were determined by Mann-Witney U test (a, b) or unpaired Student t test (d).

[0070] Fig.11 The deletion of CIS N-terminal region or PEST enhances the ability of CIS to inhibit JAK1 kinase activity, and the interaction of CIS-SH2 with phosphopeptide is necessary for CIS inhibition of JAK1 kinase activity. In the presence of increasing amounts of human full-length CIS (CIS), CIS lacking PEST motif (ΔPEST), CIS lacking both N-terminal region and PEST motif (ΔNT / ΔPEST), or CIS lacking N-terminal 34 residues (ΔN34), in the absence of (a) or in the presence of (b) excessive phenyl phosphate (PP) as a competitor, the kinase domain (JH1) of JAK1 is used for kinase inhibition assay. (c) Alternatively, 50 μM JAK1-Y1034 or JAK3-Y980, Y981 phosphopeptides are used as competitors. Data are normalized to non-CIS controls. All CIS structures contain SOCS boxes and are expressed and purified as a trimeric complex consisting of CIS, elongin B and elongin C. Inset: Table showing IC50 values ​​for (a).

[0071] Fig.12 The absence of CIS N-terminal region or PEST motif does not have a major effect on the binding to phosphopeptides. Isothermal calorimetry (ITC) was used to determine (a) human full-length CIS, CIS lacking PEST motif (ΔPEST), CIS lacking both N-terminal region and PEST motif (ΔNT / ΔPEST), or CIS lacking N-terminal 34 residues (ΔN34) binding to the affinity of phosphopeptides (JAK1-Y1034) corresponding to tyrosine in the activation loop of the JAK1 kinase domain. (b) Human full-length CIS and CISΔNT / ΔPEST binding to the affinity of phosphopeptides (JAK3-Y980, Y981) corresponding to tyrosine in the activation loop of the JAK3 kinase domain. 300 μM phosphopeptides were titrated into 30 μM GST-CIS-SH2-BC ternary complex solutions. ITC titration curves are shown. The titration curves all fit the single-point model well.

[0072] Fig.13The CIS-SH2 domain binds to the extended peptide interface. The affinity of CIS lacking both the N-terminal region and the PEST motif (ΔNT / ΔPEST) binding to the phosphopeptide (JAK1-Y1034) corresponding to the tyrosine in the activation loop of the JAK1 kinase domain was determined using isothermal calorimetry (ITC). The peptide is wild-type or contains alanine substitutions at the +5, +3 or -3 positions. 300 μM phosphopeptides were titrated into 30 μM GST-CIS-SH2-BC ternary complex solutions. ITC titration curves are shown. The titration curves all fit the single-point model well.

[0073] Fig.14 CIS inhibition is dose-dependent and requires a functional SH2 domain. - / - , Cish + / - and Cish + / + NK cells were purified from the spleen of mice, labeled with the cell tracking dye CTV and cultured in increasing concentrations of IL-15 for 6 days before flow cytometry analysis. A decrease in total fluorescence (geometric mean) indicates increased proliferation. (b) Equal amounts of Cish - / - , Cish + / - and Cish + / + NK cells from the spleen of mice were expanded in IL-15 for 10 days. Absolute NK cell counts after culture. (c) As described above, NK cells were then washed to be free of cytokines and left to stand for 4 h, then treated with the specified 100 ng / mL IL-15 and 10 μM MG132. Cell lysates were analyzed by immunoblotting using the specified CIS and actin antibodies as loading controls.

[0074] Fig.15 The kinetics of CIS induction are consistent with the inhibition of JAK / STAT signaling in human NK cells. Patient-derived human NK cells (a) or NK lymphocyte lines (b) SNK-10, (c) NKL and NK6, (d) NK-92 were washed to be free of cytokines and left to stand for 4h (a) or 16h (bd), and then treated with IL-15 for a specified time. In some cases, cells were incubated with the proteasome inhibitor MG132 (10 μM). Cells were lysed and immunoblotted with antibodies for designated phosphorylation (p) and total protein.

[0075] Fig.16The kinetics of Cish mRNA induction are consistent with the inhibition of JAK / STAT signaling in human NK cells. Human NK lymphocyte lines KHYG-1 (ac) and NK-92 (DF) were washed to cytokine-free and left overnight, then treated with IL-15 for a specified time. Cells were lysed and Cish, Socs1, Socs3 mRNA expression was analyzed by real-time quantitative PCR (Q-PCR). Relative expression was determined by normalizing the amount of each gene of interest to the housekeeping gene 18s ribosomal RNA. There were three biological replicates for each case and the assay was performed in duplicate.

[0076] Fig.17 Schematic summarizing the identification of ubiquitination (U) and phosphorylation (P) sites by mass spectrometry. P = phosphorylation, U = ubiquitination, * indicates residues conserved between mouse and human CIS. FLAG-tagged mouse CIS was expressed in 293T cells and purified by affinity enrichment using an anti-FLAG antibody, followed by trypsin digestion and LC-MS / MS analysis. Bold circles indicate residues identified in this study. Additional ubiquitination sites were reported by Jensik et al., 2015.

[0077] Fig.18 TGFβ blocks IL-15-driven proliferation in wild-type, but not CIS-deficient NK cells. fl / fl ) or Cish - / - Mouse (20,000 cells / well Lin neg CD49a neg CD49b + NK1.1 + NKp46 + ) of spleen NK cells, and cultured for 5 days in RPMI or TGF-β-free medium (MaxTex) under the following conditions: rIL-15 (50 ng / mL), rIL-15 (50 ng / mL) with rTGFb1 (1 ng / mL), rIL-15 (50 ng / mL) with rTGFb1 (6.25 ng / mL) or rIL-15 (50 ng / mL) with rTGFb1 (25 ng / mL). The loss of CFSE (proliferation) was monitored by FACS.

[0078] Fig.19 TGFβ or BRAF (B-Raf protein kinase) inhibition and Cish deficiency are superior to either single or combined treatment. + / + and Cish - / - Mice were injected with 1×10 6BRAF mutant melanoma cell lines (SM1LWT1) were injected with control (ctr) Ig, anti-TGF-β (1D11) antibody, BRAF inhibitor (PLX4720), or 1D11 and PLX4720. Melanoma burden in the lungs was determined by microscopic counting at day 14 post-injection. Mean ± SEM *p<0.05, **p<0.005, ***p<0.0005.

[0079] Fig. 20 Combining Cish deficiency with checkpoint inhibitors or cytokine stimulation showed improved anti-metastatic effects. (A) 5-6 B6.WT (Cish + / + ) or B6.Cish - / - Mice were injected intravenously with 2×10 5 B16F10 melanoma cells were treated with control Ig (cIg) (250 μg ip on days 0, 3, and 6), anti-PD-1 (250 μg ip on days 0, 3, and 6), mouse IFN-αβ (25 μg ip on days 0, 1, 2, and 3), or recombinant IL-2 (10,000 IU ip on days 0, 1, 2, and 3). (B) Five to eleven B6.WT (Cish + / + ) or B6.Cish - / - The mice were injected intravenously with 7.5×10 5 B16F10 melanoma cells were treated with cIg (250 μg ip on days 0, 3, and 6), anti-PD1 / anti-CTLA-4 combination (250 μg ip on days 0, 3, and 6, respectively), or recombinant IL-2 (10,000 IU ip on days 0, 1, 2, 3, and 4). (C) Seven to ten B6.WT (Cish + / + ) and B6.Cish - / - The mice were injected intraperitoneally with 1×10 5 100,000 IU intraperitoneally on days 0, 1, 2, 3, and 4) of parental RMA-S cells. Mice were monitored for tumor development and euthanized when abdominal swelling and discomfort occurred. The improvement in survival between groups was assessed by log-rank Mantel-Cox test. (D) Five to 15 B6.WT (Cish + / + ) or B6.Cish - / - Mice were injected intravenously with 5×10 5 RM-1 prostate cancer cells and treated with cIg, anti-CD96, anti-PD-1, anti-CTLA-4, or anti-PD1 / anti-CTLA-4 combination (250 μg intraperitoneally, each on days 0 and 3). (E) 8-10 B6.WT (Cish + / + ) or B6.Cish- / - The mice were injected intravenously with 7.5×10 5 B16F10 melanoma cells were treated with 250 μg cIg or anti-CD96 mAb (ip, on days 0 and 3). (F) Five to six B6.WT (Cish + / + ) or B6.Cish - / - The mice were injected intravenously with 7.5×10 5 LWT1 melanoma cells were treated with vehicle or PLX4720 (10 mg / kg ip, daily from day 0 to 6). Lungs were collected and macrometastases were counted on day 14 (A, D, F) or day 13 (B, E). Each symbol shows a single mouse and results are plotted as mean ± SEM. Statistically significant differences were determined by one-way ANOVA with Tukey post hoc test (for multiple comparisons) as described above (*: p<0.5; **: p<0.01; ***: p<0.001; ****: p<0.0001).

[0080] Fig.21 Combining Cish deficiency with BRAF or MEK kinase inhibitors showed improved anti-metastatic effects. + / + ) and B6.Cish - / - Mice were intravenously inoculated with 7.5×10 5 LWT1 melanoma cells were treated with vehicle, BRAF inhibitor (PLX4720; daily treatment for 6 days; 10 mg / kg intraperitoneal) and / or MEK inhibitor (MEKi; trametinib, 0.6 mg / kg gavage on days 0 and 3). Lungs were collected on day 14 and macrometastases were counted. Each symbol shows a single mouse and results are plotted as mean ± SEM. Statistically significant differences were determined by one-way ANOVA with Tukey post hoc test (for multiple comparisons) as described above (ns not significant; ***: p<0.001; ****: p<0.0001).

[0081] Fig. 22 To protect Cish-deficient mice from MCA-induced tumor development. (A) 15 B6.WT (Cish + / + ) and 18 B6.Cish - / - Groups of male mice were inoculated subcutaneously on the hind flank with 300 μg of MCA dissolved in 0.1 ml corn oil. The mice were then monitored for 250 days for the development of fibrosarcoma, and data were recorded as the percentage of tumor-free mice (tumors > 3 mm in diameter were recorded as positive). (B) 16-18 B6.WT (Cish + / + ) and 14 B6.Cish - / -Groups of male mice were inoculated subcutaneously in the hind flank with 300 μg of MCA dissolved in 0.1 ml of corn oil. Mice were treated with 250 μg of hamster cIg, 50 μg of anti-asialoGM1 (anti-asGM1; NK cell depletion), or 250 μg of anti-IFN-γ antibody (ip injection on days -1, 0, 7, 12, 24, 28, 35, and 42). Mice were monitored for fibrosarcoma development over 200 days. The square diameter of the tumor was measured weekly with a caliper, with two perpendicular diameters (mm 2 When the square diameter of the tumor reaches >150mm 2 Statistically significant differences in survival rates between groups (*: p<0.05; ***: p<0.001) were determined by log-rank Mantel-Cox test (A) followed by Bonferroni correction for multiple testing (B).

[0082] Fig.23 Cish-deficient mice showed enhanced survival in an acute myeloid leukemia model. + / + (WT) and Cish - / - Mice were injected intravenously with 5×10 5 MLL-AF9 cells. When splenomegaly and / or hind leg paralysis were detected, mice were euthanized according to ethical guidelines. Survival curve results are from two independent experiments. Each group has n≥5 mice / experiment. ***p<0.05.

[0083] Fig.24 Loss of CIS function in NK cells results in enhanced turnover and differentiation of more mature NK cells in vivo. - / - and Cish + / + The spleens of mice were collected and processed into single cell suspensions. Surface and intracellular staining was performed by flow cytometry to determine: (A) Cish + / + and Cish - / -Total NK cells were identified as NK1.1+NKp46+ and further subdivided into immature NK cells (CD27+CD11b-; Imm), M1 (CD27+CD11b+), and M2 (CD27-CD11b+) subsets, with M2 representing the most mature and cytotoxic NK cell population. (B) Number of DNAM1+KLRG1+NK cells. In general, DNAM+ cells showed more proinflammatory cytokine production and enhanced response to IL-15, while KLRG1 was considered an alternative maturity marker (C) Percentage of Ki67+ cells in each NK cell subset (Imm, M1, M2). Ki67 is a marker for cell proliferation. n=6 mice / group. p<0.05. Overall, these data show that although the total number of NK cells is in Cish + / + and Cish - / - There were no differences between mice, but Cish - / - NK cells are more mature and may show increased cytokine production and cytotoxicity, all of which are - / - A subpopulation showed increased cell cycling.

[0084] Fig.25 Both NK cells and CD8 T cells are required for enhanced control of MCA1956 sarcoma. + / + ) and B6.Cish - / - The mice were subcutaneously injected with 1×10 6 MCA1956 fibrosarcoma cells were inoculated with control Ig (cIg: 50 μg rabbit IgG + 100 μg rat IgG1), 50 μg anti-asialoGM1 (anti-asGM1; NK cell depletion), or 100 μg anti-CD8β (CD8 + T cell depletion) tumors. Mean ± SEM of 6-7 mice / group. WT and Cish - / - Statistically significant differences between groups (*p<0.05).

[0085] Fig.26 For Cish - / - CD8+ T cells showed enhanced IFNγ production. + / + (WT) and Cish - / -Peripheral lymph node CD8+ T cells of mice were isolated for 4 days and IFNγ production in response to 4h PMA / ionomycin was assessed by flow cytometry. n=3 mice. Mean±SEM ***P<0.0005, ****P<0.0001. Data were analyzed using two-way ANOVA.

[0086] Fig. 27 For Cish - / - CD8+ T cells showed enhanced proliferation under activation conditions. + / + (WT) and Cish - / - Mouse peripheral lymph node CD8+ T cells were co-cultured for 4 days in the presence (lower panel) or absence (upper panel) of αCD28 stimulation (no αCD3) in IL-15. The percentage of cells occupying each compartment was evaluated by flow cytometry. The data represent n=3 mice / genotype. Mean ± SEM is shown

[0087] Fig.28 IL-15 levels in tumors and the tumor microenvironment regulate Cish expression levels in resident NK cells. + / + or IL-15 - / - Mice (stromal IL-15 status + or -) were lethally irradiated and treated with Cish LacZ / + Bone marrow reconstitution. Ten weeks later, these chimeric mice were subjected to injection of 1×10 5 The mice were attacked or left unattacked with 100 E0771 breast cancer cells. Mice were killed one week later, breast tumors were collected and excised, and NK cells resident in the tumor were stained for β-galactosidase (Cish expression) and analyzed by flow cytometry. Mean ± SEM is shown. Statistical significance is shown and determined by Student t test.

[0088] Sequence Listing Index

[0089] SEQ ID NO:1 JAK1 activation cyclic phosphopeptide

[0090] SEQ ID NO:2 JAK1 phospho-mimetic peptide

[0091] SEQ ID NO:3 IL-2Rβ phosphopeptide

[0092] SEQ ID NO:4 IL-2Rβ phosphopeptide

[0093] SEQ ID NO:5 IL-2Rβ phosphopeptide

[0094] SEQ ID NO:6 Human CIS protein isoform 1

[0095] SEQ ID NO: 7 Human CIS protein isoform 1 fragment

[0096] SEQ ID NO: 8 Human CIS protein isoform 1 SOCS frame

[0097] SEQ ID NO:9 Mouse (Mus musculus) CIS protein isoform 1

[0098] SEQ ID NO: 10 Rattus norvegicus CIS protein

[0099] SEQ ID NO: 11 Homo sapiens JAK1 protein

[0100] SEQ ID NO: 12 Homo sapiens JAK3 protein

[0101] SEQ ID NO: 13 Homo sapiens IL-2 receptor subunit β precursor

[0102] SEQ ID NO: 14 Homo sapiens extensin B

[0103] SEQ ID NO: 15 Homo sapiens elongin C

[0104] SEQ ID NO: 16 Homo sapiens stagmin-5

[0105] SEQ ID NO: 17 Homo sapiens JAK1 protein JH1 kinase domain peptide

[0106] SEQ ID NO: 18 STAT5b peptide

[0107] SEQ ID NO:19 JAK1 peptide

[0108] SEQ ID NO:20 JAK3 peptide

[0109] SEQ ID NO:21 IL-2Rβ phosphopeptide

[0110] SEQ ID NO:22 IL-2Rβ phosphopeptide

[0111] SEQ ID NO:23 mIL-2Rβ phosphopeptide

[0112] SEQ ID NO:24 IL2Rβ phosphopeptide

[0113] SEQ ID NO:25 IL2Rγ phosphopeptide

[0114] SEQ ID NO:26 IL2Rγ phosphopeptide

[0115] SEQ ID NO:27 IL2Rγ phosphopeptide

[0116] SEQ ID NO:28 IL2Rγ phosphopeptide

[0117] SEQ ID NO:29 CIS PEST domain peptide

[0118] SEQ ID NO:30 CIS PEST domain phosphopeptide

[0119] SEQ ID NO:31 CIS N-terminal phosphopeptide

[0120] SEQ ID NO:32 CIS PEST domain phosphopeptide

[0121] SEQ ID NO:33 CIS SH2 / SB domain phosphopeptide

[0122] SEQ ID NO:34 CIS N-terminal glycosylated peptide

[0123] SEQ ID NO:35 CIS SH2 glycosylated peptide

[0124] SEQ ID NO:36 CIS SH2 glycosylated peptide

[0125] SEQ ID NO:37 CIS PEST glycosylated peptide

[0126] SEQ ID NO:38 CIS SH2 / SB domain glycosylated peptide DETAILED DESCRIPTION

[0127] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.

[0128] General techniques and definitions

[0129] Unless specifically defined otherwise, all technical and scientific terms used herein should be understood to have the same meaning as commonly understood by one of ordinary skill in the art (e.g., in cell culture, cell biology, molecular genetics, cancer biology and treatment thereof, infectious diseases, especially acute infections, immunology, pharmacology, protein chemistry, and biochemistry).

[0130] Unless otherwise indicated, the cell culture and immunological techniques utilized in the present invention are standard procedures well known to those skilled in the art. Such techniques are described and explained in various original references such as J. Perbal, A Practical Guide to Molecular Cloning, John Wiley and Sons (1984), J. Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbour Laboratory Press (1989), TA Brown (ed.), Essential Molecular Biology: A Practical Approach, Vols. 1 and 2, IRL Press (1991), DM Glover and BD Hames (eds.), DNA Cloning: A Practical Approach, Vols. 1-4, IRL Press (1995 and 1996), and FM Ausubel et al. (eds.), Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience (1988, including all current latest versions), Ed Harlow and David Lane (eds.) Antibodies: A Laboratory Manual, Cold Spring Harbour Laboratory, (1988), and JE Coligan et al. (eds.) Current Protocols in Immunology, John Wiley & Sons (including all current latest versions).

[0131] As used herein, unless stated to the contrary, the term about means + / - 10%, more preferably + / - 5%, of a specified value.

[0132] Throughout this specification, the word "comprise" or variations such as "comprising" or "containing" will be understood to mean the inclusion of stated elements, integers or steps or groups of elements, integers or steps but not the exclusion of any other elements, integers or steps or groups of elements, integers or steps.

[0133] As used in this application, the term "or" is intended to mean an inclusive "or" rather than an exclusive "or". That is, unless specified otherwise or the context clearly dictates otherwise, "X employs A or B" is intended to mean any of the natural inclusive permutations. That is, if X employs A; X employs B; or X employs both A and B, then "X employs A or B" is satisfied in any of the foregoing cases. In addition, at least one of A and B and / or the same generally means A or B or both A and B. Furthermore, the articles "a" and "an" as used in this application and the appended claims may generally be construed to mean "one or more" unless specified otherwise or the context clearly dictates otherwise.

[0134] As used herein, the term "CIS inhibitor" refers to any agent that inhibits CIS signaling activity in NK cells. Such agents can be used to specifically reduce CIS signaling activity in NK cells by any of many different modes of action, including but not limited to reducing the total level of CIS protein (such as by reducing CIS mRNA levels), inhibiting its binding to target proteins (e.g., JAK1) or its interaction with signaling complex binding partners (such as elongated protein B and elongated protein C). As used herein, specifically excluded from "CIS inhibitors" are agents that widely or globally affect proteins other than CIS (e.g., alkylating agents or cross-linking agents) or inhibit basic cell processes such as translation (e.g., translation inhibitors) or non-selectively change protein degradation. Examples of CIS inhibitors include, for example, polynucleotides (e.g., siRNA and mRNA), small molecules, peptides, polypeptides, or combinations thereof. In some embodiments, one or more such CIS inhibitors are used in combination with delivery and / or targeting agents, such as nanoparticle-mediated delivery.

[0135] As used herein, the term "competitive inhibitor" or "competitive inhibition" refers to a mode of inhibition of a target protein in which the inhibitor binds to a functionally critical site on the target protein itself (e.g., a ligand binding site) or on a ligand of the target protein (e.g., a binding partner protein), thereby causing a steric hindrance in the interaction between the protein target and the ligand. A competitive inhibitor may, but need not, have a higher affinity for the biologically active site for which it competes.

[0136] As used herein, the term "CIS inhibitory NK cells" refers to NK cells in which CIS activity is inhibited by any of a number of individual or combined strategies. For example, CIS inhibitory NK cells include, but are not limited to, Cish "knockout" NK cells in which the Cish gene has been genetically deleted or modified, such as by gene editing; CIS protein "knockdown" NK cells in which the expression of CIS protein has been reduced by using a gene silencing strategy (e.g., using siRNA or RNAi) or the expression of a dominant negative CIS sequence variant or a dominant negative CIS fragment; or, CIS inhibitory NK cells are NK cells that have been exposed to CIS inhibitors (e.g., small molecule compounds, peptides or peptide mimetics), and the CIS inhibitors inhibit the activity of CIS, such as by inhibiting its binding to a target protein (e.g., JAK1) or its interaction with a signaling complex binding partner (such as elongin B and elongin C or stagnation protein-5). Alternatively, the CIS inhibitor can be a peptide or fragment derived from CIS that inhibits CIS activity in a trans-acting manner. In some embodiments, the CIS-suppressive NK cells are irreversibly CIS-suppressed, for example by genetic modification. In other embodiments, the CIS-suppressive NK cells are reversibly CIS-suppressed, such that CIS-suppression in the cells decreases over time.

[0137] As used herein, the term "fragment" refers to a biologically active portion of a protein that retains at least one function or domain (e.g., a CIS fragment). For example, a CIS fragment may include an SH2 domain and a SOCS box, and a JAK1 fragment may include a JH1 kinase domain. In some cases, the activity of a fragment refers to its ability to specifically bind to a binding partner (e.g., a protein or a fragment thereof). As used herein, a "fragment" does not encompass a full-length protein.

[0138] As used herein, the term "NK cell responsiveness disorder" refers to a disorder suitable for effective treatment by one or more NK cell activities (e.g., NK cell cytotoxicity-induced tumor cell death or death of infected cells, and interferon-γ (IFN-γ) production). Examples of NK cell responsiveness disorders include, but are not limited to, cancer (e.g., melanoma, prostate cancer, breast cancer, and liver cancer) and infection, such as viral infection (e.g., HSV, hepatitis virus, human cytomegalovirus, influenza virus, flavivirus, and HIV-1 infection), bacterial infection (e.g., mycobacteria, Listeria, and Staphylococcus infection) and protozoan infection (e.g., Plasmodium infection) and fungal infection (e.g., Aspergillus infection).

[0139] As used herein, the term "peptide" refers to an amino acid polymer ranging from two to about fifty amino acids (e.g., 4, 6, 8, 10, 12, 15, 20, 25, 30, 35, 40, or 45 amino acids in length). The term peptide encompasses both unmodified peptides, phosphorylated peptides (e.g., phosphopeptides), and other chemically derived peptides, but does not encompass peptide mimetics,

[0140] As used herein, the term "polypeptide" or "protein" refers to amino acid polymers that are generally greater than about 50 amino acids in length and generally possess characteristic secondary and tertiary structures.

[0141] As understood by the skilled person, CIS inhibitors and CIS inhibitory NK cells will be administered in a therapeutically effective amount. As used herein, the term "effective amount" or "therapeutically effective amount" refers to a sufficient amount of the CIS inhibitor administered to alleviate one or more symptoms of the disease or condition to be treated to a certain extent. The result can be a reduction and / or alleviation of the signs, symptoms or causes of the disease or any other desired changes in the biological system. For example, an "effective amount" for therapeutic use is the amount of the CIS inhibitor required to provide a clinically significant reduction in disease symptoms without excessive adverse side effects. In any individual case, an appropriate "effective amount" can be determined using technology such as a dose escalation study. The term "therapeutically effective amount" includes, for example, a preventive effective amount. The "effective amount" of a CIS inhibitor is an amount that effectively achieves the desired pharmacological effect or therapeutic improvement without excessive adverse side effects. It should be understood that due to the metabolic changes of the compound of any one of the subject's age, weight, general condition, condition to be treated, severity of the condition to be treated, and the judgment of the prescribing physician, an "effective amount" or "therapeutically effective amount" may vary from subject to subject. By way of example only, a therapeutically effective amount can be determined by routine experimentation, including, but not limited to, a dose escalation clinical trial. Where more than one therapeutic agent is used in combination, a "therapeutically effective amount" of each therapeutic agent may refer to an amount of the therapeutic agent that is therapeutically effective when used alone, or may refer to a reduced amount that is therapeutically effective due to its combination with one or more additional therapeutic agents.

[0142] As used herein, the term "small molecule" refers to a molecule having a molecular weight of less than 2000 Daltons.

[0143] As used herein, the term "chemically modified mRNA" or "chemically modified siRNA" refers to a synthetic RNA generated in vitro, wherein a portion (e.g., 10%, 30%, 50% or 100%) of at least one type of nucleotide, such as cytosine, is chemically modified to increase its stability within a cell or in vivo. For example, in some cases, the modified cytosine is 5-methylcytosine. Such polynucleotides are particularly suitable for delivery / transfection to cells in vivo, particularly when combined with a transfection / delivery agent. In some cases, a chemically modified mRNA is a chemically modified mRNA in which most (e.g., all) cytosines are 5-methylcytosines, and most (e.g., all) uracils are pseudouracils. The synthesis and use of such modified RNAs are described, for example, in WO 2011 / 130624.

[0144] As used herein, the terms "treat" or "treatment" refer to both direct treatment of a subject by a medical professional (e.g., by administering a therapeutic agent to the subject) or indirect treatment by at least one party (e.g., a doctor, nurse, pharmacist, or pharmaceutical sales representative) by providing any form of instructions that (i) instruct the subject to self-treat (e.g., self-administer a drug) according to the claimed method or (ii) instruct a third party to treat the subject according to the claimed method. The meaning of the terms "treat" or "treatment" also encompasses preventing or reducing the disease to be treated, such as by administering a therapeutic agent at an early enough stage of the disease to prevent or slow its progression.

[0145] As used herein, the term "at risk" refers to a higher likelihood of developing a health condition than the general population. Thus, treatment of an individual deemed "at risk" for a particular condition is designed to prevent the subject from developing the condition or at least reduce the risk of developing the condition to a level no greater than that present in the general population as a whole.

[0146] As used herein, the terms "co-administered," "co-administered," and the like are meant to encompass administration of selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are administered by the same or different routes of administration, or at the same or different times.

[0147] Treatment

[0148] Methods described herein include treating a subject with NK cell responsiveness disorder or being at risk of NK responsiveness disorder by administering a CIS inhibitor for treatment or prevention of an effective amount. As described herein, CIS (UniprotKBQ9NSE2) acts as a potent checkpoint inhibitor of IL-15-induced responses in NK cells. Not bound by theory, it is believed that the function of CIS in NK cells is suppressed, greatly enhancing the sensitivity of these cells to IL-15, and maintaining its activation to achieve a therapeutic effect.

[0149] In other embodiments, a method for adoptive cell therapy comprises administering CIS suppressor NK cells to a subject having a NK cell responsive disorder.

[0150] In some embodiments, the subject suffering from NK cell responsiveness disorder or being in the risk of suffering from NK cell responsiveness disorder suffers from proliferative conditions such as cancer. In some embodiments, the cancer suffered by the subject suffering from cancer is characterized by the presence of one or more tumors in the subject. Examples of cancers suitable for treatment by the method of the present invention include but are not limited to the following cancers: metastatic melanoma, metastatic prostate cancer, metastatic breast cancer, triple-negative breast cancer, bladder cancer, brain cancer, esophageal cancer, liver cancer, head and neck cancer, squamous cell lung cancer, non-small cell lung cancer, Merkel cell carcinoma, sarcoma, hepatocellular carcinoma, multiple myeloma, pancreatic cancer, colorectal cancer, cervical cancer, gastric cancer, kidney cancer, metastatic renal cell carcinoma, leukemia, ovarian cancer and malignant glioma. In some preferred embodiments, cancer is metastatic melanoma, metastatic prostate cancer or metastatic breast cancer. In some embodiments, the subject has received allogeneic tissue transplantation related to cancer treatment, for example, after hematopoietic stem cell transplantation for the treatment of leukemia.

[0151] Also described herein is a method for increasing the response of NK cells to IL-15 by suppressing CIS in NK cells. In some embodiments, the response of NK cells to IL-15 is increased by suppressing CIS in NK cells in vitro (e.g., in cultured NK cells). In other embodiments, the response of NK cells to IL-15 is increased by suppressing CIS in NK cells in vivo, for example, by applying CIS inhibitors to subjects. In some embodiments, this method includes reducing the expression of CIS in NK cells in vitro. Optionally, the NK cells wherein the expression of CIS in vitro is reduced can be derived from the subject and then transplanted to the donor patient's autologous NK cells after the expression of CIS in vitro is reduced. In other embodiments, NK cells can be allogeneic NK cells, i.e., obtained from a donor source different from a recipient subject. In some embodiments, the subject is a cancer patient. In other embodiments, the subject is a NK cell donor. Optionally, such methods can include contacting NK cells in vitro or in vivo with exogenous IL-15.

[0152] Diagnostic Methods

[0153] As disclosed herein, IL-15 induces Cish expression as part of a negative feedback loop that reduces NK cell immune responses to tumors. As disclosed herein, in the case of elevated levels of IL-15 in the microenvironment, Cish expression in tumor-infiltrating NK cells of a specific tumor / tumor type also increases. While not wishing to be bound by theory, it is believed that increased Cish expression in tumor-infiltrating NK cells indicates that Cish inhibition will be effective in enhancing NK-mediated immune responses to tumors. Therefore, in some embodiments, in patients with tumors, the likelihood of a response to treatment by Cish inhibition in the patient is assessed by determining the level of IL-15 in the tumor microenvironment (e.g., by tumor biopsy), wherein an increase in the level of IL-15 in the tumor microenvironment relative to a threshold level of IL-15 indicates an increased likelihood of a response to treatment.

[0154] Similarly, in some embodiments, the induction of increased expression of Cish in tumor-infiltrating NK cells in a subject having a tumor is determined by determining the level of IL-15 in the tumor microenvironment, wherein an increase in the level of IL-15 in the tumor microenvironment relative to a threshold level of IL-15 indicates induction of increased expression of Cish in tumor-infiltrating NK cells.

[0155] A "threshold" level of IL-15 can be determined based on, for example, comparison of control tissue levels of IL- 15. Suitable threshold levels can be readily determined by a skilled artisan using routine experimentation.

[0156] In other embodiments, the subject to be treated suffers from infection. In some embodiments, the infection to be treated is a viral infection, including but not limited to herpes simplex virus, adenovirus, vaccinia virus, human cytomegalovirus, influenza virus, poxvirus or papillomavirus infection. In other embodiments, the subject suffering from NK cell responsiveness disorder suffers from bacterial infection, such as mycobacterium, listeria or staphylococcus infection. In other embodiments, the subject to be treated suffers from protozoan infection (e.g., Plasmodium infection). In other embodiments, the subject to be treated suffers from fungal infection (e.g., Aspergillus infection).

[0157] As used herein, the term "subject" can be any animal. In one example, the animal is a vertebrate. For example, the animal can be a mammal, a bird, a chordate, an amphibian, or a reptile. Exemplary subjects include, but are not limited to, humans, primates, livestock (e.g., sheep, cows, chickens, horses, donkeys, pigs), companion animals (e.g., dogs, cats), laboratory test animals (e.g., mice, rabbits, rats, guinea pigs, hamsters), captive wild animals (e.g., foxes, deer). In one example, the mammal is a human.

[0158] Symptoms, diagnostic tests, and prognostic tests for each of the above conditions are known in the art. See, for example, Harrison's Principles of Internal Medicine. .” 19th Edition, Volumes 1 and 2, 2015, The McGraw-Hill Companies, Inc.

[0159] Many animal models are used to establish a range of therapeutically effective doses of CIS inhibitors for treating any of the aforementioned NK responsiveness disorders. For example, many mouse cancer models have been established, such as melanoma models (Walker et al., 2011), prostate cancer models (Grabowska et al., 2014), and breast cancer models (Borowsky, 2011).

[0160] CIS inhibitors

[0161] As used herein, CIS inhibition refers to reducing one or more of net Cish gene expression, net CIS protein level, or CIS activity (e.g., its inhibition of JAK1 kinase activity or its targeting of JAK1 for proteolysis). The inhibition of CIS can include the CIS activity level in the presence of a given dose of a CIS inhibitor or produced by a given dose of a CIS inhibitor, relative to the CIS activity level in the absence of which is reduced by at least about 10% to 100%, for example, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95% or other percentages of CIS activity reduction of about 10% to about 100%. In some embodiments, a CIS inhibitor is administered to a subject to be treated. In other embodiments, a CIS inhibitor is administered ex vivo to NK cells to obtain CIS inhibitory NK cells, which are then administered to a subject as a therapeutic agent. In some embodiments, a CIS inhibitor is a reversible CIS inhibitor. In other embodiments, a CIS inhibitor is an irreversible CIS inhibitor.

[0162] Examples of types of CIS inhibitors useful in the present invention include, but are not limited to, peptides, peptidomimetics, small molecules, polynucleotides, or polypeptides.

[0163] Peptides

[0164] In some embodiments, the CIS inhibitor for treatment methods is a peptide. Suitable peptides can inhibit the ability of CIS to increase the ubiquitination of JAK1 and / or inhibit CIS from reducing the enzymatic activity of JAK1 kinases, such as the ability of its target protein to be phosphorylated. In some embodiments, the peptide is a phosphopeptide that binds to CIS to competitively inhibit the ability of CIS to interact with endogenous phosphorylated target proteins. In some embodiments, the phosphopeptide is derived from the amino acid sequence of the JAK1 activation loop and corresponds to amino acids 1027-1042 of JAK1 (the activation loop sequence is shown below), wherein Tyr1034 is phosphorylated:

[0165] (SEQ ID NO:1)A 102 7IETDKE pY YTVKDDRD

[0166] Alternatively, the peptide may be a JAK1 activation cyclic phospho-mimetic peptide, such as (SEQ ID NO: 2) K 1032 E-[F2PMP]2-TV, wherein [F2PMP]2 is a phosphotyrosyl mimetic 4-(phosphonodifluoromethyl)phenylalanine moiety as described by Yao et al. (2005).

[0167] In other embodiments, the peptide is a phosphopeptide or phosphopeptide mimetic whose sequence is derived from the cytoplasmic domain of IL-2Rβ (GenBank Accession No. NP_000869.1). For example:

[0168] (SEQ ID NO:3)C 352 QV pY FTYDPYSE

[0169] (SEQ ID NO:4)Y 358 DP pY SEEDPDEG

[0170] (SEQ ID NO:5)D 389 DA pY CTFPSRDD

[0171] In some embodiments, the peptide CIS inhibitor is a phosphopeptide or phosphopeptide mimetic comprising an amino acid sequence of one of SEQ ID NOs: 1-5. In other embodiments, the amino acid sequence of the peptide CIS inhibitor consists of one of SEQ ID NOs: 1-5.

[0172] According to traditional peptide synthesis methods, the peptides used in the methods of the present invention can be prepared by a variety of synthetic methods for peptide synthesis, via condensation reactions of one or more amino acid residues. Preferably, the peptide is synthesized according to a standard solid phase method, such as can be performed on an Applied Biosystems Model 430A peptide synthesizer (Applied Biosystems, Foster City, Calif.) according to the manufacturer's instructions. Other methods for synthesizing peptides (by solid phase methods or in liquid phase) are well known to those skilled in the art. When solid phase synthesis is utilized, the C-terminal amino acid is attached to an insoluble resin support, which can generate a separable bond by reacting with the carboxyl group in the C-terminal amino acid. For example, in some cases, the insoluble resin support used is a p-hydroxymethylphenoxymethyl polystyrene (HMP) resin. Other useful resins include, but are not limited to: phenylacetamidomethyl (PAM) resin (the resin is used together with the Boc method of solid phase synthesis) for the synthesis of some N-methyl-containing peptides; and MBHA (p-methylbenzhydrylamine) resin for the generation of peptides with a C-terminal amide group. During peptide synthesis, the branched amino and carboxyl groups can be protected / deprotected as needed using well-known protecting groups. In some embodiments, the base-labile 9-fluorenylmethyloxycarbonyl (Fmoc) group or tert-butyloxycarbonyl (Boc group) is used to protect the N-α-amino group. Side chain functional groups consistent with Fmoc synthesis can be protected using the following specified protecting groups: arginine (2,2,5,7,8-pentamethylchroman-6-sulfonyl); asparagine (O-tert-butyl ester); cysteine ​​glutamine and histidine (trityl); lysine (tert-butyloxycarbonyl); serine and tyrosine (tert-butyl). Modification using alternative protecting groups of peptides and peptide derivatives will be obvious to those skilled in the art.

[0173] Peptide mimetics

[0174] In some embodiments, CIS inhibitors are peptide mimetics. All peptides are sensitive to enzymatic degradation in vivo. Therefore, it is particularly advantageous to maintain or even enhance the biological activity of the basic peptide, but to use peptide mimetics with a larger circulation half-life for the treatment method of the present invention. Peptide mimetics, such as peptide mimetics based on peptides with an amino acid sequence of any one of SEQ ID NO: 1-5, can be easily synthesized in large quantities by non-fermentation methods.

[0175] Although a peptide backbone is characterized by one or more internal peptide bonds, a peptide will have a peptide bond connecting each amino acid residue. Thus, compounds in which one or more amide bonds have been replaced by alternative linkers but in which at least one amide bond is retained are considered peptidomimetics.

[0176] The peptidomimetic backbone will typically be linear or will mimic the linear chains of fused cyclic groups of the peptide backbone.

[0177] Peptide mimetics are generally characterized by maintaining the polarity, three-dimensional size and function (biological activity) of their peptide equivalents, but wherein the peptide bond has been replaced, usually replaced by a more stable bond. So-called "stable" means more tolerant to enzymatic degradation of hydrolases. Usually, the bond (amide bond substitute) that replaces the amide bond retains many properties of the amide bond, such as conformation, steric hindrance, electrostatic properties, the possibility of forming hydrogen bonds, etc. "Drug Design and Development", Krogsgaard, Larsen, Liljefors and Madsen (ed.) 1996, Horwood Acad.Pub, Chapter 14 provides a general discussion of the prior art of the design and synthesis of peptide mimetics. Suitable amide bond substitutes include: N-alkylation, retro-amides, thioamides, thioesters, phosphonates, ketomethylene, hydroxymethylene, fluorovinyl, vinyl, methyleneamino, methylenethio, alkanes and sulfonamido.

[0178] Peptides and peptidomimetics will typically have backbones of 4 to 20, preferably 7 to 16 atoms in length. Molecules having backbones at the upper end of these ranges will typically include beta and / or gamma amino acids or their equivalents.

[0179] In some embodiments, the peptide mimetic will be derived from a CIS autoinhibitory peptide sequence. In some embodiments, the CIS autoinhibitory peptide sequence is a PEST peptide sequence, such as a peptide sequence selected from SEQ ID NOs: 29, 30, 32, and 37. In other embodiments, the CIS autoinhibitory peptide sequence is a CIS N-terminal peptide sequence, such as a peptide sequence selected from SEQ ID NOs: 31 and 34.

[0180] Small molecules

[0181] In some embodiments, CIS inhibitor is a small molecule. In some embodiments, small molecule specific binding to CIS and reduce its activity, such as CIS and binding partner or target protein interaction. Suitable small molecule CIS inhibitors for the present invention can be identified using the screening method defined herein. For example, the compound can be bound to the Src homology 2 (SH2) domain of CIS (amino acid 66-216 of human CIS; UniprotKB Q9NSE2; and SEQ ID NO:6), SOCS box 6) or the N-terminal region (amino acid 1-65) of CIS.

[0182] In some embodiments, the compound administered can be a precursor compound, commonly referred to as a "prodrug", which is inactive or has a relatively low activity, but after administration, it is converted (i.e., metabolized) to an active CIS inhibitor. In those embodiments, the compound administered can be referred to as a prodrug. Alternatively or in addition thereto, the compound administered can be metabolized to generate an active metabolite, which has the activity of reducing the expression of CIS activity in a cell population compared to isogenic cells lacking the compound. The use of such active metabolites is also within the scope of the present disclosure.

[0183] Depending on the substituents present in the compound, the compound may optionally exist in the form of a salt. Salts of compounds suitable for the method are those in which the counterion is pharmaceutically acceptable. Suitable salts include those formed with organic or inorganic acids or bases. Specifically, suitable salts formed with acids include those formed with inorganic acids, strong organic carboxylic acids, or with organic sulfonic acids, such as alkane carboxylic acids with unsubstituted or substituted (e.g., halogen-substituted) 1 to 4 carbon atoms, such as saturated or unsaturated dicarboxylic acids, such as hydroxycarboxylic acids, such as amino acids, such as substituted or unsubstituted (e.g., halogen-substituted) (C 1-4 )-alkyl or aryl sulfonic acid. Pharmaceutically acceptable acid addition salts include those formed from the following acids: hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, citric acid, tartaric acid, acetic acid, sulfuric acid, lactic acid, pyruvic acid, acetic acid, trifluoroacetic acid, succinic acid, perchloric acid, fumaric acid, maleic acid, glycolic acid, lactic acid, salicylic acid, oxaloacetic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, formic acid, benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, isethionic acid, ascorbic acid, malic acid, phthalic acid, aspartic acid and glutamic acid, lysine and arginine. Pharmaceutically acceptable base salts include ammonium salts, alkali metal salts (e.g., potassium and sodium salts), alkaline earth metal salts (e.g., calcium and magnesium salts), and salts formed with organic bases (e.g., dicyclohexylamine, N-methyl-D-glucamine (glucomine), morpholine, thiomorpholine, piperidine, pyrrolidine, mono-, di- or tri-lower alkylamines (e.g., ethylamine, tert-butylamine, diethylamine, diisopropylamine, triethylamine, tributylamine or dimethylpropylamine) or mono-, di- or tri-hydroxy lower alkylamines (e.g., mono-, di- or triethanolamine). Corresponding inner salts may also be formed.

[0184] Those skilled in the art of organic and / or medicinal chemistry will appreciate that many organic compounds can form complexes with solvents, wherein they react with the solvent or precipitate or crystallize from the solvent. These complexes are referred to as "solvates". For example, complexes formed with water are referred to as "hydrates". When a drug substance is incorporated into a solvent such as water, a solvate (such as a hydrate) is present in the crystal lattice in a stoichiometric or non-stoichiometric amount. Drug substances present as solvates (such as hydrates) are screened in a conventional manner because these drug substances may be encountered at any stage. Therefore, it is understood that the compounds used in the present invention can exist in the form of solvates (such as hydrates). Solvate forms suitable for compounds of the present invention are those in which the associated solvent is pharmaceutically acceptable. For example, hydrates are examples of pharmaceutically acceptable solvates.

[0185] The compound used for the present invention can exist in amorphous form or crystalline form. Many compounds exist in many polymorphic forms, and the use of all such forms of compounds is encompassed in the present disclosure. Standard procedures can be used to identify small molecules for the present disclosure, such as screening compounds that bind to CIS in a candidate compound library, and then determining whether any compound combined reduces CIS activity. In some embodiments, screening compounds of the present invention includes assessing whether the compound inhibits CIS activity in cells. Small molecules for the present invention can also be identified using a computer simulation screening program as described herein, which can include screening known library compounds to identify candidates that reduce CIS activity. In some embodiments, small molecule CIS inhibitors are irreversible CIS inhibitors. In other embodiments, small molecule CIS inhibitors are reversible CIS inhibitors.

[0186] Polynucleotide

[0187] In some embodiments, the CIS inhibitor is a polynucleotide that can inhibit CIS activity by at least one of the many different mechanisms described.

[0188] RNA interference

[0189] In some embodiments, the polynucleotide CIS inhibitor acts by targeting its mRNA, thereby reducing the expression of CIS protein. For example, the polynucleotide can be RNAi.

[0190] The term "RNA interference", "RNAi" or "gene silencing" generally refers to a process in which a double-stranded RNA molecule reduces the expression of a nucleic acid sequence that shares most or all homology with the double-stranded RNA molecule. However, it has been shown that RNA interference can also be achieved using non-RNA double-stranded molecules (see, e.g., US 20070004667).

[0191] In some embodiments, the CIS inhibitor includes a nucleic acid molecule comprising and / or encoding a double-stranded region for RNA interference against Cish mRNA encoding CIS (human Cish mRNA: GenBank Accession No. NM_013324.5). The nucleic acid molecule is typically RNA, but may include chemically modified nucleotides and non-nucleotides.

[0192] The double-stranded region should be at least 19 consecutive nucleotides, such as about 19 to 23 nucleotides, or can be longer, such as 30 or 50 nucleotides or 100 nucleotides or longer. The full-length sequence corresponding to the entire gene transcript can be used. Preferably, their length is about 19 to about 23 nucleotides.

[0193] The degree of identity of the double-stranded region of the nucleic acid molecule to the target transcript should be at least 90%, more preferably 95-100%.The nucleic acid molecule may of course contain unrelated sequences which may act to stabilize the molecule.

[0194] As used herein, the term "short interfering RNA" or "siRNA" refers to a nucleic acid molecule comprising ribonucleotides capable of inhibiting or down-regulating gene expression, such as by mediating RNAi in a sequence-specific manner, wherein the double-stranded portion is less than 50 nucleotides in length, preferably about 19 to about 23 nucleotides in length. For example, the siRNA can be a nucleic acid molecule comprising self-complementary sense and antisense regions, wherein the antisense region comprises a nucleotide sequence complementary to a nucleotide sequence in a target nucleic acid molecule or a portion thereof, and the sense region has a nucleotide sequence corresponding to a target nucleic acid sequence or a portion thereof. The siRNA can be assembled from two separate oligonucleotides, wherein one strand is a sense strand and the other strand is an antisense strand, wherein the antisense strand and the sense strand are self-complementary.

[0195] As used herein, the term siRNA is intended to be equivalent to other terms used to describe nucleic acid molecules capable of mediating sequence-specific RNAi, such as microRNA (miRNA), short hairpin RNA (shRNA), short interfering oligonucleotides, short interfering nucleic acids (siNA), short interfering modified oligonucleotides, chemically modified siRNA, post-transcriptional gene silencing RNA (ptgsRNA), etc. In addition, as used herein, the term RNAi is intended to be equivalent to other terms used to describe sequence-specific RNA interference, such as post-transcriptional gene silencing, translation inhibition, or epigenetics. For example, siRNA molecules can be used to silence genes epigenetically at the post-transcriptional level or the pre-transcriptional level. In a non-limiting example, epigenetic regulation of gene expression by siRNA molecules can be produced by siRNA-mediated chromatin structure modification, thereby changing gene expression.

[0196] By "shRNA" or "short hairpin RNA" is meant an RNA molecule in which less than about 50 nucleotides, preferably about 19 to about 23 nucleotides, base pair with a complementary sequence located on the same RNA molecule, and wherein the sequence and the complementary sequence are separated by a non-pairing region of at least about 4 to about 15 nucleotides, which form a single-stranded loop over the stem structure created by the two regions of base complementarity.

[0197] Included shRNAs are two-finger or two- and multi-finger hairpin dsRNAs, in which the RNA molecule contains two or more such stem-loop structures separated by a single-stranded spacer.

[0198] Once a nucleic acid molecule comprising a double-stranded region is designed, it can be produced by any method known in the art, such as by in vitro transcription, recombinantly, or by synthetic means.

[0199] Modifications or analogs of nucleotides may be introduced to improve the properties of nucleic acid molecules. Improved properties include increased nuclease resistance and / or increased ability to penetrate cell membranes. Thus, the terms "nucleic acid molecule" and "double-stranded RNA molecule" include synthetic modified bases such as, but not limited to, inosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyladenine, 2-propyladenine and other alkyladenines, 5-halouracil, 5-halocytosine, 6-azacytosine and 6-azathymine, pseudouracil, 4-thiouracil, 8-haloadenine, 8-aminoadenine, 8-thioladenine, 8-thioalkyladenine, 8-hydroxyadenine and other 8-substituted adenines, 8-haloguanine, 8-aminoguanine, 8-thiolguanine, 8-thioalkylguanine, 8-hydroxyguanine and other substituted guanines, other aza- and deazaadenines, other aza- and deazaguanines, 5-trifluoromethyluracil, and 5-trifluorocytosine.

[0200] Chemically modified siRNAs particularly suitable for in vivo delivery are described in the art, for example, in WO2014201306, WO2007051303. Exemplary siRNAs that can be used to target Cish mRNA can be commercially obtained, for example, from ThermoFisher (Catalog Nos. 146713 and 146714); Origene (Catalog No. SR300830) and MyBioSource (Catalog No. MBS8232244).

[0201] Polynucleotide encoding a peptide or polypeptide

[0202] In some embodiments, polynucleotide-based CIS inhibitors encode one or more polypeptides so that polynucleotides are delivered to NK cells to cause the encoded peptide or polypeptide CIS protein inhibitor to express. In some embodiments, once the encoded peptide or polypeptide is expressed in NK cells, endogenous CIS protein is inhibited from interacting with one or more of its interacting partners (e.g., elongated protein B, elongated protein C, or stagnation protein-5) or target proteins (e.g., Tyr1034 phosphorylated JAK1 or any one of Tyr355, Tyr361, or Tyr392 phosphorylated IL-2Rβ).

[0203] In some embodiments, the polynucleotide encodes a dominant negative inhibitor of CIS activity. In one embodiment, the encoded dominant negative inhibitor is a polynucleotide comprising a CIS wherein the SH2 domain is inactive. 107 Arg → 107 In some embodiments, the encoded dominant negative inhibitor is a CIS comprising an amino acid sequence with a mutation in Lys(R107K). In other embodiments, the encoded dominant negative inhibitor is a CIS comprising an amino acid sequence with a mutation in the stagmin-5 binding site in the SOCS frame (e.g., P241A / L242A / P243). In other embodiments, the encoded dominant negative inhibitor is a CIS comprising an amino acid sequence with a L223A substitution.

[0204] In some embodiments, the polynucleotide CIS inhibitor encodes a programmable nuclease that inhibits CIS activity by inactivating or reducing the expression of the Cish gene. As used herein, the term "programmable nuclease" refers to a nuclease that is "targeted" ("programmed") to recognize and edit a predetermined genomic location. In some embodiments, the encoded polypeptide is a programmable nuclease that is "targeted" or "programmed" to introduce a genetic modification into the Cish gene or its regulatory region. In some embodiments, the genetic modification is a deletion or replacement in the Cish gene or its regulatory region. Such programmable nucleases are particularly suitable for generating ex vivo CIS-inhibitory Cish - / - NK cells, such as for the generation of Cish for adoptive cell therapy - / - Autologous NK cells.

[0205] In some embodiments, programmable nucleases can be programmed to recognize genomic positions by a combination of zinc finger protein (ZFP) domains bound by DNA. ZFP recognizes specific 3-bp in a DNA sequence, and a combination of ZFPs can be used to recognize a specific genomic position. In some embodiments, programmable nucleases can be programmed to recognize genomic positions by a transcription activator-like effector (TALE) DNA binding domain. In an alternative embodiment, programmable nucleases can be programmed to recognize genomic positions by one or more RNA sequences. In an alternative embodiment, programmable nucleases can be programmed by one or more DNA sequences. In an alternative embodiment, programmable nucleases can be programmed by one or more hybrid DNA / RNA sequences. In an alternative embodiment, programmable nucleases can be programmed by one or more of RNA sequences, DNA sequences, and hybrid DNA / RNA sequences.

[0206] Programmable nucleases that can be used according to the present disclosure include, but are not limited to, RNA-guided engineered nucleases (RGENs) derived from the bacterial clustered regularly interspaced short palindromic repeats (CRISPR)-cas (CRISPR-associated) system, zinc finger nucleases (ZFNs), transcription activator-like nucleases (TALENs), and argonautes.

[0207] In some embodiments, the nuclease is an RNA-guided engineered nuclease (RGEN). In some embodiments, the RGEN is from an archaeal genome or a recombinant form thereof. In some embodiments, the RGEN is from a bacterial genome or a recombinant form thereof. In some embodiments, the RGEN is from a type I (CRISPR)-cas (CRISPR-associated) system. In some embodiments, the RGEN is from a type II (CRISPR)-cas (CRISPR-associated) system. In some embodiments, the RGEN is from a type III (CRISPR)-cas (CRISPR-associated) system. In some embodiments, the nuclease is a class I RGEN. In some embodiments, the nuclease is a class II RGEN. In some embodiments, the RGEN is a multi-component enzyme. In some embodiments, the RGEN is a single-component enzyme. In some embodiments, the RGEN is CAS3. In some embodiments, the RGEN is CAS10. In some embodiments, the RGEN is CAS9. In some embodiments, the RGEN is Cpf1 (Zetsche et al., 2015). In some embodiments, the RGEN is targeted by a single RNA or DNA. In some embodiments, the RGEN is targeted by more than one RNA and / or DNA.In some embodiments, the programmable nuclease can be a DNA-programmed argonaute (WO 14 / 189628).

[0208] In some embodiments, the polynucleotide CIS inhibitor is provided in the form of an expression vector for delivery to NK cells in vivo or in vitro using any of a number of transfection methods known in the art, such as recombinant viral transduction, liposome-based transfection, electroporation, or nanoparticle-based transfection.

[0209] As used herein, "expression vector" is a DNA or RNA vector that can express one or more polynucleotides in a host cell (e.g., NK cell). The vector is typically a plasmid or a recombinant virus. Suitable expression vectors can be used, examples of which include, but are not limited to, plasmids or viral vectors. In some embodiments, the viral vector is a retrovirus, a lentivirus, an adenovirus, a herpes virus, or an adeno-associated virus vector.

[0210] Such vectors will include one or more promoters for expressing polynucleotides (such as dsRNA for gene silencing). Suitable promoters include, but are not limited to, retroviral LTRs; SV40 promoters; and human cytomegalovirus (CMV) promoters. Cellular promoters (such as eukaryotic promoters) may also be used, including but not limited to histone, RNA polymerase III (for shRNA or miRNA expression), β-actin promoters. In some embodiments, the promoter is a NK cell selective promoter, such as human NKp46 promoter (see, e.g., Walzer et al., 2007). Based on the teachings contained herein, the selection of suitable promoters will be apparent to those skilled in the art.

[0211] In other embodiments, polynucleotide CIS inhibitors are synthetic, chemically modified mRNAs encoding dominant negative CIS. Chemically modified mRNAs and their synthesis are described in detail, for example, in WO 2011 / 130624. Typically, chemically modified mRNAs include (i) 5' synthetic caps for enhancing translation; (ii) cellular interferon responses that confer RNA enzyme tolerance and attenuation, otherwise modified nucleotides that greatly reduce translation efficiency; and (iii) 3' poly-A tails. Typically, chemically modified mRNAs are synthesized in vitro from DNA templates comprising SP6 or T7 RNA polymerase promoters operably connected to an open reading frame encoding dominant negative CIS. Chemically modified mRNA synthesis reactions are carried out in the presence of a mixture of modified and unmodified nucleotides. In some embodiments, the modified nucleotides included in the in vitro synthesis of chemically modified mRNAs are pseudouridine and 5-methylcytosine. The key step in cell mRNA processing is to add a 5' cap structure, which is a 5'-5' triphosphate bond between the 5' end of RNA and a guanosine nucleotide. The cap is enzymatically methylated at the N-7 position of guanosine to form the mature mCAP. When preparing dominant-negative CIS chemically-modified mRNA, a 5' cap is typically added and then transfected into NK cells to stabilize the modified mRNA and significantly enhance translation. In some embodiments, a 4:1 mixture of a cap analog and GTP is used in the transcription reaction to obtain a 5'-capped chemically-modified mRNA. In a preferred embodiment, the anti-reverse cap analog (ARCA) 3'-O-Me-m7G(5')ppp(5')G is used to generate chemically-modified mRNA that can be efficiently translated in NK cells. Systems for in vitro synthesis are commercially available, an example of which is mRNAExpress TM mRNA synthesis kit (System Biosciences, Mountain View, Calif.). The synthesis and use of such modified RNA for in vitro and in vivo transfection is described, for example, in WO 2011 / 130624 and WO / 2012 / 138453.

[0212] Peptides

[0213] In some embodiments, a CIS inhibitor is a polypeptide that can inhibit CIS activity by at least one of a number of different mechanisms, such as specifically binding to CIS or a CIS binding partner, thereby reducing the interaction between CIS and the binding partner, or competing with CIS for the interaction with the binding partner.

[0214] Antibody

[0215] In some embodiments, the CIS inhibitor is an antibody or CIS binding fragment thereof that binds to CIS and inhibits its interaction with a binding partner or target protein.Preferably, the antibody is an antibody modified to penetrate or be taken up (passively or actively) into mammalian cells, particularly NK cells.

[0216] As used herein, the term "antibody" includes polyclonal antibodies, monoclonal antibodies, bispecific antibodies, fusion dimers, tribodies, heterologous conjugate antibodies and chimeric antibodies. It is also envisioned that antibody fragments that retain at least most (about 10%) antigen binding relative to the corresponding full-length antibody. Such antibody fragments are referred to as "antigen-binding fragments" herein. Antibodies include many forms of modifications, including, for example, but not limited to, domain antibodies (including VH or VL domains), dimers of heavy chain variable regions (VHH, as described for Camelidae), dimers of light chain variable regions (VLL), Fv fragments containing only light chain (VL) and heavy chain (VH) variable regions (which can be connected directly or through a linker) or Fd fragments containing heavy chain variable regions and CH1 domains.

[0217] The term "antibody" also encompasses scFv consisting of the variable regions of heavy and light chains (linked together to form single-chain antibodies), and oligomers of scFv (such as dimers and trimers). It also encompasses fragments of antibodies containing a portion of the variable region and constant region, such as Fab, (Fab')2 and FabFc2 fragments. It also encompasses antibody fragments and oligomers of antibody fragments grafted with complementary determining regions (CDRs). The heavy and light chain components of Fv can be derived from the same antibody or different antibodies, thereby producing a chimeric Fv region. The antibody can be of animal (e.g., mouse, rabbit or rat) or human origin, or can be chimeric or humanized.

[0218] As used herein, the term "antibody" includes these various forms. Antibodies for use in the methods of the present invention can be readily prepared using the guidelines provided herein and those methods well known to those skilled in the art (these methods are described in the references cited above and in publications such as Harlow & Lane, Antibodies: a Laboratory Manual, Cold Spring Harbor Laboratory, (1988)).

[0219] The antibody can be an Fv region comprising a variable light chain (VL) and a variable heavy chain (VH), wherein the light chain and the heavy chain can be connected directly or through a linker. As used herein, a linker refers to a molecule that is covalently attached to the light chain and the heavy chain and provides sufficient spacing and flexibility between the two chains so that they can achieve a conformation in which they can specifically bind to the epitope to which they are directed. Protein linkers are particularly preferred because they can be expressed as an intrinsic component of the Ig portion of the fusion polypeptide.

[0220] In another embodiment, a recombinantly produced single-chain scFv antibody, preferably a humanized scFv, is used in the methods of the invention.

[0221] In one embodiment, the antibody has intracellular delivery capability. Antibodies with intracellular delivery capability include antibodies such as the following: camelid and llama antibodies, shark antibodies (IgNAR), scFv antibodies, endosomes or nanobodies (e.g., scFv endosomes and VHH endosomes). Yeast SPLINT antibody libraries can be used to test endosomes that can destroy protein-protein interactions. Such reagents may include cell-penetrating peptide sequences or nuclear localization peptide sequences, such as those disclosed by Constantini et al. (2008). Also useful for in vivo delivery are Vectocell or Diato peptide carriers, such as those disclosed by De Coupade et al. (2005).

[0222] In addition, the antibody can be fused to a cell penetrating agent, such as a cell penetrating peptide. Cell penetrating peptides include Tat peptides, penetrating proteins (Penetratin), short amphipathic peptides (such as those from Pep and MPG families), oligoarginine and oligolysine. In one example, the cell penetrating peptide is also conjugated to a lipid (C6-C18 fatty acid) domain to improve intracellular delivery (Koppelhus et al., 2008). Examples of cell penetrating peptides can be found in Howl et al. (2007) and Deshayes et al. (2008). Therefore, the present invention also provides therapeutic uses of antibodies fused to cell penetrating peptide sequences at optionally N-terminal or C-terminal ends via a covalent bond (e.g., peptide bond).

[0223] Antibodies targeting CIS are available from a number of sources, such as Santa Cruz Biotechnology (eg, catalog number sc-74581).

[0224] CIS suppressor NK cells

[0225] Any CIS inhibitor suitable for inhibiting CIS in ex vivo NK cells (e.g., in cultured NK cells) to obtain CIS-inhibitory NK cells can be used for adoptive cell therapy of NK-responsive disorders. In some embodiments, the CIS-inhibitory NK cells to be administered are autologous, i.e., derived from the subject to be treated. In other embodiments, the CIS-inhibitory NK cells to be administered are allogeneic NK cells.

[0226] In some embodiments, CIS inhibitory NK cells are NK cells genetically modified to have reduced CIS expression.For example, in some embodiments, CIS inhibitory NK cells are obtained by transient or stable transfection or viral transduction of CIS shRNA or CIS antisense expression vectors, and the CIS shRNA or CIS antisense expression vectors, when expressed, reduce the expression level of CIS in genetically modified cells.In other embodiments, CIS inhibitory NK cells are genetically modified NK cells, in which one or two Cish alleles are modified by targeted genomes, such as by the deletion of one or more exons, the introduction of stop codons or the inactivation of promoters.The method for modifying genomic loci in cell lines and primary cells has been well established in the field.For example, programmable nucleases (e.g., Cas9-CRISPR systems) are very effective and routinely used for targeted breaks of genes.

[0227] In other embodiments, NK cells are contacted ex vivo with a CIS inhibitor, such as a peptide, peptidomimetic, polynucleotide, or polypeptide.

[0228] NK cells can be obtained by any of a number of different methods, including isolation and expansion of NK cells from a primary source, differentiation and expansion from hematopoietic stem cells (HSCs), differentiation and expansion from human induced pluripotent stem cells (hiPSCs), or differentiation from another pluripotent stem cell type.

[0229] In some embodiments, for autologous adoptive cell therapy, NK cells are isolated from a human subject, such as a patient to be treated.

[0230] NK cells can be isolated or enriched by staining cells from a tissue source (e.g., peripheral blood) with antibodies to CD56 and CD3 and selecting for CD56 + CD3 - TSNK cells. TSNK cells can be isolated using a commercially available kit, such as an NK cell isolation kit (Miltenyi Biotec). NK cells can also be isolated or enriched by removing cells other than NK cells from a cell population containing NK cells. For example, NK cells can be isolated or enriched by consuming cells showing non-NK cell markers using antibodies such as CD3, CD4, CD14, CD19, CD20, CD36, CD66b, CD123, HLA DR, and / or CD235a (glycophorin A). Negative separation can be performed using a commercially available kit, such as an NK cell negative separation kit (Dynal). Cells separated by these methods can be additionally sorted, for example to separate CD56 + / CD16 - and CD56- / CD16 + cell.

[0231] Cell separation can be achieved, for example, by flow cytometry, fluorescence activated cell sorting (FACS), or preferably magnetic cell sorting using microbeads conjugated to specific antibodies. Cells can be separated, for example, using magnetic activated cell sorting (MACS) technology, a method of separating particles based on their ability to bind magnetic beads (e.g., about 0.5-100 μM diameter) containing one or more specific antibodies (e.g., anti-CD56 antibodies). Magnetic cell separation can be performed using, for example, AUTOMACS TM Separator (Miltenyi) is carried out and automated. Many useful modifications can be carried out on magnetic microspheres, including covalent addition of antibodies that specifically recognize specific cell surface molecules or haptens. Then the beads are mixed with cells to allow binding. Then the cells are passed through a magnetic field to separate cells with specific cell surface markers. In one embodiment, these cells can then be separated and remixed with magnetic beads coupled to antibodies for other cell surface markers. Cells are passed through a magnetic field again to separate cells that bind two antibodies. These cells can then be diluted to a separate culture dish, such as in a microtiter dish for clonal separation.

[0232] Differentiation of human NK cells from HSCs is described, for example, in US8,926,964, and differentiation of human NK cells from hiPSCs is described in US20130287751.

[0233] Methods for culturing and expanding NK cells, particularly human NK cells, to obtain clinical-grade NK cells for adoptive cell therapy are described in the art, as reviewed, for example, by Childs et al. (2013).

[0234] Administration of CIS inhibitors

[0235] In some embodiments, a method of treating a subject having a NK-responsive disorder or preventing such a disorder comprises administering to the subject a pharmaceutical composition containing at least one CIS inhibitor or a pharmaceutically acceptable salt, pharmaceutically acceptable N-oxide, pharmaceutically active metabolite, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof in a therapeutically effective amount.

[0236] CIS inhibitors are administered to prevent, cure or at least partially prevent symptoms of patients who have and / or are diagnosed with NK responsiveness disorders (e.g., cancer or infection). The effective amount for this use will depend on the severity and course of the infection, previous therapy, the patient's health, body weight, response to treatment, and tolerance of the infectious agent to treatment. This is considered good for those skilled in the art who determine such therapeutically effective amounts by routine experiments (including but not limited to dose escalation clinical trials).

[0237] In preventive applications, compositions containing CIS inhibitors are administered to patients susceptible to or at risk of developing NK responsive disorders (e.g., cancer or infection), for example, individuals who are immunocompromised (for prevention of infection) or highly susceptible to a particular type of cancer based on genotype. This amount is defined as a "prophylactically effective amount or dose," i.e., a dose sufficient to prevent or reduce the occurrence of infection. In this use, the exact amount also depends on the specific disorder, the patient's health, weight, time schedule, etc. It is considered good for those skilled in the art to determine such a preventively effective amount by routine experiments (e.g., a dose escalation clinical trial).

[0238] In the event that the subject's condition does improve, the administration of the CIS inhibitor may be given continuously, based on reliable medical advice; or the dose of the administered drug may be temporarily reduced or temporarily stopped for a certain length of time (i.e., a "drug holiday"). The length of the drug holiday may vary between 2 days and 1 year, including, by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, 35 days, 50 days, or 60 days. The dose reduction during the drug holiday may be 10%-100%, including, by way of example only, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.

[0239] The amount of a given CIS inhibitor suitable as a therapeutically effective dose will vary depending on factors such as the type and potency of the CIS inhibitor to be administered, the severity / stage of the subject's health condition, the characteristics of the subject or host in need of treatment (e.g., body weight), and previous or concurrent treatments, but can still be routinely determined in a manner known in the art based on the specific circumstances surrounding the case, including, for example, the specific agent administered, the route of administration, the condition being treated, and the subject or host being treated. However, in general, dosages for adult treatment will typically be in the range of 0.02-5000 mg per day or about 1-1500 mg per day. The desired dosage can be conveniently provided in a single dose or in divided doses administered simultaneously (or over a short period of time) or at appropriate intervals, for example, twice, three times, four times or more sub-doses per day.

[0240] The foregoing ranges are merely suggestive, as the number of variables regarding a single treatment regimen is large, and large deviations from these recommended values ​​are not uncommon. Such dosages may vary depending on many variables, not limited to the activity of the CIS inhibitor used, the type and severity of the NK cell responsiveness disorder to be treated, the mode of administration, and the judgment of the practitioner.

[0241] Toxicity and therapeutic efficacy of such treatment regimens can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, including but not limited to LD 50 (a dose lethal to 50% of the population) and ED 50 The dose ratio between toxic and therapeutic effects is the therapeutic index, which can be expressed as LD 50 and ED 50 The ratio between . CIS inhibitors that exhibit a high therapeutic index are preferred. Data obtained from cell culture assays and animal studies can be used to formulate a range of doses for use in human and non-human subjects. The dose of such compounds is preferably within the range that includes the ED with minimal toxicity. 50 The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.

[0242] Administration of CIS suppressive NK cells

[0243] NK suppressor cells can be administered by any suitable route known in the art. In some embodiments, cells are administered systemically by intra-arterial or intravenous infusion. It will be appreciated by those skilled in the art that the route of administration of selected CIS suppressor NK cells will depend in part on the specific NK responsiveness disorder to be treated. For example, in the case where the subject suffers from the presence of one or more tumors, in some embodiments, the route of administration will include intratumoral administration and / or peritumoral administration. Other exemplary routes of administration include intraperitoneal, intrathecal and intralymphatic administration.

[0244] The CIS suppressor NK cells can be administered to an individual in any amount or quantity that produces a detectable therapeutic or prophylactic benefit to the individual, such as an effective amount, wherein the individual has cancer or a viral infection. In some embodiments, the dose of CIS suppressor cells to be administered is simply the absolute number of cells, for example, about 1×10 5 cells, 5×10 5 cells, 1×10 6 cells, 7×10 6 cells, 1×10 7 cells, 6×10 7 cells, 2×10 8 cells, 5×10 8 cells, 1×10 9 cells, 6×10 9 cells, 2×10 10 cells, 5×10 10 cells or 1×10 11 cells.

[0245] In other embodiments, the CIS suppressor NK cells are present in a number relative to the body weight of the subject to be treated, for example, about 1×10 cells / kg of the subject to be treated. 5 cells, 5×10 5 cells, 1×10 6 cells, 7×10 6 cells, 1×10 7 cells, 6×10 7 cells, 2×10 8 cells, 5×10 8 cells, 1×10 9 cells or 6×10 9 The cells are administered to a subject.

[0246] In other embodiments, in the case where the subject to be treated suffers from one or more tumors, CIS inhibitory NK cells are administered according to the CIS inhibitory NK cells and the roughly required ratio of the number of tumor cells in the subject to be treated. For example, CIS inhibitory NK cells can be administered with a ratio (NK cells and tumor cells) of about 1: 1, 1: 1, 3: 1, 4: 1, 5: 1, 9: 1, 10: 1, 15: 125: 1, 30: 1, 40: 1, 50: 1, 55: 1, 60: 1, 65: 1, 75: 1, 80: 1, 90: 1, 95: 1 or 100: 1. The number of tumor cells can be estimated by, for example, determining the number of tumor cells in a tissue sample (e.g., a blood sample, a biopsy sample, etc.). In some embodiments, for example, for solid tumors, the number of tumor cells can be estimated by a combination of cell counting and tumor imaging in a biopsy sample to estimate the tumor volume and the number of resident cells.

[0247] Combination therapy

[0248] CIS inhibitors and CIS inhibitory NK cell compositions can also be used in combination with other agents of therapeutic value in the treatment of NK responsive health conditions (e.g., cancer and viral infections). Generally speaking, other agents do not necessarily have to be administered in the same pharmaceutical composition, and due to different physical and chemical characteristics, they can preferably be administered in different ways. If possible, in the same pharmaceutical composition, the feasibility of the mode of administration and administration is determined within the knowledge of a skilled clinician. Initial administration can be performed according to established protocols known in the art, and then, based on the observed effects, a skilled clinician can modify dosage, mode of administration, and time of administration.

[0249] Depending on the nature and stage of the infection, the patient's condition and the actual choice of therapeutic agent used, the CIS inhibitor and the additional therapeutic agent can be administered simultaneously (e.g., simultaneously, substantially simultaneously or within the same treatment regimen) or sequentially. During the treatment regimen, after evaluating the disease being treated and the patient's condition, the determination of the order of administration of each therapeutic agent and the number of repeated administrations is within the knowledge of a skilled physician.

[0250] It is known to those skilled in the art that when drugs are used in therapeutic combinations, the therapeutically effective dose can vary. Methods for experimentally determining therapeutically effective doses of drugs and other agents for use in combination therapy regimens are described in the literature. For example, the use of metronomic dosing, i.e., providing more frequent, lower doses to minimize toxic side effects, has been extensively described in the literature. Combination therapy also includes periodic treatments that are started and stopped at different times to assist in the clinical management of the patient.

[0251] For combination therapy, dosages of co-administered therapeutic agents will, of course, vary depending on the type of co-agent utilized, on the particular CIS inhibitor and on the NK cell responsive disorder being treated.

[0252] It is understood that the dosage regimen for treating, preventing or ameliorating one or more conditions for which relief is sought may be modified according to a number of factors. These factors include the condition from which the subject suffers, as well as the age, weight, sex, diet and general medical condition of the subject. Therefore, the dosage regimen actually utilized may vary widely, so the dosage regimens shown herein may be deviated from.

[0253] The CIS inhibitor and other therapeutic agents constituting the combined therapy disclosed herein can be a combined dosage form or a separate dosage form intended to be administered substantially simultaneously. The medicaments constituting the combined therapy can also be administered in sequence, wherein any of the therapeutic compounds is administered by a scheme requiring two-step administration. The two-step administration scheme may require the administration of an active agent in sequence or the administration of a separate active agent separately. Depending on the properties of each medicament, such as the efficacy, solubility, bioavailability, plasma half-life and kinetic characteristics of the medicament, the time period between multiple administration steps can be in the range of several minutes to several hours. The circadian rhythm changes of many physiological parameters can also be evaluated to determine the optimal dose interval.

[0254] In addition, the administration or co-administration of CIS inhibitors for treating infection can be used in conjunction with a variety of procedures that may provide additional or synergistic benefits to the patient. By way of example only, a patient may undergo genetic testing to identify genetic variations in their own genome or the genome of the pathogen to optimize treatment parameters, such as the type of CIS inhibitor to be administered, dosing regimen, and co-administration with additional therapeutic agents.

[0255] Initial administration can be via any practical route, such as, for example, intravenous injection, bolus injection, infusion over 5 minutes to about 5 hours, pills, capsules, inhalation, injection, transdermal patch, buccal delivery, etc. or a combination thereof. After the occurrence of a disease or condition is detected or suspected, the compound should be administered as soon as practicable and for the length of time required to treat or prevent the NK cell responsiveness disorder.

[0256] Optionally, when combined with treatment with a CIS inhibitor, a therapeutically effective dose of IL-15 or an IL-15 agonist may also be administered to the subject. IL-15 agonists include functional homologues of IL-15, such as those described by Wu (2013). In other embodiments, any treatment of the present invention may also include the administration of one or more immunotherapeutics. Immunotherapeutics suitable for use in combination with CIS inhibition or in combination with IL-15 or an IL-15 agonist for CIS inhibition may include, but are not limited to, antibodies against programmed cell death 1 receptor (PD-1), antibodies against programmed death ligand 1 (PD-L1), antibodies against cytotoxic T lymphocyte-associated protein 4 (CTLA-4), antibodies against transforming growth factor beta (TGF-b), antibodies against Tactile (CD96), or combinations thereof.

[0257] In other embodiments, in other embodiments, any treatment of the present invention may also include the administration of a B-Raf protein kinase inhibitor or a MEK protein kinase inhibitor. Examples of B-Raf protein kinase inhibitors include, but are not limited to, PLX4032 (Vemurafenib), PLX-4720, Dabrafenib (GSK2118436), AZ628, RAF265 (CHIR-265), Encorafenib (LGX818), SB590885, and combinations thereof. Examples of MEK protein kinase inhibitors include, but are not limited to, Trametinib (GSK1120212), Cobimetinib (Cobimetinib), Binimetinib (MEK162), Selumetinib (PD-325901), and combinations thereof. In some embodiments, any of the above treatments may additionally include the administration of a TGF-β receptor antagonist. Examples of suitable TGF-β receptor antagonists include, but are not limited to, Galunisertib (LY2157299), GW 788388, LY 364947, R268712, SB 525334, and SD208.

[0258] Dosage form

[0259] Compositions for use in the present invention may be formulated for administration to a subject via any conventional means, including but not limited to oral, parenteral (eg, intravenous, subcutaneous, or intramuscular), buccal, inhalation, intranasal, rectal, or transdermal routes of administration.

[0260] Pharmaceutical compositions comprising a CIS inhibitor (e.g., a peptide mimetic), alone or in combination with one or more other therapeutic agents, can be formulated into any suitable dosage form, including, but not limited to, aqueous oral dispersions, liquids, sprays, gels, syrups, elixirs, slurries, suspensions, and the like for oral ingestion by a patient to be treated, solid oral dosage forms, aerosols, controlled release formulations, fast melt formulations, effervescent formulations, lyophilized formulations, tablets, powders, pills, dragees, capsules, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate and controlled release formulations.

[0261] Pharmaceutical preparations for oral use can be obtained by the following steps: one or more solid excipients are mixed with one or more compounds, the resulting mixture is optionally ground, and after adding suitable adjuvants (if necessary), the granular mixture is processed to obtain tablets or dragee cores. Suitable excipients include, for example, fillers, such as sugars, including lactose, sucrose, mannitol or sorbitol; cellulose preparations, such as, for example, corn starch, wheat starch, rice starch, potato starch, gelatin, tragacanth gum, methylcellulose, microcrystalline cellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose; or other fillers such as: polyvinyl pyrrolidone (PVP or povidone) or calcium phosphate. If necessary, disintegrants such as cross-linked sodium carboxymethyl cellulose, polyvinyl pyrrolidone, agar or alginic acid or its salts such as sodium alginate can be added.

[0262] In another aspect, the dosage form can include a microencapsulated formulation. In some embodiments, one or more compatible materials are present in the microencapsulated material. Exemplary materials include, but are not limited to, pH regulators, corrosion promoters, defoamers, antioxidants, flavoring agents, and carrier materials such as binders, suspending agents, disintegrants, fillers, surfactants, solubilizers, stabilizers, lubricants, wetting agents, and diluents.

[0263] Microencapsulated formulations of CIS inhibitors can be prepared by methods known to those of ordinary skill in the art. These known methods include, for example, spray drying, turntable-solvent method, hot melt method, spray cooling method, fluidized bed, electrostatic deposition, centrifugal extrusion, rotary suspension separation, polymerization at liquid-gas or solid-gas interface, pressure extrusion or spray solvent extraction bath. In addition to these methods, a variety of chemical techniques can also be used, such as complex coacervation, solvent evaporation, polymer-polymer incompatibility, interfacial polymerization in liquid medium, in-situ polymerization, drying in liquid and desolvation in liquid medium. In addition, other methods such as rolling, extrusion / spheronization, coacervation or nanoparticle coating can also be used.

[0264] Solid oral dosage forms of drugs including preparations can also be formulated to provide controlled release of CIS inhibitors. Controlled release refers to the release of one or more active agents from the dosage forms into which they are incorporated over an extended period of time according to the desired characteristics. Controlled release characteristics include, for example, sustained release, extended release, pulse release, and delayed release characteristics. Compared with immediate release compositions, controlled release compositions allow the delivery of medicaments to the subject over an extended period of time according to predetermined characteristics. This rate of release can provide medicaments of therapeutically effective levels over an extended period of time, thereby providing a long-term pharmacological response compared to traditional immediate release dosage forms, while minimizing side effects. This long-term response provides many inherent benefits that the corresponding short-acting immediate release formulations do not achieve.

[0265] In some embodiments, solid dosage forms can be formulated as enteric coated delayed release oral dosage forms, i.e., oral dosage forms of pharmaceutical compositions that utilize enteric coatings to affect the release in the small intestine of the gastrointestinal tract. Enteric coated dosage forms can be compression or molding or extruded tablets / castings (coated or uncoated) of granules, powders, pellets, beads or particles containing active ingredients and / or other composition components (which themselves are coated or uncoated). Enteric coated oral dosage forms can also be capsules (coated or uncoated) of pellets, beads or particles containing solid carriers or compositions (which themselves are coated or uncoated).

[0266] As used herein, the term "delayed release" refers to such delivery: it allows release to be achieved at some generally predictable positions in the intestinal tract, away from the position that can be achieved without change in delayed release. In some embodiments, the method for delayed release is coating. Any coating should be applied to a sufficient thickness so that the entire coating is insoluble in gastrointestinal fluids at a pH less than about 5, but dissolves at a pH of about 5 and greater. It is expected that any anionic polymer that exhibits pH-dependent solubility characteristics can be used as an enteric coating in the methods and compositions for achieving delivery to the lower gastrointestinal tract. In some embodiments, the polymer is an anionic carboxyl polymer.

[0267] In some embodiments, the coating can and usually does contain a plasticizer and possibly other coating excipients well known in the art, such as colorants, talc and / or magnesium stearate. Suitable plasticizers include triethyl citrate (Citroflex 2), triacetin (triacetin), acetyl triethyl citrate (Citroflec A2), Carbowax400 (polyethylene glycol 400), diethyl phthalate, tributyl citrate, acetylated monoglycerides, glycerol, fatty acid esters, propylene glycol and dibutyl phthalate. Specifically, anionic carboxylic acrylic polymers will usually contain 10-25% by weight of plasticizer, particularly dibutyl phthalate, polyethylene glycol, triethyl citrate and triacetin. Coatings are applied using traditional coating techniques such as spray coating or pan coating. The coating thickness must be sufficient to ensure that the oral dosage form remains intact until the desired local delivery site is reached in the intestinal tract.

[0268] In addition to plasticizers, colorants, anti-adherents, surfactants, defoamers, lubricants (eg, carnauba wax or PEG) may be added to the coating to solubilize or disperse the coating material and improve coating properties and coated products.

[0269] In other embodiments, a pulse dosage form is used to deliver a CIS inhibitor formulation. The pulse dosage form can provide one or more rapid-release pulses at a predetermined time point or at a specific site after the control lag time. The pulse dosage form can be administered using many pulse preparations known in the art. For example, such preparations include but are not limited to those described in US 5,011,692, 5,017,381, 5,229,135 and 5,840,329. Other pulse release dosage forms suitable for the preparations of the present invention include but are not limited to, for example, US 4,871,549, 5,260,068, 5,260,069, 5,508,040, 5,567,441 and 5,837,284. In one embodiment, a controlled release dosage form is a pulse release solid oral dosage form comprising at least two groups of particles (i.e., multi-particles), each group containing a preparation. The first group of particles provides a substantially rapid-release dose of the CIS inhibitor when ingested. The first group of particles can be uncoated or include a coating and / or a sealant. The second group of particles includes coated particles mixed with one or more binders, the coated particles comprising about 2% to about 75%, about 2.5% to about 70%, or about 40% to about 70% of the total amount of the total dose of active agent in the formulation. The coating includes a pharmaceutically acceptable ingredient in an amount sufficient to provide a delay of about 2 hours to about 7 hours after ingestion before the release of the second dose. Suitable coatings include one or more differentially degradable coatings, such as, by way of example only, pH sensitive coatings (enteric coatings), such as acrylic resins blended alone or with cellulose derivatives (e.g., ethylcellulose), or non-enteric coatings having variable thickness to provide differential release of the formulation.

[0270] Many other types of controlled release systems are known to those of ordinary skill in the art and are suitable for use with the formulations. Examples of such delivery systems include, for example, polymer-based systems such as polylactic and polyglycolic acids, polyanhydrides and polycaprolactones; porous matrices, non-polymer-based systems (which are lipids), including sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as monoglycerides, diglycerides and triglycerides; hydrogel release systems; silicone rubber systems; peptide-based systems; wax coatings, bioerodible dosage forms, compressed tablets using traditional adhesives, and the like. See, e.g., U.S. Patents 4,327,725, 4,624,848, 4,968,509, 5,461,140, ​​5,456,923, 5,516,527, 5,622,721, 5,686,105, 5,700,410, 5,977,175, 6,465,014, and 6,932,983.

[0271] Liquid preparation dosage forms for oral administration may be aqueous suspensions selected from, but not limited to, pharmaceutically acceptable aqueous oral dispersions, emulsions, solutions, elixirs, gels and syrups.

[0272] Aqueous suspensions and dispersants can maintain a homogeneous state as defined in The USP Pharmacists'Pharmacopeia (2005 edition, Chapter 905) for at least 4 hours. Homogeneity should be determined by a sampling method consistent with the homogeneity of the entire composition. In one embodiment, an aqueous suspension can be resuspended as a homogeneous suspension by continuing physical stirring less than 1 minute. In another embodiment, an aqueous suspension can be resuspended as a homogeneous suspension by continuing physical stirring less than 45 seconds. In yet another embodiment, an aqueous suspension can be resuspended as a homogeneous suspension by continuing physical stirring less than 30 seconds. In yet another embodiment, a homogeneous aqueous dispersion can be maintained without stirring.

[0273] In addition to the additives listed above, liquid preparations may also include inert diluents commonly used in the art, such as water or other solvents, solubilizers and emulsifiers. Exemplary emulsifiers are ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, sodium lauryl sulfate, sodium docusate, cholesterol, cholesterol esters, taurocholic acid, phosphatidylcholine, oils such as cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol, fatty acid esters of sorbitan or mixtures of these substances, etc.

[0274] Injectable preparations

[0275] Preparations suitable for intramuscular, subcutaneous or intravenous injection may include physiologically acceptable sterile aqueous or non-aqueous solutions, dispersants, suspensions or emulsions and sterile powders for reconstitution into sterile injectable solutions or dispersants. Examples of suitable aqueous and non-aqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol, cremophor, etc.), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Suitable fluidity can be maintained, for example, by using a coating such as lecithin, by maintaining the desired particle size and by using a surfactant for dispersion. Preparations suitable for subcutaneous injection may also contain additives, such as preservatives, wetting agents, emulsifiers and dispersants. Prevention of microbial growth may be ensured by a variety of antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, etc. It may also be desirable to include isotonic agents such as sugars, sodium chloride, etc. Prolonged absorption of the injectable drug form can be brought about by the use of agents delaying absorption, such as aluminum monostearate and gelatin.

[0276] For intravenous injection, the compound can be formulated in an aqueous solution, preferably in a physiologically compatible buffer such as Hanks solution, Ringer's solution or physiological saline buffer. For transmucosal administration, a penetrant suitable for the barrier to be penetrated is used in the formulation. Such penetrants are generally known in the art. For other parenteral injections, appropriate formulations may include aqueous or non-aqueous solutions, preferably physiologically compatible buffers or excipients. Such excipients are generally known in the art.

[0277] Parenteral injection may involve bolus injection or continuous infusion. Injectable preparations may be provided in unit dosage form, such as ampoules or multidose containers with preservatives added. Pharmaceutical compositions may be in a form suitable for parenteral injection, as a sterile suspension, solution or emulsion soluble in an oily or aqueous vehicle, and may contain preparatants such as suspending agents, stabilizers and / or dispersants. Pharmaceutical preparations for parenteral administration include aqueous solutions of active compounds in water-soluble form. In addition, suspensions of active compounds may be prepared into suitable oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may include substances that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol or dextran. Optionally, the suspension may also include a suitable stabilizer or an agent that increases the solubility of the compound to allow the preparation of a high concentration solution. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle (eg, sterile pyrogen-free water) before use.

[0278] The pharmaceutical composition can be a unit dosage form suitable for single administration of an exact dose. In a unit dosage form, the preparation is divided into unit doses containing an appropriate amount of one or more compounds. The unit dose can be in the form of a package containing a discontinuous amount of preparation. Non-limiting examples are powders in packaged tablets or capsules and vials or ampoules. Aqueous suspension compositions can be packaged in single-dose non-reusable openable containers. Alternatively, a multi-dose reusable openable container can be used, in which case a preservative is usually included in the composition. As an example only, preparations for parenteral injection can be provided in unit dosage form, including but not limited to ampoules or multi-dose containers added with a preservative.

[0279] Methods for Identifying CIS Inhibitors

[0280] Also provided are methods for identifying CIS inhibitors, i.e., "screening" methods. In some embodiments, the screening method comprises at least the following steps: (i) contacting CIS or a fragment thereof with at least one CIS binding partner in the presence of a test agent; and (ii) determining whether the test agent competes with the CIS protein binding partner for binding to CIS or a fragment thereof. In some embodiments, the CIS binding partner used in the assay is selected from JAK1, IL-2Rβ, elongin B, elongin C, or tardatin 5, or a fragment thereof.

[0281] In some embodiments, the method is performed in vitro using substantially pure protein components. In other embodiments, the method can be performed on protein components that are naturally or heterologously expressed in cells. In some embodiments, one or more protein components can also include a label to facilitate detection of the labeled protein in the assay, such as a small epitope tag, a fusion fluorescent protein, a fluorophore, or any other label that facilitates direct or indirect detection (e.g., by using an antibody) of the labeled protein. In other embodiments, the protein to be assayed does not require labeling.

[0282] Methods for identifying CIS inhibitors that inhibit the interaction of CIS with binding partners and target proteins include, but are not limited to, ELISA-type assays, fluorescence resonance energy transfer (FRET) and time-resolved (TR) FRET assays and AlphaScreen-based TM Bead interaction, chemical cross-linking followed by High-Mass MALDI mass spectrometry (see, e.g., Arkin et al. (2012), Inhibition of Protein-Protein Interactions: Non-Cellular Assay Formats; Sittampalam et al., eds.; Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences). High-throughput assay formats are particularly useful for screening large libraries of test agents for suitable test agents.

[0283] Alternatively, screening for inhibitors of protein-protein interactions can be performed in cells, for example in protein complementation assays and "two-hybrid" or "three-hybrid" assays using yeast, bacteria or mammalian assay systems. Such assays and their use in discovering protein-protein interaction inhibitors are described in the art, for example in Male et al. (2013).

[0284] In other embodiments, the screening method comprises the following steps: (i) contacting CIS or its fragment with a test agent; and (ii) determining whether the test agent is bound to CIS or its fragment. In some embodiments, the method also includes determining whether the test agent competes with a CIS PEST domain peptide or a CIS N-terminal peptide for the binding of CIS or its fragment. Although not wishing to be bound by theory, it is believed that such peptides correspond to the autoinhibitory domain in CIS. Therefore, it can be expected that the test agent that can compete with such autoinhibitory peptides for the binding of CIS also inhibits CIS activity, such as increasing JAK kinase activity as described herein. In some embodiments, the sequence of the CIS PEST domain peptide used in the above-mentioned determination is selected from SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 32 and SEQ ID NO: 37. In other embodiments, the sequence of the N-terminal domain peptide used in the determination is selected from SEQ ID NO: 31 and 34. Many assays for detecting binding of analytes to target proteins are known in the art, including but not limited to optical biosensor assays (e.g., based on surface plasmon resonance, optical gradient or interferometry), mass spectrometry, isothermal calorimetry, differential scanning calorimetry and differential scanning fluorimetry, NMR, X-ray crystallography. High-throughput affinity-based assays for identifying protein binding compounds are reviewed, for example, by Zhu et al. (2009). The use of small molecule microarrays is also contemplated, as described, for example, by Casalena et al. (2012). Optical or fluorescence detection, such as, for example, fluorescence activated cell sorting (FACS) using mass spectrometry, MALDI-TOF, biosensor technology, evanescent fiber optics or fluorescence resonance energy transfer is clearly encompassed within the scope of the present invention.

[0285] Also envisioned is a screening method based on monitoring the effect of a test agent on CIS activity assessed in vitro. In some embodiments, the screening is an in vitro biochemical assay to assess the effect of a test agent on the ability of CIS to increase the ubiquitination of a target protein (e.g., JAK1), wherein the assay comprises the following steps:

[0286] (i) incubating a phosphorylated JAK1 protein (e.g., JAK1 phosphorylated at Tyr1034) or a CIS-binding fragment thereof in vitro in the presence of:

[0287] (a) a trimeric complex comprising CIS or a fragment thereof, wherein the CIS or a fragment thereof comprises at least an SH2 domain and a SOCS box; extensin B and extensin C;

[0288] (b) ubiquitination mixture; and

[0289] (c) test reagents; and

[0290] (ii) determining whether the test agent inhibits CIS-induced ubiquitination of the phosphorylated JAK1 protein or its CIS-binding fragment relative to the level of CIS-induced ubiquitination in the absence of the test agent. Test agents that reduce CIS-dependent ubiquitination of JAK1 or fragments are considered candidate CIS inhibitors.

[0291] In an exemplary embodiment, the CIS E3 ligase complex (trimeric CIS-elongin B-elongin C with tardatin 5 and Rbx2; 2.5 μM) was incubated with ubiquitin (50 μM), human E1 (100 nM), purified recombinant E2 (UbcH5c, 2.5 μM) and Flag-tagged full-length JAK1 at 37°C for various times in the presence of 2.5 mM Mg / ATP. FLAG-tagged phosphorylated JAK1 was generated by expressing in 293T cells and recovered by immunoprecipitation with anti-FLAG and elution of free FLAG peptide. JAK1 ubiquitination was visualized by Western blotting with anti-phospho-JAK1 followed by separation on a 4-20% Tris / glycine gel. High-throughput screening for modulators of E3 ligase activity has been described in the art, for example in Rossi et al. (2014), and such screening platforms are also commercially available, such as the UbiPro TM Drug discovery platform.

[0292] In other embodiments, the screening method for identifying CIS inhibitors is an in vitro biochemical assay that evaluates the effect of a test agent on the ability of CIS to inhibit JAK1 kinase activity, wherein the assay comprises the following steps:

[0293] i) incubating a JAK1 protein or a fragment thereof comprising a JH1 kinase domain in vitro in the presence of:

[0294] (a) a trimeric complex comprising CIS or a fragment thereof, wherein the CIS or a fragment thereof comprises at least an SH2 domain and a SOCS box; extensin B and extensin C;

[0295] (b) JAK1 kinase substrates; and

[0296] (c) test reagents; and

[0297] ii) determining whether the test agent increases phosphorylation of the JAK1 kinase substrate relative to phosphorylation of the JAK1 kinase substrate in the absence of the test agent. Test agents that reduce CIS-dependent inhibition of JAK1 kinase activity, i.e., increase JAK1 kinase activity relative to JAK1 kinase activity in the absence of the test agent, are considered candidate CIS inhibitors.

[0298] In some embodiments, the JAK1 kinase substrate to be tested is STAT5 or a STAT5 peptide. In some embodiments, the amino acid sequence of the STAT5 peptide substrate to be used is: SEQ ID NO: 18RRAKAADGYVKPQIKQVV.

[0299] Protein kinase assays, including high throughput kinase assays, are known in the art, as described, for example, in Babon et al. (2013) and Von Ahsen et al. (2005). In an exemplary embodiment, 130 μM STAT5b peptide (SEQ ID NO: 18RRAKAADGYVKPQIKQVV) was mixed with 5 nM human JAK1 (see SEQ ID NO: 11 for the corresponding amino acid sequence) in 20 mM Tris pH 8.0, 100 mM NaCl, 5 mM 2-mercaptoethanol, 0.2 mg ml -1 BSA, 2 mM MgCl2, 100 μM ATP, and 1 μCi γ-[ 32 P]ATP was incubated at 25°C for 30–60 min. The recombinant trimeric complex CIS-SH2-elongin B-elongin C (see SEQ ID NOs: 7, 14 and 15 for the corresponding amino acid sequences) was provided at concentrations ranging from 0 to 30 μM. After incubation, the reactions were spotted on P81 phosphocellulose paper and quenched in 5% H3PO4. The paper was then washed with 5% H3PO4 (4 × 200 ml, 15 min) and exposed to a phosphorimager plate. Quantification was performed using the phosphorimager software and the IC was calculated based on the number of integrated pixels. 50 curve.

[0300] In other embodiments, the identification of CIS inhibitors is performed by computer simulation in a method comprising the following steps: (i) generating a three-dimensional structural model of CIS or a fragment thereof; and (ii) computer simulation design or screening of test agents that bind to the modeled structure. In some embodiments, the three-dimensional structural model is a complex of a JAK1 polypeptide or a fragment thereof bound to CIS or a fragment thereof or a complex of an IL-2Rβ cytoplasmic domain polypeptide or a CIS binding fragment thereof bound to CIS or a fragment thereof.

[0301] CIS inhibitors can be identified by computer simulation screening of CIS binding by any method known to those skilled in the art. Methods for computer simulation screening of ligands that bind to proteins include, but are not limited to, those provided in, for example, Good, (2001), Zhang et al. (2015), Cerqueira et al. (2015), Kuenemann et al. (2015), and Westermaier et al. (2015).

[0302] For molecules that bind to CIS proteins, a suitable level of stereochemical complementarity will generally be required. Generally speaking, the design of molecules with stereochemical complementarity can be achieved by chemically and / or geometrically optimizing the "fit" between the molecule and the target receptor. According to the present invention, there are at least two methods for designing molecules that are stereochemically complementary to CIS proteins or fragments thereof.

[0303] The first approach involves docking computer-simulated molecules from a three-dimensional structure database ("virtual test agents") directly into the receptor site, using mostly but not exclusively geometric criteria to assess the fit of a particular molecule to the site. In this approach, the number of internal degrees of freedom (and the corresponding local minima in the molecular conformational space) is drastically reduced to the geometric (hard-sphere) interaction of only two rigid bodies, one of which (the active site) contains a "pocket" or "groove" that forms the binding site for the second body (the complementary molecule, acting as a ligand).

[0304] This method is demonstrated by Ewing et al. (2001), whose ligand design algorithm is implemented in the commercial software package DOCK 4.0 released by Regents of the University of California, and is further described in a document entitled "Overview of the DOCK Program Suite" provided by the publisher. Recently, Autodock 4 has been described. According to the Kuntz algorithm, the shape of the region of interest is defined as a series of intersecting spheres of different radii. Then, one or more existing crystallographic data databases, such as the Cambridge Structural Database System maintained by Cambridge University (University Chemical Laboratory, Lensfield Road, Cambridge CB2 1EW, UK), the Protein Data Bank maintained by Research Collaboratory for Structural Bioinformatics (Rutgers University, NJ, USA), LeadQuest (Tripos Associates, Inc., St. Louis, MO), Available Chemicals Directory (Molecular Design Ltd., San Leandro, CA) and the NCI database (National Cancer Institute, USA) are searched for molecules that are close to the defined shape.

[0305] The molecules thus identified can then be modified according to geometric parameters to meet criteria related to chemical complementarity, such as hydrogen bonding, ionic interactions, and Van der Waals interactions. Different scoring functions can be used to sort the database and select the best molecules (see, e.g., Bohm et al., 1999). The software package FlexX sold by Tripos Associates, Inc. (St. Louis, MO) is another program that can be used for this direct docking method.

[0306] The second preferred method requires evaluating the interaction of the corresponding chemical groups ("probes") with the active sites at the sample positions inside and around the site, and obtaining a series of energy values ​​that can generate three-dimensional isosurfaces at selected energy levels. The chemical probe method of ligand design is implemented in many commercial software packages, such as GRID (a product of Molecular Discovery Ltd., West Way House, Elms Parade, Oxford OX2 9LL, UK). According to this method, at the beginning, the chemical prerequisites of the site-complementary molecules are identified by probing the active sites using different chemical probes, such as water, methyl groups, amine nitrogen, carboxyl oxygen and hydroxyl groups. Thereby determining the favorable sites for interaction between the active site and each probe, and the three-dimensional patterns of these sites obtained can generate the inferred complementary molecules. This can be done by a program that can search a three-dimensional database to identify molecules that include the desired pharmacophore pattern, or by a program that performs a de novo design using favorable sites and probes as input.

[0307] Suitable programs for searching three-dimensional databases to identify molecules with the desired pharmacophore include: MACCS 3D and ISIS / 3D (Molecular Design Ltd., San Leandro, CA), ChemDBS 3D (Chemical Design Ltd., Oxford, UK), and Sybyl / 3DB Unity (Tripos Associates, Inc., St. Louis, MO).

[0308] Chemical structure databases are available from a number of sources, including the Cambridge Crystallographic Data Centre (Cambridge, UK), Molecular Design, Ltd. (San Leandro, CA), Tripos Associates, Inc. (St. Louis, MO), and Chemical Abstracts Service (Columbus, OH).

[0309] De novo design programs include Ludi (Biosym Technologies Inc., San Diego, CA), Leapfrog (Tripos Associates, Inc.), Aladdin (Daylight Chemical Information Systems, Irvine, CA), and LigBuilder (Peking University, China).

[0310] Current computer modeling software (using computer-aided drug design or CADD) can be used to design mimetics (such as peptide mimetics and organic mimetics) to fit, for example, peptide binding sites (Walters, 1993, in "Computer-Assisted Modeling of Drugs", in Klegerman & Groves (ed.), Pharmaceutical Biotechnology, 1993, Interpharm Press: Buffalo Grove, 111., pp. 165-174; and Munson, 1995, Principles of Pharmacology, Chapman & Hall, Chapter 12). Mimetics prepared using such techniques are also included within the scope of the present disclosure. In one example, mimetics simulate the phosphopeptide of the JAK1 activation loop known to interact with the CIS SH2 domain.

[0311] Mimetics can be generated using software that can derive virtual peptide models from multiple peptide structures. This can be done using software derived from the SLATE algorithm (Perkin et al., 1995; Mills et al., 2001; De Esch et al., 2001).

[0312] Other methods for designing peptide analogs, derivatives and mimetics are also well known in the art, see, for example, Floris et al. (2011).

[0313] Molecules found to bind to CIS can be synthesized or obtained in large quantities from suitable sources, such as commercial suppliers. The obtained test agents can then be used in any of the above assays to verify their ability to bind to CIS and / or inhibit the binding of CIS binding partners or target proteins to CIS or CIS fragments.

[0314] As with all drug screening assays, further refinement of the drug's structure will generally be necessary and may be performed by serial repetition of any and / or all of the steps provided by the particular drug screening assay.

[0315] In other embodiments, the method for identifying CIS inhibitors is a phenotypic assay, which comprises the following steps: (i) providing cells expressing CIS; and (ii) determining whether the test agent reduces the CIS activity in the cells compared to cells not contacted with the test agent. In some embodiments, the cell type used for the screening method is NK cells. In some embodiments, in the case of using NK cells, determining whether the test agent reduces the CIS activity in the cells includes determining the effect of the test agent on the IL-15 inducible response in the NK cells. Suitable IL-15 inducible responses include, but are not limited to, NK cell proliferation, interferon-γ (IFN-γ) production, intracellular granzyme expression, JAK1 tyrosine phosphorylation, JAK1 degradation, regulation of gene expression or cytotoxicity One or more. Any of these endpoints can be evaluated by any of many standard methods known in the art. For example, cell proliferation assays are described in Riss et al. (2013), Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; cytokine quantification assays are described in Whiteside (2002); JAK1 kinase activity assays are described in, for example, Babon et al. (2013); ubiquitin-mediated JAK1 degradation assays are described in, for example, Lee et al. (2008); gene expression assays, such as RNAseq, such as Hoek et al. (2015); and NK cell-mediated cytotoxicity assays are described in, for example, Giamann et al. (2006) and Jang et al. (2012). In some embodiments, the test agent used for cell-based assays in one of the interaction or binding screening methods is initially identified as a candidate CIS inhibitor. In some embodiments, the CIS activity measured in the cell is inhibition of JAK1 kinase activity (eg, decreased phosphorylation of a STAT5 substrate), inhibition of STAT5 tyrosine phosphorylation, downregulation of STAT5 promoter activity, or increased degradation of JAK1 in NK cells.

[0316] Suitable test agents for use in the screening methods include peptides, peptidomimetics, small molecules, polynucleotides or polypeptides, but those skilled in the art will appreciate that where the test agent is directed to reducing CIS activity by targeting the Cish gene or Cish mRNA, such agents will be evaluated in cellular assays.

[0317] In some embodiments, a suitable CIS or CIS fragment for use in any of the methods for identifying a CIS inhibitor comprises an amino acid sequence that is at least 70% identical to at least one of SEQ ID NOs: 6-10, e.g., at least 75%, 80%, 85%, 88%, 90%, 92%, 95%, 99%, or 100% identical to at least one of SEQ ID NOs: 6-10.

[0318] (SEQ ID NO:6; human CIS protein isoform 1; UniprotKB Q9NSE2)

[0319] MVLCVQGPRPLLAVERTGQRPLWAPSLELPKPVMQPLPAGAFLEEVAEGTPAQTESEPKVLDPEEDLLCIAKTFSYLRESGWYWGSITASEARQHLQKMPEGTFLVRDSTHPSYLFTLSVKTTRGPTNV RIEYADSSFRLDSNCLSRPRILAFPDVVSLVQHYVASCTADTRSDSPDPAPTPALPMPKEDAPSDPALPAPPPATAVHLKLVQPFVRRSSARSLQHLCRLVINRLVADVDCLPLPRRMADYLRQYPFQL

[0320] (SEQ ID NO:7; human CIS protein isoform 1 fragment: residues 66-258, wherein residues 174-202 are deleted, i.e., lacking an internal PEST sequence; used to form a trimeric complex with extensins B and C)

[0321] DLLCIAKTFSYLRESGWYWGSITASEARQHLQKMPEGTFLVRDSTHPSYLFTLSVKTTRGPTNVRIEYADSSFRLDSNCLSRPRILAFPDVVSLVQHYVASCTADTRSATAVHLKLVQPFVRRSSARSLQHLCRLVINRLVADVDCLPLPRRMADYLRQYPFQL

[0322] (SEQ ID NO: 8; Human CIS protein isoform 1 SOCS box (from GenBank accession number: NP_034025.1)

[0323] SSARSLQHLCRLVINRLVADVDCLPLPRRMADYLRQYPFQL

[0324] (SEQ ID NO: 9; mouse CIS protein isoform 1; GenBank accession number: NP_034025.1)

[0325] MVLCVQGSCPLLAVEQIGRRPLWAQSLELPGPAMQPLPTGAFPEEVTEETPVQAENEPKVLDPEGDLLCIAKTFSYLRESGWYWGSITASEARQHLQKMPEGTFLVRDSTHPSYLFTLSVKTTRGPTN VRIEYADSSFRLDSNCLSRPRILAFPDVVSLVQHYVASCAADTRSDSPDPAPTPALPMSKQDAPSDSVLPIPVATAVHLKLVQPFVRRSSARSLQHLCRLVINRLVADVDCLPLPRRMADYLRQYPFQL

[0326] (SEQ ID NO: 10; Rattus norvegicus CIS protein; GenBank accession number: AAI61930.1)

[0327] MVLCVQGSCPLLVVEQIGQRPLWAQSLELPGPAMQPLPTGAFPEEVTEETPVQSENEPKVLDPEGDLLCIAKTFSYLRESGWYWGSITASEARQHLQKMPEGTFLVRDSTHPSYLFTLSVKTTRGPTN VRIEYADSSFRLDSNCLSRPRILAFPDVVSLVQHYVASCTADTRSDSPDPAPTPALPVPKPDAPGDPVLPIPVATAVHLKLVQPFVRRSSARSLQHLCRLVINRLVTDVDCLPLPRRMADYLRQYPFQL

[0328] In some embodiments, the amino acid sequence of CIS or a fragment thereof comprises the amino acid sequence of one of SEQ ID NOs: 6-10. In other embodiments, the amino acid sequence of CIS or a fragment thereof consists of one of the amino acid sequences of one of SEQ ID NOs: 6-10.

[0329] In some embodiments, the CIS binding partner or target protein is selected from JAK1, JAK3, IL-2Rβ, elongin B, elongin C and tardalin 5 or a fragment thereof.

[0330] JAK1 or a CIS-binding fragment thereof may comprise an amino acid sequence that is at least 70% identical to at least one of SEQ ID NOs: 11-16, e.g., at least 75%, 80%, 85%, 88%, 90%, 92%, 95%, 99% or 100% identical to at least one of SEQ ID NOs: 11-16.

[0331] (SEQ ID NO: 11; Homo sapiens JAK1 protein; UniProtKB-P23458; activation loop in bold; Tyr1034 underlined)

[0332]

[0333]

[0334] (SEQ ID NO: 12; Homo sapiens JAK3 protein; UniProtKB-P52333; Tyr980 is in bold and underlined)

[0335]

[0336]

[0337] (SEQ ID NO: 13; Homo sapiens IL-2 receptor subunit β precursor; UniProtKB-P14784; signal peptide amino acids 1-26 are underlined; the mature sequence numbers of Tyr355, Tyr361 and Tyr392 are each in bold and underlined)

[0338]

[0339]

[0340] (SEQ ID NO: 14; Homo sapiens extensin B; UniProtKB-Q15370)

[0341] MDVFLMIRRHKTTIFTDAKESSTVFELKRIVEGILKRPPDEQRLYKDDQLLDDGKTLGECGFTSQTARPQAPATVGLAFRADDTFEALCIEPFSPPELPDVMKPQDSGSSANEQAVQ

[0342] (SEQ ID NO: 15; Homo sapiens extensin C; UniProtKB-Q15369)

[0343] MDGEEKTYGGCEGPDAMYVKLISSDGHEFIVKREHALTSGTIKAMLSGPGQFAENETNEVNFREIPSHVLSKVCMYFTYKVRYTNSSTEIPEFPIAPEIALELLMAANFLDC

[0344] (SEQ ID NO:16; Homo sapiens arrestin-5; UniProtKB–Q93034)

[0345] MATSNLLKNKGSLQFEDKWDFMRPIVLKLLRQESVTKQQWFDLFSDVHAVCLWDDKGPAKIHQALKEDILEFIKQAQARVLSHQDDTALLKAYIVEWRKFFTQCDILPKPFCQLEITLMGKQGSNKKSNVEDSIVRKLMLDTWNESIFSNIKNRLQDSAMKLVHAERLGEAFDSQLVIGVRESYVNLCSNPEDKLQIYRDNFEKAYLDSTERFYRTQAPSYLQQNGVQNYMKYADAKLKEEEKRALRYLETRRECNSVEALMECCVNALVTSFKETILAECQGMIKRNETEKLHLMFSLMDKVPNGIEPMLKDLEEHIISAGLADMVAAAETITTDSEKYVEQLLTLFNRFSKLVKEAFQDDPRFLTARDKAYKAVVNDATIFKLELPLKQKGVGLKTQPESKCPELLANYCDMLLRKTPLSKKLTSEEIEAKLKEVLLVLKYVQNKDVFMRYHKAHLTRRLILDISADSEIEENMVEWLREVGMPADYVNKLARMFQDIKVSEDLNQAFKEMHKNNKLALPADSVNIKILNAGAWSRSSEKVFVSLPTELEDLIPEVEEFYKKNHSGRKLHWHHLMSNGIITFKNEVGQYDLEVTTFQLAVLFAWNQRPREKISFENLKLATELPDAELRRTLWSLVAFPKLKRQVLLYEPQVNSPKDFTEGTLFSVNQEFSLIKNAKVQKRGKINLIGRLQLTTERMREEENEGIVQLRILRTQEAIIQIMKMRKKISNAQLQTELVEILKNMFLPQKKMIKEQIEWLIEHKYIRRDESDINTFIYMA

[0346] (SEQ ID NO: 17; Homo sapiens JAK1 protein JH1 kinase domain; residues 854-1154)

[0347] DIVSEKKPATEVDPTHFEKRFLKRIRDLGEGHFGKVELCRYDPEGDNTGEQVAV)KSLKPESGGNHIADLKKEIEILRNLYHENIVKYKGICTEDGGNGIKLIMEFLPSGSLKEYLPKNKNKINLKQQLKYAVQICKGMDYLGSRQYVHRDLAARNVLVESEHQVKIGDFGLTKAIETDKE Y YTVKDDRDSPVFWYAPECLMQSKFYIASDVWSFGVTLHELLTYCDSDSSPMALFLKMIGPTHGQMTVTRLVNTLKEGKRLPCPPNCPDEVYQLMRKCWEFQPSNRTSFQNLIEGFEALLK

[0348] A polypeptide or polypeptide class can be defined by the degree of identity (% identity) of its amino acid sequence to a reference amino acid sequence or by the % identity to one reference amino acid sequence being greater than another. The % identity of a polypeptide to a reference amino acid sequence is typically determined by GAP analysis (Needleman and Wunsch (1970); GCG program) with parameters of gap creation penalty=5, gap extension penalty=0.3. The query sequence is at least 15 amino acids in length and the GAP analysis aligns the two sequences over a region of at least 15 amino acids. More preferably, the query sequence is at least 50 amino acids in length and the GAP analysis aligns the two sequences over a region of at least 50 amino acids. More preferably, the query sequence is at least 100 amino acids in length and the GAP analysis aligns the two sequences over a region of at least 100 amino acids. Even more preferably, the query sequence is at least 250 amino acids in length and the GAP analysis aligns the two sequences over a region of at least 250 amino acids. Even more preferably, the GAP analysis aligns the two sequences over the entire length.

[0349] A number of considerations are useful to a skilled artisan in determining whether a particular amino acid sequence variant of a protein or peptide is suitable for use in the present invention. These considerations include, but are not limited to: (1) known structure-function relationships of interactions between the protein or peptide and known protein binding partners or binding partner motifs; (2) the presence of amino acid sequence conservation between naturally occurring homologs (e.g., paralogs and orthologs) of the protein of interest, as revealed by sequence alignment algorithms. It is noteworthy that a number of bioinformatics algorithms are known in the art that can successfully predict functional effects, i.e., the "tolerance" of a particular amino acid substitution in the amino acid sequence of a protein to its function. Such algorithms include, for example, the "Functional Analysis through Hidden Markov Models" (FATHMM) algorithm described by Shihab et al. (2013); and the "sorting permissive from permissive" algorithm described by Ng et al. (2003); and more recently by Sim et al. (2012).

[0350] The SIFT calculator is available online at the website: sift.bii.a-star.edu.sg / . The FATHMM calculator is available online at the website: fathmm.biocompute.org.uk. For any amino acid sequence of interest (e.g., a sequence corresponding to any of the SEQ ID NOs provided herein), an "amino acid substitution matrix" can be generated that provides the predicted neutrality or deleteriousness of any given amino acid substitution on the function of the corresponding protein, such as the ability to bind to an interaction partner.

[0351] Non-naturally occurring sequence variants of proteins can be generated by many known methods. These methods include, but are not limited to, "gene shuffling" as described in US6,521,453; "RNA mutagenesis" as described by Kopsidas et al. (2007); and "error-prone PCR methods". Error-prone PCR methods can be divided into (a) methods that reduce the fidelity of the polymerase by unbalancing the nucleotide concentration and / or adding compounds such as manganese chloride, (b) methods that utilize nucleotide analogs (see, e.g., US6,153,745), and (c) methods that utilize "mutagenized" polymerases.

[0352] Retention confirmation, loss or gain of function of amino acid sequence variants of the proteins used in the assays can be determined in a variety of types of assays, such as binding assays, kinase assays or ubiquitination assays, depending on the protein function being assessed.

[0353] Example

[0354] Example 1 Materials and Methods

[0355] Mouse

[0356] Cish- / - Generously provided by Professor James Ihle and Dr. Evan Parganas of St. Jude Children's Research Hospital, Memphis USA and maintained in C57BL / 6 background. Cish+ / + refers to C57BL / 6 wild-type control mice. Rosa26-CreERT2 (Taconic Artemis), Socs3-loxP (Croker et al., 2003), Ifng- / -Socs1- / - (Alexander et al., 1999) and Ncr1-iCre (Narni-Mancinelli et al., 2011) mice have been described above. Male and female mice between 6-14 weeks of age were used. All mice were bred and maintained at the Walter and Eliza Hall Institute. Experiments on animals followed the National Health and Medical Research Council (NHMRC) Code of Practice for the Care and Use of Animals for Scientific Purposes guidelines and were approved by the Walter and Eliza HallInstitute Animal Ethics Committee or the QIMR Berghofer Medical Research Institute Animal Ethics Committee.

[0357] Purification and culture of NK cells

[0358] Murine natural killer cells were collected from multiple organs (spleen, bone marrow, blood) and single cell suspensions were prepared by forcing the organs through a 70 μm sieve. Lymphocytes were isolated from the liver by suspension in isotonic percoll (Amersham Pharmacia Biotech) and centrifugation at 1800 × g. NK cells were purified using anti-CD49b (DX5) microbeads (Miltenyi Biotec) according to the manufacturer's instructions. The cells were purified by lysing the cells in 4% (v / v) 4% paraformaldehyde (PFA)-containing 4% paraformaldehyde (PFA)-containing 4% paraformaldehyde (PFA)-containing 5% paraformaldehyde (PFA)-containing 6 ... -1 ; Sigma) and recombinant hIL-15 (50 ng ml -1 NK cells were expanded for 5-10 days in Dulbecco's modified Eagle's medium (IMDM) from Peprotech.

[0359] RNA sequencing and bioinformatics analysis

[0360] At the Australia Genomic Research Facility, Melbourne, Illumina HiSeq2000 was used to analyze the 50 ng ml -1 1×10 cells grown in IL-15 for 7 days 6 Cish + / + and Cish - / - NK1.1 + NKp46 + TCR - Two biological replicates of NK cells and 1 × 10 6 Freshly separated Cish + / + and Cish - / - NK1.1 + NKp46 + TCRβ -Two biological replicates of NK cells were subjected to 100 base pair single-end RNA sequencing. The reads were aligned to the GRCm38 / mm10 build of the mouse genome using the Subread aligner. Genewise counts were obtained using FeatureCounts. Reads covering exons in the NCBI RefSeq database annotation build 38.1 were included. Genes were filtered from downstream analysis if they could not achieve a CPM (count per million mapped reads) value of at least 0.5 in at least two libraries. The counts were converted to log2 counts per million, and quantile normalization and precision weighting were performed using the voom function of the limma package. Differential expression in RNAseq experiments was evaluated using linear models and empirical Bayesian methods. Genes were called differentially expressed if they achieved a false discovery rate of 0.1 or less in one or both of the two cell types being compared and also had at least 8 FPKM (fragments per kilobase per million mapped reads). Heat maps were generated using the gplots package, and negative log2 FPKM values ​​were reset to zero. All analyses were performed using the Bioconductor R package.

[0361] In vitro NK cell proliferation assay

[0362] Target cells (CHO, B16F10) were seeded into 100 μl of culture medium in the wells of a 96X E-plate. The system dynamically monitors cell growth until they reach the logarithmic growth phase and form a monolayer (approximately 24 hours). + / + and Cish - / - NK cells were added directly to a single well containing target cells. For background control, NK cells were added to wells not containing target cells, and target cells were added to wells not having NK cells added. After adding NK cells, the system continued to measure every 15 min until 48 h.

[0363] Flow cytometry and cell sorting

[0364] Single cell suspensions were stained using appropriate monoclonal antibodies in phosphate buffered saline (PBS) containing 2% (v / v) FCS. If necessary, intracellular staining was performed according to the manufacturer's instructions using the FoxP3 / transcription factor staining buffer kit (eBioscience). FACS Verse, Fortessa, and AriaII (BD Biosciences) were used for cell sorting and analysis, with dead cells excluded by propidium iodide or Fluoro-Gold staining. All single cell suspensions were diluted in PBS and then analyzed and counted using an Advia hematology analyzer (Siemens). Unless otherwise indicated, the antibodies were expressed for NK1.1 (PK136; 1:100), CD19 (1D3; 1:500), CD3 (17A2; Biolegend; 1:400), CD122 (TM-b1; 1:200), CD132 (4G3; 1:200), NKp46 (29A1.4; 1:100), TCR-β (H57-5921; 1:500), KLRG1 (2F1; 1:100), CD27 (LG.7F9; 1:200), FoxP3 (FJK-16s; eBioscienc Specific antibodies for leukemia / glitinide (ELISA; 1:400), CD25 (PC61; Biolegend; 1:100), Sca-1 (D7; 1:100), B220 (RA3-6B2; eBioscience; 1:100), Gr-1 (1A8; 1:200), granzyme A (GzA-3G8.5; eBioscience; 1:200), granzyme B (NGZB; eBioscience; 1:200), CD107a (104B; 1:100), and IFN-γ (XMG1.2; 1:100) were from BD Pharmingen.

[0365] Real-time quantitative PCR (Q-PCR)

[0366] Total RNA was isolated using RNeasy plus kit (QIAGEN), and cDNA synthesis was performed using Superscript III (Invitrogen) according to the manufacturer's instructions. PCR reactions were performed in 10 μL (5 μL FastStart SYBR Green Master Mix (Roche), 0.5 pmol forward and reverse primers, and 4 μL cDNA). Primer sequences and PCR conditions have been described (Kolesnik and Nicholson, 2013). Real-time Q-PCR was performed on an ABI Prism 7900HT sequence detection system (Applied Biosystems). mRNA levels were quantified for a standard curve, which was generated using serial dilutions of oligonucleotides corresponding to each amplified PCR fragment and using SDS2.2 software (Applied Biosystems). Relative expression was determined by normalizing the amount of each gene of interest to the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Three biological replicates were performed for each case, and the assay was performed in duplicate. Statistical analysis was performed using an unpaired t-test with a 95% confidence level.

[0367] Western blotting and transient transfection

[0368] Approximately 1.5 × 10 8 NK cells were lysed in 2.5 mL KALB lysis buffer (Nicholson et al., 1995) supplemented with protease inhibitors (Complete Cocktail tablets, Roche), 1 mM PMSF, 1 mM Na3VO4 and 1 mM NaF and incubated on ice for 1 h. The lysate was clarified by centrifugation at 16,060 × g for 15 min at 4 °C. The protein concentration was determined by the BCA method (Pierce, Rockford). -1293T cells were maintained in DMEM containing streptomycin and 10% FCS and transiently transfected with a single vector or cDNA expressing Flag-tagged mouse Jak1, Jak3, Cish or Cish mutants or Myc-tagged mouse Cish using FuGene6 (Promega) according to the manufacturer's instructions. In some cases, cells were pretreated with 10 μM MG132 for 4 h to block proteasomal degradation. 48 h after transfection, cells were lysed in KALB buffer (Nicholson et al., 1995). FLAG protein was immunoprecipitated using M2-beads (Sigma) and the protein was eluted in SDS sample buffer. Immunoprecipitation, gel electrophoresis and Western blotting were performed essentially as described (Linossi et al., 2013). The following primary antibodies were used: antibodies to CIS (Clone D4D9), phosphorylated STAT3 (Y705); phosphorylated AKT1 (Ser473), AKT and MAPK were obtained from Cell Signalling Technology. Antibodies to phosphorylated STAT5A / B (Y694 / 699) were obtained from Millipore, phosphorylated JAK1 (Y1022 / 1023) and STAT5A were obtained from Invitrogen, and JAK1, STAT3, and β-actin were obtained from Santa Cruz Biotechnology Inc. Rat anti-Flag antibody was a generous gift from Prof. D. Huang and Dr. L. O'Reilly (Walter and Eliza Hall Institute).

[0369] Synthesis of CYT-387 Kinase Affinity Reagent and Covalent Coupling to NHS-Sepharose

[0370] Amino-functionalized CYT-387 derivatives were prepared using procedures similar to those described for the synthesis of CYT-387 (see Figure 2). The modified CYT-387 compound was immobilized onto NHS-activated Sepharose 4 Fast Flow beads (GE Healthcare) as described above (Schirle et al., 2012). Briefly, 1 mL of NHS-Sepharose bead slurry was washed twice with 5 mL of DMSO and centrifuged at 80 × g for 3 min to precipitate the matrix between washes. One packed matrix volume (500 μL) was resuspended with DMSO to prepare a 50% slurry. CYT-387 (2 μM final volume) was added to 1 mL of NHS-bead slurry, followed by 20 μL of triethylamine and inverted to mix. The reaction slurry was incubated overnight in an upright cylindrical reactor at room temperature in the dark. The next day, 25 μL of ethanolamine was added to the reaction and incubated again in an upright cylindrical reactor at room temperature in the dark overnight. The CYT-387-coupled NHS-Sepharose beads were washed twice with 5 mL DMSO and the matrix was resuspended in ethanol and stored at 4 °C protected from light.

[0371] Enrichment of kinases from cell lysates

[0372] The CYT-387-bound resin was washed twice with KALB lysis buffer and then subjected to kinase enrichment. Six separate kinase enrichments were performed using 160 μL of 50% Cyt387-bound resin (Cish - / - or Cish + / + Each three times), the resin was incubated with 2 mL (~10 mg) of protein lysate. The incubation was performed on a dark drum at 4°C for 3 h. After the incubation, the protein-bound Cyt387 resin was washed 3 times with KALB buffer and eluted by 3 consecutive rounds of 60°C 0.5% SDS / 5mM DTT (200 μL, 100 μL, 100 μL) incubation for 3 min.

[0373] Trypsin digestion

[0374] Resin-captured proteins and eluates from equal amounts of whole cell lysates (~400 μg) from each biological replicate were prepared for mass spectrometry analysis using the FASP protein digestion kit (Protein Discovery, Knoxville, TN) as described above (Wisniewski et al., 2009), but with the following modifications. Proteins were reduced with tris (2-carboxyethyl) phosphine (TCEP) (5 mM final concentration), digested with 4 μg sequencing-grade modified Trypsin Gold (Promega) dissolved in 50 mM NH4HCO3 and incubated overnight at 37°C. The eluted peptides were then washed with two 40 μL washes with 50 mM NH4HCO3 and acidified in 1% formic acid (final concentration).

[0375] Mass spectrometry and data analysis

[0376] The acidified peptide mixture was analyzed by nanoliter reversed-phase liquid chromatography tandem mass spectrometry (LC-MS / MS) on a nanoAcquity system (Waters, Milford, MA, USA) coupled to a Q-Exactive mass spectrometer equipped with a nanoelectrospray ion source for automated MS / MS (Thermo Fisher Scientific, Bremen, Germany). The peptide mixture was loaded into a 20 mm trapping column with an inner diameter of 180 μm (nanoAcquity UPLC 2G-V / MTrap 5 mmSymmetry C18) in buffer A (0.1% formic acid, 3% acetonitrile, Milli-Q water) and separated by reverse phase chromatography from 3-55% buffer B (0.1% formic acid, 80% acetonitrile, Milli-Q water) using a 150 mm column with an inner diameter of 75 μm (nanoAcquity UPLC 1.7 μm BEH130 C18) on a 60 min linear gradient set at a constant flow rate of 400 nL / min. The Q-Exactive was run in data dependent mode, automatically switching between a full scan and subsequent MS / MS scans of the ten most abundant peaks. The instrument was controlled using Exactive Series 2.1 build 1502 and Xcalibur 3.0. Full scans (m / z 350–1,850) were acquired at 200 m / z at a resolution of 70,000. The 10 most intense ions were sequentially isolated with a target of 10,000 ions and an isolation width of 2 m / z and fragmented using HCD with a normalized collision energy of 19.5 and a step collision energy of 15%. The maximum ion accumulation time27 was set to 50 ms for the full MS scan and 200 ms for MS / MS. The bottom fill ratio was set to 5% and dynamic exclusion was enabled and set to 90 s. Raw files consisting of high-resolution MS / MS spectra were processed with MaxQuant (version 1.5.0.25) for feature detection and protein identification using the Andromeda search engine36. The extracted peak lists were searched against the UniProtKB / Swiss-Prot mouse database (LudwigNR) and a separate reverse decoy database to empirically assess the false discovery rate (FDR) using a strict trypsin specificity that allowed up to 3 false cleavages. The minimum required peptide length was set to 7 amino acids. Modifications: Carbamidomethylation of Cys was set as a fixed modification, while N-acetylation of proteins, oxidation of Met, addition of pyroglutamate (at the N-terminal Glu and Gln), phosphorylation (Ser, Thr, and Tyr), and deamidation (Asn, Gln, and Arg) were set as variable modifications. The mass tolerances for precursor ions and fragment ions were 20 ppm and 0.5 Da, respectively.The "match between runs" option in MaxQuant was used to transfer identifications made between runs based on matched precursors with high mass accuracy (Cox et al., 2014). PSMs and protein identifications were filtered using a target-decoy approach at a false discovery rate (FDR) of 1%. Protein identifications were based on a minimum of two unique peptides.

[0377] Quantitative Proteomics Pipeline

[0378] Further analysis was performed using a custom pipeline developed with Pipeline Pilot (Biovia) and R, which was developed using MaxQuant output files allPeptides.txt, peptides.txt and evidence.txt. Features were defined as combinations of peptide sequences, charges and modifications. Features that were not present in at least half of the number of repeats in each group were removed. Proteins identified from hits in the reverse database and proteins with only one unique peptide were also removed. In order to correct for injection volume variability, the feature intensity was converted to the logarithm of base 2, and then each value was normalized by multiplying the maximum median intensity of all repeats by the ratio of the median repeat intensity. Features assigned to the same protein differed in intensity range due to their chemical and physical properties and charge state. In order to further correct these differences, each intensity value was multiplied by the maximum value of the median intensity of all features of the protein and the ratio of the median intensity of the feature. Missing values ​​were filled using a random normal distribution of values, where the mean value was set to the mean value of the actual distribution of the values ​​minus 1.8 times the standard deviation, and the standard deviation was 0.5 times the standard deviation of the measured intensity distribution (Cox et al., 2014). The probability of differential expression between groups was calculated using the Wilcoxon rank sum test, excluding any non-unique sequences and any features with modifications other than oxidation and carbamidomethylation. The probability values ​​were corrected for multiple testing using the Benjamini–Hochberg method. The function y = -log 10A cutoff of (0.05) + c / (x-x0) (Keilhauer et al., 2015) was used to identify significantly enriched proteins. c was set to 0.2, and x0 was set to 1, indicating proteins with a 2-fold (log2 protein ratio of 1 or greater) or 4-fold (log2 protein ratio of 2) change in protein expression, respectively. Log2-transformed aggregate peptide intensities (non-filled) were visualized in a heat map generated in one-matrix CIMminer, a program developed by the Genomics and Bioinformatics Group (Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute).

[0379] Preparation of GST-CIS protein for peptide screening

[0380] A portion of human Cish (encoding residues 66-258) was cloned into the vector pGTVL2. Human extensin C (residues 17–112) and full-length extensin B were cloned into the vector pACYCDUET as described above (Bullock et al., 2006). Both plasmids were transformed into BL21(DE3) for co-expression of the CIS / extensin C / extensin B ternary complex (CIS-SH2-BC). The expression of Cish2 was performed at 18°C ​​with 0.4 mM isopropyl β- D -1-thiogalactoside (IPTG) induced cultures in Luria broth overnight and collected cells by centrifugation. The pellet was resuspended in 50mM HEPES pH7.5, 500mM NaCl, 5mM imidazole, 5% glycerol and the cells were lysed by sonication. DNA was precipitated by adding 0.15% polyethyleneimine pH8 and insoluble material was removed by centrifugation at 21,000rpm. GST-tagged CIS protein complex was purified on a glutathione sepharose column and eluted with 20mM reduced glutathione in a buffer containing 50mM HEPES, 300mM NaCl, 0.5mM TCEP. The purified protein was concentrated to 0.75mg ml -1 and stored at -80°C.

[0381] Peptide array synthesis and screening

[0382] Peptide arrays were synthesized on functionalized nitrocellulose membranes using an Invatis spot array synthesizer as described (Li and Wu, 2009). For array probing, membrane-bound peptides were blocked in 5% skim milk in Tris-buffered saline / 0.05% Tween-20 (TBS-T) pH 7.2 for 5 h at room temperature. After washing with TBS-T, 0.8 ng ml -1 GST-CIS-SH2-BC complex was added to the blocking buffer and incubated overnight at 4 °C. At the same time, 4 ng ml -1 GST protein was added to the peptide array alone as a negative control. The peptide array membrane was washed 3× with TBS-T and peroxidase-labeled anti-GST antibody (Bio-Rad) was added for 1 h at room temperature and then detected with a chemiluminescent substrate (Bio-Rad Clarity Western ECL substrate), which was visualized using a Molecular Imager (ChemiDoc XRS; Biorad).

[0383] Isothermal Titration Calorimetry (ITC)

[0384] Isothermal calorimetric titration was performed using Microcal ITC200 (GE Healthcare). Phosphopeptides were obtained from Genscript. An optimized GST-CIS protein construct in which the internal PEST region (Δ174-202) was deleted was prepared. The resulting ternary GST-CIS-SH2-SB complex was dialyzed against buffer (20mM Tris pH8.0, 100mM NaCl, 2mM 2-mercaptoethanol). Unless otherwise stated, experiments were performed at 298K. Typically, 12×3.15μl 300μM phosphopeptide injections were titrated to 30μM GST-CIS-SH2-SB ternary complex solution. The dilution heat of GST-CIS-SH2-BC was subtracted from the raw data of the binding experiment. Data were analyzed using the evaluation software Microcal Origin version 5.0. The binding curve was fitted with a single-point binding mode, and all K values ​​were determined from repeated experiments. D value.

[0385] E3 ligase assay

[0386] CIS-mediated ubiquitination of JAK1 was performed essentially as described above (Babon et al., 2013). The CIS E3 ligase complex (CIS-SH2-BC and stagnate protein 5 and Rbx2; 2.5 μM) was incubated with ubiquitin (50 μM), human E1 (100 nM), purified recombinant E2 (UbcH5c, 2.5 μM) and full-length JAK1 at 37°C for different times in the presence of 2.5 mM Mg / ATP. FLAG-tagged JAK1 was generated by expressing in 293T cells and recovered using anti-FLAG immunoprecipitation and free FLAG peptide elution. JAK1 ubiquitination was visualized by Western blotting with anti-phospho-JAK1 followed by separation on a 4-20% Tris / glycine gel.

[0387] Kinase assay

[0388] Kinase inhibition assays were performed essentially as described (Babon et al., 2012). Briefly, 130 μM STAT5b peptide (SEQ ID NO: 18RRAKAADGYVKPQIKQVV) was mixed with 5 nM JAK1 in 20 mM Tris pH 8.0, 100 mM NaCl, 5 mM 2-mercaptoethanol, 0.2 mg ml -1 BSA, 2 mM MgCl2, 100 μM ATP and 1 mCi γ-[32P]ATP were incubated at 25°C for 30–60 min. Recombinant CIS-SH2-BC was present at a concentration range of 0–30 μM. After incubation, the reactions were spotted on P81 phosphocellulose paper and quenched in 5% H3PO4. The paper was washed with 5% H3PO4 (4 × 200 ml, 15 min) and exposed to phosphorimager plates (Fuji). IC was calculated using Fuji software and Graphpad Prism 50 The curve was quantified.

[0389] Tumor cell lines

[0390] The C57BL / 6 murine lymphoma cell line RMA is a T-cell lymphoma derived from the Rauscher murine leukemia virus-induced RBL-5 cell line. The cell lines RMA-mCherry and m157BL / 6 were generated by transduction with retroviral vectors encoding mCherry or GFP (murine stem cell vectors), respectively. +B16F10 melanoma, E0771 and E0771.LMB mCherry+ breast cancer, LWT1 melanoma, and RM-1 prostate cancer cell lines were maintained as described above (Ferrari deAndrade et al., 2014; Gilfillan et al., 2008; Stagg et al., 2011a and b; Swann et al., 2007; Rautela et al., 2005; Johnstone et al., 2015).

[0391] Experimental tumor metastasis

[0392] Groups of 6-14 mice per experiment were used for experimental tumor metastasis. These group sizes were used to ensure adequate power to detect biological differences. No mice were excluded based on pre-established criteria for this study, and no active randomization was applied to the experimental groups. The investigators were not blinded to group assignment during the experiments and / or when evaluating the results. All tumor experiments were performed once unless otherwise stated. Single-cell suspensions of B16F10 melanoma, RM-1 prostate cancer, or LWT1 melanoma cells were injected intravenously into the tail vein of the indicated mouse strains (2.5-7.5×10 5 Some mice also received 100 μg of anti-CD8β (53.5.8) (depleted CD8 + T cells), 50 μg anti-asialoGM1 (deplete NK cells) or 250 μg anti-IFN-γ (H22) (neutralize IFN-γ as described above) (Chan et al., 2014; Allard et al., 2013). Some groups of mice received: control Ig (500 μg intraperitoneal, cIg, 1-1) or combination anti-PD-1 (RMP1-14) / anti-CTLA-4 (UC10-4F10) (250 μg intraperitoneal each) on days 0, 3 and 6 relative to tumor inoculation (day 0). Lungs were collected on day 14 and fixed in Bouin's solution for B16F10 metastasis counting. 44 Alternatively, NK cell expansion was analyzed by flow cytometry. f / f Ncr1-iCre mice ( Sathe et al., 2014 ) were injected intravenously with 3×10 6 In vitro amplified Cish + / + or Cish - / - NK cells or PBS. Then 8 hours later, 1×10 5 Mice were injected with 1.5 × 10 B16F10 melanoma cells. 6 In vitro amplified Cish + / + or Cish - / -Mice were treated with NK cells or PBS delivered intravenously. Mice were sacrificed on day 18 after tumor injection and lung perfusion was performed. Lungs were then collected and metastasis counts were performed.

[0393] Orthotopic E0771.L.MB and spontaneous E0771 metastasis

[0394] To generate primary tumors, 1 × 10 5 E0771.LMB mCherry+ tumor cells were implanted into 8- to 10-week-old female Cish - / - or Cish + / + Fourth inguinal mammary gland of mice [in 20 μl PBS]. Primary tumor volume was measured three times a week using electronic calipers. The maximum longitudinal diameter (length) and the maximum transverse diameter (width) were measured. Tumor volume was estimated by the modified ellipsoid formula: Volume = 1 / 2 (length × width) 2 For spontaneous metastasis experiments, 400–600 mm 3 Lungs were harvested 14 days later and metastatic burden was quantified by ex vivo imaging using an IVIS Lumina XR-III (Caliper LifeSciences) or by duplex Q-PCR for mCherry relative to vimentin expression as described above (Rautela et al., 2005).

[0395] CYT-387 Synthesis

[0396] Liquid chromatography mass spectrometry (LCMS) was performed on a Finnigan LCQAdvantage Max using reverse phase high performance liquid chromatography (HPLC) analysis (column: Gemini 3μC18 20×4.0 mm 110A) solvent A: water 0.1% formic acid, solvent B: acetonitrile 0.1% formic acid, gradient: 10-100% B over 10 min, detection: 100-600 nm and electrospray ionization (ESI). All compounds submitted for biochemical assays were assessed to have a purity of 95% as determined by HPLC analysis at 254 nm UV absorption. Rf purification system (Teledyne, ISCO, Lincon, NE, USA) and pre-packed silica gel column (particle size 0.040-0.063 mm) were used for chromatography. All commercial reagents were used as received. Cbz = carboxybenzyl. 4-(4-aminophenyl)piperazine-1-carboxylic acid benzyl ester (S1) and 4-(4-chloropyrimidin-2-yl)benzoic acid ethyl ester (S2) can be prepared as described above (WO 2014 / 26242 and WO 2008 / 109943).

[0397]

[0398] Benzyl 4-(4-((2-(4-(ethoxycarbonyl)phenyl)pyrimidin-4-yl)amino)phenyl)piperazine-1-carboxylate (S3)

[0399] p-TsOH (0.978 g, 5.13 mmol) was added to a magnetically stirred suspension of pyrimidine S2 (1.50 g, 5.71 mmol) and aniline S1 (2.31 g, 7.42 mmol) in dioxane (20 mL). The mixture was heated to reflux for 24 h. The mixture was cooled, diluted in DCM (250 mL) and washed with NaHCO3 (100 mL), the aqueous layer was separated and extracted with EtOAc (3 × 50 mL). The combined organics (Na2SO4) were dried, filtered and concentrated onto silica, and flash chromatography (1:9 to 1:0, v / v, EtOAc: cyclohexane) was performed with the material. The fractions thus obtained were concentrated, the yellow precipitate was filtered and washed with methanol to give the title compound (S3) (1.61 g, 52%) as a yellow solid. 1 H NMR (600MHz, DMSO-d6): δ9.51(s,1H),8.52(d,J=5.1Hz,1H),8.25(d,J=8.3Hz,2H),8.08(d,J=8.4Hz,2H),7.65(d,J=9.0Hz,2H),7.37-7.35(m,5 H),7.31(q,J=4.4Hz,1H),6.93(d,J=9.0Hz,2H),5.09(s,2H),4.33(q,J= 7.1Hz, 2H), 3.58-3.48 (m, 4H), 3.04-3.03 (m, 4H), 1.33 (t, J = 7.1Hz, 3H). LCMS:t R =6.14min,m / z=538.0[M+H] + .

[0400] Ethyl 4-(4-((4-(piperazin-1-yl)phenyl)amino)pyrimidin-2-yl)benzoate (S4)

[0401] Compound S3 (500 mg, 0.93 mmol) was dissolved in MeOH (75 mL) and THF (50 mL), and the solution was passed through 'H-cube' at 1 mL / min in full H2 mode using a Pd / C (10%) column at 45°C. The product was collected and concentrated under low pressure to give the title compound (S4) (352 mg, 94%) as a dark solid. 1H NMR (600MHz, CDCl3): δ8.46(dd,J=8.0,5.2Hz,1H),8.16-8.14(m,2H),8.11(d,J=8.3Hz,2H),7.59(dd,J=8.9,1.9Hz,1H),7.55(d,J=8.9H z,1H),7.16-7.13(m,1H),6.96(dt,J=9.1,4.6Hz,2H),4.41(q,J=7.1Hz,2H),3.36-3.28(m,4H),3.25-3.18(m,4H),1.42(t,J=7.1Hz,3H). LCMS:t R =5.78min,m / z=404.0[M+H] + .

[0402] 4-(4-((4-(4-(5-((tert-butoxycarbonyl)amino)pentanoyl)piperazin-1-yl)phenyl)amino)pyrimidin-2-yl)benzoic acid (S5)

[0403] Under N2, to a magnetically stirred solution of N-Boc-aminovaleric acid (194 mg, 0.96 mmol), EDCI (201 mg, 1.05 mmol), HOBt (146 mg, 1.05 mmol), Et3N (232 μL, 1.75 mmol) in DMF (2 mL) was added compound S4 (350 mg, 0.87 mmol) and the mixture was stirred for 12 h. The reaction mixture was washed with water (2 mL) and the aqueous washings were extracted with EtOAc (2×2 mL). The organic fractions were combined, dried (Na2SO4), filtered and concentrated. The crude material was purified by flash chromatography to give a light yellow solid (373 mg). The substance was dissolved in THF / MeOH (2 mL 1:3 mixture), and lithium hydroxide (123 mg, 3.09 mmol) was added, and the mixture was stirred at reflux for 2 h. The mixture was concentrated to a yellow solid and suspended in water and acidified to pH=2 with HCl (5% aqueous solution). The precipitate was collected by filtration, washed with MeOH (1 mL) and then Et2O (2 x 1 mL), and dried under reduced pressure to give the title compound (S5) (224 mg, 60%) as a red solid. 1H-NMR (600MHz, DMSO-d6): δ9.49 (s, 1H), 8.52-8.51 (m, 1H), 8.22 (t, J = 6.8Hz, 2H) ,8.06(d,J=8.1Hz,2H),7.65-7.64(m,2H),7.36(dd,J=4.7,0.3Hz,1H),6.94-6.91 (m,2H),6.77-6.75(m,1H),3.57-3.55(m,4H),3.36(td,J=1.1,0.5Hz,2H),3.05-2 .99(m,4H),2.91-2.87(m,2H),2.33-2.31(m,2H),1.46-1.45(m,2H),1.34(s,9H). LCMS:t R =6.34min,m / z=575.0[M+H] + .

[0404] 4-(4-((4-(4-(5-aminopentanoyl)piperazin-1-yl)phenyl)amino)pyrimidin-2-yl)-N-(cyanomethyl)benzamide (S6)

[0405] At room temperature and N2, triethylamine (264 μL, 1.99 mmol) was added to a magnetically stirred solution of compound S5 (190 mg, 0.33 mmol) in DMF (6 mL, anhydrous), and the mixture was ultrasonicated for 5 min. EDCI (76 mg, 0.40 mmol) and HOBt (54 mg, 0.40 mmol) were then added, and the mixture was stirred for 5 min under N2. Aminoacetonitrile hydrochloride (61 mg, 0.66 mmol) was then added, and the reaction was stirred for 12 h at room temperature and N2. The reaction mixture was concentrated and the crude material was purified by flash chromatography to obtain a coupled product (155 mg, 76%) as a yellow solid. The substance was immediately dissolved in dioxane (0.5 mL), HCl (1 mL of a 4 M solution in dioxane) was then added, and the reaction mixture was stirred at room temperature for 2 h. The precipitate was then collected by filtration, washed with dioxane before being dissolved in MeOH, quenched with NH3 (4M solution in MeOH) and then concentrated. The crude material was purified by flash chromatography to afford the title amine (S6) (51 mg, 40%) as a yellow solid. 1H-NMR (600MHz, CD3OD): δ8.37(d,J=5.2Hz,1H),8.16(d,J=8.3Hz,2H),7.91(d,J=8.3Hz,2H),7.5 7(d,J=8.8Hz,2H),7.20(d,J=5.2Hz,1H),6.93(d,J=8.9Hz,2H),4.34(s,2H),3.69(t,J=5.1Hz,2H ),3.63(t,J=5.0Hz,2H),3.30-3.29(m,2H),3.07(t,J=5.0Hz,2H),3.03(t,J=5.1Hz,2H),2.67(t ,J=7.2Hz,2H),2.41(t,J=7.4Hz,2H),1.62(dt,J=15.3,7.6Hz,2H),1.51(td,J=11.3,6.1Hz,2H). LCMS:t R =4.18min,m / z=513.0[M+H] + .

[0406] Example 2 IL-15 induces the expression of SOCS genes (including CIS) in NK cells

[0407] To date, there has been great interest in understanding the inhibitory signals that inhibit NK cell responses, but it is still not understood how intracellular IL-15 signaling is turned off. Members of the inhibitor of cytokine signaling (SOCS) gene family are STAT5 responsive genes and are normally induced to limit the extent of cytokine receptor signaling as part of a classic negative feedback system. In order to investigate which SOCS proteins may regulate IL-15 signaling, thereby regulating NK cell development and function, the inventors first analyzed IL-15-induced SOCS expression in cultured NK cells. Cish, Socs1, Socs2, and Socs3 mRNAs were induced in NK cells within 2h of IL-15 treatment, and the early and transient induction of Cish represented the induction of Socs by its target cytokine ( Figure 1 a). Consistent with the rapid induction of mRNA in response to saturating concentrations of IL-15, CIS protein was detected in NK cell lysates within 60 min of stimulation ( Figure 1 b).

[0408] Example 3 Cish-Naked NK cells are IL-15 hypersensitive

[0409] To investigate the physiological role of CIS in IL-15 signaling, the present inventors used mice lacking germline Cish. - / - )(Palmer et al., 2015) first demonstrated that Cish mRNA and protein were absent from NK cells ( Figure 5 a) Cish-nude mice are healthy, fertile, and do not show any phenotypic abnormalities when they reach 10 months of age. The frequency and function of hematopoietic cells, including conventional CD4 + and CD8 + T cells 9 The frequency and function of regulatory T cells and type 2 innate lymphoid cells (ILC2) appeared normal ( Figure 5 bg) NK cells in Cish - / - Mice also develop normally ( Figure 1 c. Figure 5 b), as in mice deficient in Socs1 and Socs3 alone or in both ( Figure 6 a) However, compared with Socs1- or Socs3-deficient NK cells, Cish - / - NK cells show significant hyperproliferation in response to IL-15 in vitro ( Figure 1 d, Figure 6 b) When Cish - / - and control C57BL / 6 NK cells (Cish + / + ) When co-cultured 1:1 in titration of IL-15, Cish - / - NK cells at more than 5ng ml -1 showed enhanced proliferation at concentrations of Figure 1 d) In addition, Cish - / - NK cells represented ∼95% of cells recovered from co-cultures at non-mitogenic IL-15 concentrations, thus demonstrating superior IL-15-mediated NK cell survival in the absence of CIS ( Figure 1 d) Cish - / - The hypersensitivity of NK cells is also manifested in enhanced IL-15-driven IFN-γ production, which is further enhanced by co-stimulation via the activating receptors NKp46 and NK1.1, suggesting that IL-15 has an important role in synergizing with these receptors ( Figure 1 e). When co-cultured with Chinese hamster ovary (CHO) target cells, + / + Compared with NK cells, Cish - / - NK cells show greater cytotoxicity at low NK:target cell ratios ( Figure 1 f and Figure 6 c) Cish - / - NK cells are also more potent than Cish + / + NK cells killed B16F10 melanoma cells more efficiently and displayed higher intracellular granzyme levels when challenged with RMA-m157 cells, confirming the broad hypercytotoxicity of NK cells in the absence of Cish ( Figure 6c, d).

[0410] To examine the extent of aberrant IL-15 signaling in Cish-naive NK cells, the present inventors isolated Cish + / + and Cish - / - NK cells were subjected to 100 bp single-end RNA sequencing. + / + and Cish - / - NK cells were purified directly from the spleen (ex vivo) or after culture in IL-15 (in vitro). - / - Few differentially expressed genes were observed in NK cells ( Figure 7 a) This is consistent with the body's Cish - / - The normal frequency of NK cells and the low Cish expression in mature NK cells together suggest that CIS is not a major regulator of NK cell biology at steady state. In contrast, Cish expression in cells exposed to high concentrations of IL-15 in vitro - / - More than 1000 differentially expressed genes were detected in NK cells ( Figure 1 g and Figure 7 a, b, c). The most highly upregulated genes included members of the killer cell lectin-like receptor, Klra1 and Klra6, and members associated with NK cell effector functions, such as the serine proteases Gzme, Gzmf, Gzmd, Gzmg, and their inhibitors Serpinb9b, Serpinb9, and Serpin1a ( Figure 1 g. Figure 7 a) These findings are consistent with Cish - / - Together, the superior proliferation and cytotoxicity of NK cells identify CIS as a unique and nonredundant role for IL-15-mediated NK cell effector function as a key negative regulator. In addition, they propose that CIS acts as an immune checkpoint to control NK cell responses.

[0411] Example 4: Increased JAK1 levels and enzyme activity in the absence of CIS protein

[0412] SOCS proteins are adaptors of the E3 ubiquitin ligase complex that ubiquitinates SOCS-interacting proteins, targeting them for proteasomal degradation (Zhang et al., 1999). CIS was the first SOCS family protein to be discovered (Matsumoto et al., 1997), and although it has been reported to associate with the IL-2 receptor complex (Aman et al., 1999), how exactly this interaction is mediated remains unclear. - / - Hyperproliferation and enhanced effector capacity of NK cells can be manifested by changes in receptor levels and / or intracellular signaling components. However, when cultured in the presence of IL-15, Cish + / + and Cish - / -Splenic NK cells express similar receptor levels ( Figure 2 a). Therefore, the inventors examined receptor proximal signaling events. - / - In NK cells, IL-15-stimulated JAK1 tyrosine phosphorylation was increased compared with control cells and was associated with prolonged phosphorylation kinetics ( Figure 2 b, c and Figure 8 a). Interestingly, Cish - / - Total JAK1 protein levels were elevated in NK cells, which was evident in resting cells before stimulation ( Figure 2 b, c). Increased phosphorylation of JAKs was associated with increased phosphorylation of their substrate STAT5. In contrast, Cish deficiency had no effect on IL-15-dependent AKT phosphorylation ( Figure 2 b, c and Figure 8 a), indicating a distinct separation between the IL-15 driven JAK / STAT and PI3K / mTOR / AKT pathways. This was further confirmed by normal mitochondrial respiration and glycolysis, responses known to be regulated by AKT activity ( Figure 8 b).

[0413] To confirm the elevated JAK1 enzyme activity and examine the selectivity of the CIS deficiency effect, the inventors used a mass spectrometry-based approach to quantify changes in active JAK levels. Pan-JAK inhibitors (derived from CYT-387; JAK1 / 2 / 3) were synthesized, coupled to agarose gel beads and used as affinity capture reagents, followed by trypsin digestion and mass spectrometry analysis. Since the inhibitor binds to the ATP binding site in the kinase domain, kinases in the active conformation are preferentially enriched. By Cish - / - JAK1 and JAK3 peptides were detected in NK cell lysates by increasing the number and intensity of cells ( Figure 2 d). CYT-387 is known to off-target bind to other kinases, notably TBK1 and CDK2, which allowed us to perform a restricted kinome analysis. Sixty-nine kinases were enriched relative to their abundance in cell lysates, of which 16 were expressed in Cish - / - In addition to the JAK kinases, the increased activity was mainly attributed to kinases involved in regulating cell proliferation (e.g., CDK1 / 2, Prkr, Aurora kinases) ( Figure 2 e, f and Table 1). These data are consistent with a hyperproliferative phenotype and further suggest that many of these phenotypes may be secondary to increased IL-15 signaling. Label-free global proteomic analysis also highlighted changes reflecting enhanced proliferative capacity (cell cycle, DNA replication, cytoskeletal reorganization) ( Figure 8 ce and Table 2).

[0414] Table 1. Quantitative proteomic analysis after affinity enrichment of CYT-387 showing Figure 2 Related Cish - / - Differentially expressed kinases in NK cells.

[0415]

[0416]

[0417] Table 2. Quantitative proteomic analysis shows the - / - Differentially expressed proteins in NK cells (see Fig.10 ).

[0418]

[0419]

[0420]

[0421]

[0422] Example 5 Identification of interaction targets of the CIS-elongin B-elongin C trimeric complex

[0423] Like other SOCS proteins, the CIS domain contains a phosphorylated tyrosine motif and an SH2 domain that binds to the target protein. The SH2 domain, together with the elongating proteins B and C, the scaffolding protein tardatin 5, and the RING protein Rbx2, constitutes an E3 ubiquitin ligase. - / - Increased total JAK1 / 3 protein levels observed in NK cells are not due to increased RNA levels Fig. 9a), the inventors studied the possibility that CIS may directly reduce JAK protein levels through ubiquitination and proteasomal degradation. In the past, CIS has been shown to interact with IL-2Rβ and has been proposed to regulate signal transduction by blocking STAT protein recruitment to the receptor complex (Matsumoto et al., 1997; Aman et al., 1999); however, there is limited evidence to support the latter claim. As a preliminary step in identifying protein targets regulated by CIS, the inventors used a recombinant trimeric complex composed of human GST-CIS constructs (hCIS-SH2; residues 66-258) and elongated proteins B and C (hCIS-SH2-BC) to screen for a group of phosphotyrosine peptides corresponding to tyrosine in the IL-2 receptor complex (not shown). Isothermal calorimetry (ITC) was then used to verify binding to the phosphopeptides identified in the screening. The hCIS-SH2-BC complex binds with high affinity (0.8-2.1 μM) to synthetic phosphorylated peptides corresponding to tyrosines within the cytoplasmic domain of IL-2Rβ (Tyr355, Tyr361, and Tyr392), and within the activation loops of JAK1 and JAK3 (Tyr1034 and Tyr980, respectively). Figure 3 a; Fig. 9 c).

[0424] Example 6 CIS proteins are downregulated in the absence of the IL-2 receptor complex via targeted proteasomal degradation JAK levels

[0425] The inventors next investigated whether CIS could modulate JAK levels in the absence of the IL-2 receptor complex. Overexpression of JAKs in 293T cells (which lack IL-2R) causes constitutive JAK autophosphorylation. Coexpression of CIS or SOCS1 reduced JAK1 levels to comparable extents, with corresponding reductions in JAK1 phosphorylation. In contrast, SOCS3 was unable to inhibit JAK activity in this assay (SOCS3 requires receptor binding) ( Figure 3 b). Unexpectedly, although the inventors observed that CIS binds to the JAK3 Tyr980 peptide ( Figure 3 a), but JAK3 phosphorylation was not inhibited in this assay ( Figure 3 b).

[0426] The inventors next asked which CIS domains were essential for JAK1 inhibition. Mutations in the CIS-SH2 domain (R107K) or the tardatin-5 binding site (P241A / L242A / P243A) in the SOCS box were sufficient to reduce CIS inhibitory activity ( Figure 3 c). In addition, preincubation of cells with a proteasome inhibitor (MG132) reduced CIS-mediated regulation of JAK1 phosphorylation ( Figure 3c), supporting a model whereby CIS binds to JAK1 via its SH2 domain and then targets JAK1 for proteasomal degradation. Co-immunoprecipitation was used to confirm complex formation between JAK1 and CIS ( Figure 3 d). To formally confirm CIS-mediated ubiquitination of JAK1, Flag-tagged full-length JAK1 protein (produced by expression in 293T cells) was incubated with recombinant hCIS-SH2-SB complex, stagmin 5, Rbx2, E1, E2 (UbcH5c) and free ubiquitin in a cell-free system. As shown by the high molecular weight species detected by Western blotting above, CIS effectively mediates ubiquitination of phosphorylated JAK1 ( Figure 3 e). Together, these data demonstrate that CIS can directly regulate JAK protein levels.

[0427] Example 7 CIS proteins directly inhibit JAK enzymatic activity independent of their downregulation of JAK protein levels

[0428] In the past, only SOCS1 and SOCS3 were shown to bind to and regulate JAK activity. SOCS1 and SOCS3 inhibit JAKs via non-classical SH2, which binds to the "GQM" motif present in the insertion loop of JAK1, JAK2, and Tyk2, and binds the kinase inhibitory region (KIR) to the catalytic cleft (Kershaw et al., 2013). CIS does not contain a "KIR" region, and it has not been previously proposed to be able to regulate JAK enzyme activity. However, there are several lines of evidence that another mechanism is involved. First, the inventors occasionally observed inhibition of JAK1 phosphorylation in the absence of changes in total JAK1 levels (e.g., Figure 3 c). Second, although MG132 treatment of wild-type NK cells caused an increase in endogenous JAK1 phosphorylation, the inventors did not observe prolonged kinetics, and in fact a rapid decrease in JAK phosphorylation. This was associated with increased expression of CIS, which was protected from proteasomal degradation ( Fig. 9 d). Therefore, the inventors asked whether CIS could inhibit JAK1 kinase activity. Using an in vitro kinase assay, the CIS-SH2-BC complex was able to inhibit JAK1 phosphorylation of a substrate peptide, IC 50 The CIS inhibition of JAK1 was 20-fold or higher than that of JAK2, JAK3 or TYK2 ( Figure 3 f, upper panel), indicating that in addition to the classical SH2 interactions with the conserved JAK activation loop tyrosines, a unique interface with JAK1 exists. This concept is supported by the only partial reduction in inhibition found when JAK1 activation loop peptides are used as competitors ( Fig. 9 e). Although CIS showed specificity for JAK1, its inhibitory efficiency was ~100-fold lower than that of SOCS1 ( Figure 3 f, lower panel). This suggests that the absolute levels of CIS and SOCS1 contribute to specificity and dominance. In this case, receptor recruitment of CIS could increase the local concentration of CIS, allowing it to effectively inhibit JAK1 activity ( Figure 3 g). Post-translational regulation of CIS levels, either by the proteasome or by proteasomes, adds another sensitive layer of control. These data suggest new targets (JAK1) and mechanisms (kinase inhibition) of CIS action and raise the possibility that CIS is fundamentally more similar to SOCS1 than previously thought.

[0429] Example 8 Cish in mouse tumor model - / - Adoptive transfer of NK cells leads to significant reduction in tumor formation and metastasis few

[0430] Cish - / - Significantly enhanced biological responses of NK cells exposed to high concentrations of IL-15 and healthy Cish in homeostasis - / - The lack of an NK cell phenotype in mice suggests that steady-state IL-15 levels in vivo are below those required to induce Cish expression. Tumor formation-associated inflammation likely increases IL-15 trans-presentation by the stroma or infiltrating myeloid lineages and increases resident NK cell activity (Mlecnik et al., 2014).

[0431] Therefore, the inventors challenged Cish with a panel of syngeneic tumor cell lines known to be activated and controlled by NK cells. + / + and Cish - / - In this study, we investigated whether IL-15 induction of CIS acts as a checkpoint in NK cells in vivo. B16F10 melanoma cells were intravenously (iv) administered to Cish + / + Mice developed extensive metastatic nodule formation in the lungs within 14 days. In contrast, B16F10 metastatic nodules were largely absent from Cish - / - In mice ( Figure 4 a). In order to confirm that - / - The reduction in B16F10 metastasis observed in mice was dependent on the enhancement of NK cell activity, and Cish treated with anti-Asiolo GM1 (depletion of NK cells), anti-CD8 (depletion of CD8 T cells), anti-IFN-γ (blocking IFN-γ activity), or control anti-immunoglobulin (cIg) + / + and Cish - / - Depletion of NK cells or neutralization of IFN-γ, but not depletion of CD8 T cells, resulted in Cish - / - Mice are susceptible to B16F10 metastasis ( Figure 4b), identified the role of CIS in the negative regulation of NK cell activity and IFN-γ in this model. Furthermore, when adoptively transferred into mice lacking NK cells (Mcl1 f / f Ncr1-iCre; Ncr1 Mcl1Δ / Δ ) when accepting Cish - / - The lung metastasis of B16F10 mice receiving NK cells was significantly higher than that of mice receiving Cish + / + The NK cell count in mice was lower ( Figure 4 c) confirmed that Cish - / - NK cells are intrinsically more active. V600E ) melanoma cell line injected with Cish + / + and Cish - / - mice (Davies et al., 2002), and also caused a significant reduction in lung metastasis in CIS-deficient mice ( Fig.10 a). These findings are not limited to melanoma, as similar differences in lung metastasis were observed when the RM-1 prostate cancer cell line was used ( Fig.10 b).

[0432] Similarly, when Cish + / + , Cish - / - When breast cancer cells (E0771.LMB-mCherry) were intravenously administered to nude mice with NK cells, the inventors observed that + / + Compared with NK nude mice, Cish - / - The tumor burden in the lungs of mice was reduced ( Figure 4 d) Histological analysis of the lungs of these mice revealed Cish - / - Occasional E0771 micrometastases in mice, but they lack perivascularity and are enriched in Cish + / + Large metastases in the visceral pleura of mice ( Figure 4 d) With Cish + / + Compared with mice, the growth of orthotopic E0771.LMB mammary tumors in Cish - / - There was also a significant increase in mice ( Figure 4 g) When primary in situ tumors of similar size are surgically removed, only Cish + / + Mice develop spontaneous E0771.LMB metastases in the lungs, whereas Cish - / - Mice do not develop ( Figure 4 f and Fig.10 c, d), further confirming that CIS is a potent negative regulator of metastatic antitumor immunity.

[0433] Example 9 Cish in mouse melanoma model - / - Adoptive transfer of NK cells is more effective than anti-PD-1 / CTLA-4 alone Immunotherapy is more effective and has greater efficacy when combined with anti-PD-1 / CTLA-4 immunotherapy

[0434] Combination immunotherapy using antibodies against the inhibitory receptors PD-1 and CTLA-4 is currently the most effective treatment for advanced melanoma in humans (Larkin et al., 2015; Postow et al., 2015; Yoshimura et al., 2015). To compare this benchmark immunotherapy with Cish deletion in NK cells, Cish was delivered to - / - and Cish + / + Mice were injected with a high dose of B16F10 melanoma (to elicit NK cell and CD8 T cell responses) and treated with a combination of anti-PD-1 / CTLA-4 antibodies or cIg. + / + In mice, anti-PD-1 / CTLA-4 treatment significantly reduced melanoma metastasis compared with cIg, however this was inferior to the protection provided by Cish deletion alone (Cish - / - Mouse+cIg; Figure 4 g). Of note, Cish - / - Mice developed significantly fewer metastases than those treated with cIg. - / - Mouse ( Figure 4 g), highlighting the potential therapeutic benefit that could be achieved if anti-CTLA-4 / PD-1 therapy is combined with loss of CIS function.

[0435] Induction of CIS was first shown in response to interleukin (IL)-3, IL-2, and erythropoietin (EPO), and forced expression of CIS has been shown to inhibit signaling through these receptors (Matsumoto et al., 1997; Aman et al., 1999). Despite these observations, evidence for a physiological role in these pathways remains limited. - / - Mice have been reported to be CD4 + Inflammatory lung diseases associated with disrupted IL-4 / STAT6 and IL-2 / STAT5 signaling in T cells develop ( Yang et al., 2013 ), while recent reports suggest that in Cish - / - CD8 + Antigen receptor signaling is enhanced in T cells (Palmer et al., 2015). - / - The mice showed no pathology or changes in T cell frequency (Yang et al., 2013), and in the present inventors' opinion, Cish - / - CD8 + T cell development and antigen-specific responses to mouse cytomegalovirus were normal (data not shown). - / -The mice remained healthy, and our observations suggest that therapeutic antagonism of CIS is unlikely to have any major side effects.

[0436] Severe off-target effects and drug resistance currently limit our use of traditional chemotherapy, which is usually the first line of treatment for most cancers. Therefore, there is still a need to discover new targeted therapies and immunotherapies that can be used in combination and as a supplement to chemotherapy.

[0437] Ipilimumab is an antibody-based therapy that targets CTLA-4 on effector and regulatory T cells and is approved for the treatment of advanced malignant melanoma, providing 10-12% tumor response and some complex immune-related adverse events. This is a first-in-class monoclonal antibody targeting so-called immune checkpoint molecules. The antibody (same class) recognizes PD-1 (expressed on T cells and NK cells) or its ligand, PD-L1 (expressed on many tumors once T cell activation occurs), and pembrolizumab and nivolumab (anti-human PD-1) have produced 20-50% objective response rates in phase I / II trials of advanced melanoma, renal cancer, non-small cell lung cancer (NSCLC), and other cancer indications. The combination of nivolumab and ipilimumab for advanced malignant melanoma produced even more rapid and significant anti-cancer effects, including against metastatic disease. Despite these advances, some cancers (eg, prostate cancer, colorectal cancer) show modest responses, and even in melanoma there are still many patients in whom the combination of anti-CTLA-4 and anti-PD-1 / PD-L1 is ineffective.

[0438] Here, the inventors show that IL-15-induced CIS accumulation in NK cells acts as an intracellular immune checkpoint that limits NK cell function. Ablation of CIS function releases inhibition of NK cell activity, leading to a sharp reduction in experimental tumor metastasis, greater than the observations of CTLA-4 / PD-1 blockade, and no signs of adverse reactions. Our results reveal that CIS is a new NK cell checkpoint and indicate that effective therapeutic blockade of CIS function in humans can improve the prognosis of certain cancers.

[0439] Example 10 Deletion of the CIS N-terminal region or the PEST motif enhances the ability of CIS to inhibit JAK1 kinase activity

[0440] To investigate the role of the CIS N-terminal region and the PEST motif, the inventors prepared E. coli expression constructs of human CIS lacking the PEST motif (residues 173-202; ΔPEST), the first 24 residues (ΔN34), the N-terminal region (residues 1-66) and the PEST motif (ΔNTΔPEST) or corresponding to the full-length protein (CIS). All CIS proteins were expressed together with elongin B and C, and the trimeric complexes were purified as described above. The ability to inhibit the JAK1 kinase domain (JH1) was then assessed using an in vitro kinase reaction. Compared with previous data ( Figure 3 F) Consistently, CIS-ΔNTΔPEST inhibits JAK1, IC 50 In contrast, the full-length protein showed a greatly reduced ability to inhibit JAK1 (IC 50 ~32.3), and the same is true for CIS-ΔN34 (IC 50 ~96.77), indicating that the region within the N-terminus (residues 35-66) is autoinhibitory. PEST deletion alone is sufficient to inhibit IC 50 Increased to 3.32 mM (compared to full-length CIS) ( Fig.11 A).

[0441] Example 11 Interaction of CIS-SH2 with phosphopeptides is essential for CIS inhibition of JAK1 kinase activity

[0442] Addition of phenyl phosphate (PP) to the in vitro kinase reaction abolished the ability of all CIS constructs to inhibit JAK1 kinase activity ( Fig.11 Similarly, addition of free phosphopeptides corresponding to the activation loop of mono-phosphorylated JAK1 or doubly-phosphorylated JAK3 significantly reduced the ability of CIS to inhibit JAK1 kinase activity ( Fig.11 C). These data further confirm that canonical binding of the SH2 domain to the phosphotyrosine motif is required for CIS to inhibit JAK1 activity.

[0443] Example 12 Deletion of the CIS N-terminal region or the PEST motif does not have a major effect on binding to phosphopeptides

[0444] CIS constructs lacking the PEST motif (residues 173-202; ΔPEST), the first 24 residues (ΔN34), the N-terminal region (residues 1-66) and the PEST motif (ΔNTΔPEST), or corresponding to full-length CIS were expressed with extensins B and C and tested for their ability to bind JAK1 phosphopeptides using ITC. All constructs bound the phosphopeptide with an affinity of 2.2-10 μM, with the greatest reduction in binding observed for the deletion of the N-terminal 34 residues ( Fig.12A). Similarly, full-length CIS and CIS-ΔNTΔPEST bound the JAK3 phosphopeptide with comparable affinity ( Fig.12 B).

[0445] These data together indicate that the N-terminal region and / or PEST motif are autoinhibitory, and these regions have minimal effect on the ability of the SH2 domain to bind phosphopeptides, which have a major effect on the ability of CIS to inhibit JAK1 kinase activity. Without wishing to be limited by theory, post-translational modifications or conformational changes (such as for binding to phosphotyrosine) may release autoinhibition and require activation of CIS. This suggests that agents that stabilize the conformation / position of the N-terminal region and the PEST motif or block the post-translational modification of CIS can be effective CIS blockers. Similarly, agents that mimic the N-terminal region or the PEST motif can also be effective CIS blockers.

[0446] Example 13 Binding of the CIS-SH2 Domain to an Extended Peptide Interface

[0447] ITC was used to investigate which residues flanking the phosphotyrosine (JAK1 Y1034) contribute to binding affinity (and specificity). Alanine substitutions at positions +5, +3, or -3 had only a modest effect on binding (~4-fold decrease at +3) ( Fig.13 ). This indicates that the CIS-SH2 domain makes multiple contacts with its target peptide sequence.

[0448] Example 14 CIS inhibition is dose-dependent

[0449] It is not possible to reproduce the complete loss of CIS function with a small molecule inhibitor of CIS. Therefore, the inventors investigated whether the loss of one allele is sufficient to enhance the NK cell response to IL-15. + / + , Cish + / - and Cish - / - NK cells were purified from mice, labeled with CTV and expanded in vitro in the presence of increasing concentrations of IL-15 and then analyzed by flow cytometry. - / - Enhanced proliferation of NK cells, while Cish + / - NK cells displayed an intermediate phenotype, with enhanced proliferation compared to wild-type cells but still smaller than Cish - / - Observations of cells (especially at low IL-15 levels) ( Fig.14 A). This result is reflected in the absolute number of cells after culture ( Fig.14 B), and immunoblotting confirmed that loss of one CIS allele resulted in loss of the corresponding CIS protein (approximately 50%) ( Fig.14 C) These data indicate the utility of inhibiting CIS function.

[0450] Example 15 Further validation of the CIS-SH2 domain as a therapeutic target

[0451] The inventors used CRISPR technology to generate a "knock-in" mutant mouse carrying a germline mutation in the Cish gene. This mutation changes Arg107 in the SH2 domain to Lys, eliminating SH2 binding to phosphopeptides. The effect of the mutation was confirmed using recombinant protein and ITC binding (not shown) and was compared with Figure 3 C, which shows that this mutation abolishes the ability of CIS to inhibit JAK1 phosphorylation. R107K ) NK cells were purified and expanded in vitro for 10 days and the absolute cell counts were compared with those from Cish + / + , Cish + / - and Cish - / - Comparison of NK cells in mice. R107K The closest NK cell count comes from Cish - / - The number of cells in mice ( Fig.14 B). CIS-R107K protein is expressed at a level comparable to that of the wild-type protein ( Fig.14 C), confirming that the increase in cell number is a consequence of loss of CIS-SH2 function. These preliminary data suggest that loss of phosphopeptide binding is sufficient to reproduce Cish deficiency and also suggest that compounds that block SH2 function, particularly those that bind phosphopeptides, would be an effective starting point for drug development.

[0452] Example 16 The kinetics of CIS induction are consistent with the inhibition of JAK / STAT signaling in human NK cells

[0453] Human and mouse CIS share 90.7% identity at the amino acid level. Similarly, human and mouse JAK1 share 94.4% identity, while the activation loop is 100% conserved. Immunoblot analysis of primary human NK cells and many human NK cell lines showed that IL-15 treatment for 1-2 h induced CIS, accompanied by reduced JAK1 and STAT5 phosphorylation. These data are consistent with CIS inhibiting JAK / STAT signaling ( Fig.15 ). In addition, although treatment of primary human NK cells with IL-15 and a proteasome inhibitor (MG-132) for 2 h was sufficient to increase total JAK1 and CIS levels, JAK1 phosphorylation was still reduced ( Fig.15 A). This supports the premise that CIS inhibits IL-15 signaling in human NK cells via ubiquitination of JAK1 and inhibition of JAK autophosphorylation, consistent with our results using mouse NK cells.

[0454] In addition, IL-15 treatment induced Cish mRNA in human NK cell lines NK-92 and KHYG-1 ( Fig.16 ). Notably, the extent of Cish induction was much greater than that observed for Socs1 and Socs3, which are induced even at very low levels ( Fig.16 This well predicts that inhibition of CIS leads to enhanced IL-15 signaling without compensatory effects from other SOCS family members.

[0455] Example 17 Identification of phosphorylation and ubiquitination sites on CIS

[0456] The inventors have shown that CIS itself is regulated by proteasomal degradation ( Fig. 9 D and Fig.15 A), it was also proposed that post-translational modifications of CIS could regulate N-terminus / PEST-mediated autoinhibition. To identify potential phosphorylation and ubiquitination sites, FLAG-tagged CIS was expressed in 293T cells and affinity purified and then analyzed by mass spectrometry. Six phosphorylation sites were identified, five of which were conserved between mouse and human CIS ( Fig.17 and Table 3). Three phosphorylation events were detected within the PEST motif (pSDpSPDPAPpT), consistent with the idea that phosphorylation can alter the intramolecular localization and / or binding interactions of this motif and thus alter CIS function. Three ubiquitination sites were also identified ( Fig.17 , Table 3), consistent with previous reports (Jensik et al., 2015). These results identified many residues within CIS that can be modified by ubiquitination or phosphorylation.

[0457] Example 18 CIS is a therapeutic target in diseases with elevated and functional TGF-β

[0458] Several clinical trials using anti-TGF-β to prevent EMT (epithelial to mesenchymal transition) are ongoing, however TGF-β is also a potent immunosuppressant (Chen et al., 2016). The present inventors found that CIS naked NK cells were largely resistant to TGF-β-mediated proliferation in vitro ( Fig.18 ).

[0459] However, although CIS naked NK cells were tolerant to TGF-β compared with wild-type cells, there was still some inhibition of TGF-β receptor signaling, as CIS naked NK cells proliferated less than TGF-β receptor naked NK cells (TgfbRII fl / flTherefore, the inventors next investigated whether blocking CIS and TGF-β in vivo would improve tumor outcome compared to monotherapy. - / - Mice were injected with 1×10 6 Inhibition of both CIS and TGF-β (anti-TGF-β antibody, 1D11) resulted in a significant reduction in melanoma burden in the lung at 14 days compared to inhibition of CIS or TGF-β ex vivo. Fig.19 ). In addition, inhibition of both CIS and BRAF resulted in a similar significant reduction in melanoma burden in the lung at 14 days compared to inhibition of either CIS or BRAF alone. Triple therapy of CIS, BRAF, and TGF-β inhibition nearly prevented SM1LWT1 metastasis in the lung, suggesting that BRAF mutant melanoma metastasis in humans may benefit from a combination of CIS inhibition with TGF-β or BRAF blockade.

[0460] Example 19 Cish deficiency is more effective for NK cell-dependent anti-metastatic therapy

[0461] The inventors next sought to compare Cish deficiency with concurrent immunotherapy, including immune checkpoint blockade (anti-PD-1, anti-CTLA-4, anti-CD96) and cytokines (IFNα / β, IL-2), which promote NK cell function in the B16F10 experimental metastasis model. Notably, Cish-deficient mice tolerated B16F10 lung metastases better than wild-type mice treated with anti-PD-1, type I IFN (IFN-αβ), or IL-2 regimens ( Fig. 20 A). All of these immunotherapies have been used with some degree of success in treating advanced human melanoma. - / - mice, but both type I IFN and IL-2 treatment appeared to further reduce metastasis ( Fig. 20 A) Another experiment evaluated a high dose challenge with B16F10, where it is evident that - / - Both anti-PD-1 / anti-CTLA-4 combination and IL-2 were more effective than cIg in mice ( Fig. 20 B) Specifically, low-dose IL-2 was ineffective in WT mice but was ineffective in Cish - / - Compared with WT mice, IL-2 in Cish - / - The improvement in mice was also observed in the RMA-S intraperitoneal lymphoma model ( Fig. 20C) This is what people are concerned about because in WT and Cish - / - In mice, NK cell-mediated control was equivalent in untreated or PBS-treated control mice ( Fig. 20 C). Additional experiments in a second experimental metastasis model, RM-1, demonstrated that Cish deficiency had superior anti-metastatic activity in combination with anti-PD-1 / anti-CTLA-4 or anti-CD96 treatment ( Fig. 20 D) In ​​Cish - / - Excellent activity of anti-CD96 in mice was also observed in the B16F10 experimental metastasis model ( Fig. 20 E).

[0462] Overall, these experiments suggest that CIS regulation of NK cell anti-metastatic activity is independent of the anti-metastatic activity of immune checkpoint antibodies. V600E -Mice challenged with the mutant metastatic melanoma cell line LWT1, in Cish - / - Significantly reduced lung metastasis was again observed in mice. Fig. 20 F) or MEK inhibitor (trametinib) ( Fig.21 ) treatment further reduced the metastasis. In conclusion, these data suggest that targeting CIS could be well combined with other immunotherapies and that CIS holds great promise as a new target in NK cell immunotherapy.

[0463] Example 20 Treatment of sarcoma

[0464] Cish - / - Mice are highly resistant to methylcholanthrene (MCA)-induced fibrosarcoma formation ( Fig. 22 A) Depletion of NK cells or neutralization of IFNγ again significantly reduced the expression of WT and Cish - / - The survival rate of mice was significantly reduced and the protective effect of Cish deficiency was completely abolished ( Fig. 22 B) In Cish - / - The extent of protection observed in mice from experimental metastasis and de novo cancer is remarkable and clearly demonstrates that targeting CIS is promising as a new target for NK cell-based immunotherapy. These results are consistent with the observation that IL-15-induced CIS expression in NK cells and loss of Cish confers NK cells hypersensitivity to IL-15 (Delconte et al., 2016).

[0465] Example 21 Treatment of Acute Myeloid Leukemia

[0466] The seminal example of NK cell anti-tumor efficacy was in haploidentical bone marrow transplantation, in which donor NK cells reacted strongly with host acute myeloid leukemia (AML) (Ruggeri et al., 2016), suggesting that AML may be immunogenic to autologous NK cells if such NK cells are fully activated. The inventors found that when autologous bone marrow was transfected with a lentivirus encoding the AML-inducing oncogene MLL-AF9 and injected into WT mice, these mice died of AML approximately 40 days after injection ( Fig.23 ). In contrast, if Cish - / - The occurrence of AML was significantly delayed in WT mice, and only about 30% of the mice died of AML compared with 100% of WT mice. Fig.23 ). These data suggest that MLL-AF9+ AML are detected and killed by NK cells and that this is significantly enhanced in the absence of CIS.

[0467] Example 22 CIS deficiency promotes NK cell proliferation and differentiation in vivo

[0468] Initial experiments showed that under homeostasis, Cish - / - Mice have a similar + / + When examining NK cells more closely, it is clear that Cish - / - NK cells are more mature than wild-type cells (M2, DNAM1+KHLRG1+; Fig.24 A, B) and circulate more rapidly (Ki67+; Fig.24 C). Given that the total number remains the same ( Fig.24 A), this also shows that Cish - / - NK cells are dying and / or cleared from the body more rapidly.

[0469] Example 23 Enhanced control of MCA1956 sarcoma requires NK cells and CD8 T cells

[0470] When immunogenic MCA-induced fibrosarcoma MCA1956 was injected subcutaneously, Cish - / - mice showed better tumor control than WT mice ( Fig.25 Although only 1 / 10 of WT mice spontaneously rejected the tumor, 5 / 10 of Cish - / - The mice successfully cleared the primary tumor on day 30 after transplantation ( Fig.25 ). NK cells or CD8β + Depletion of T cells accelerated tumor growth and abolished the differences seen between WT and Cish-deficient mice ( Fig.25Whether NK cells directly control the growth of MCA1956 tumors or whether they play an indirect role by regulating T cell activity remains to be elucidated. Taken together, our data suggest that Cish deficiency primarily alters the natural growth of subcutaneous tumors in which NK cells are crucial.

[0471] Example 24 Cish - / - CD8 T cells exhibit increased proliferation and IFNγ production

[0472] Given the similarities in transcriptional regulation, effector programs, and cytokine dependency between NK cells and CD8 T cells, the lack of a distinct CD8 T cell phenotype in vivo was somewhat unexpected. To specifically test whether CD8 T cells are hyperresponsive to IL-15 or antigen receptor stimulation, 6-8 week old WT-Ly5.1 (n=3) and Cish - / - Peripheral lymph nodes (collected, excluding mesentery) of Ly5.2-Ly5.2 (n=3) mice were processed into single cell suspensions. CD8 enrichment of samples by magnetic bead negative selection + T cells. The resulting cells were then labeled with 5 μM CTV. WT and Cish - / - Cells were co-cultured in IMDM + 10% FCS in 96-well plates under conditions of IL-2 + αCD3, IL-15 + αCD3, IL-2 + αCD28 + αCD3, and IL-15 + αCD28 + αCD3. For all conditions, including αCD3 - Wells served as controls (not shown). Wells were set up as technical triplicates for statistical analysis. Congenic markers allowed examination of two genotypes within a single well. Cells were cultured at 37°C and 5% CO2.

[0473] IFNγ production was assessed by stimulation with PMA / ionomycin for 4 h, followed by intracellular staining and FACS analysis. - / - CD8 + T cells produced significantly more IFNγ in response to PMA / ionomycin stimulation than wild-type (WT) cells ( Fig.26 ).

[0474] Cultures were examined on day 4 of culture by FAC analysis for proliferation and surface marker expression via CTV dilution ( Fig. 27 ). In the absence of αCD3 stimulation, in the presence of IL-15 + A maximum of seven division events can be observed in the culture. The number of cells in each division cycle is determined and plotted as a function of the division number ( Fig. 27 A) Similar results were recorded in IL-2 cultures (not shown).

[0475] In all conditions examined, WT and Cish - / - CD8 + T cells were all found to proliferate and produce IFNγ in response to stimulation. In the presence of αCD3, proliferation reached a maximum on day 4 in all cultures, making comparisons between genotypes difficult (not shown). However, in the absence of αCD3 stimulation, analysis of cell number and division number showed that Cish - / - Cells proliferated more rapidly than WT controls on day 4 of culture ( Fig. 27 B) Taken together, these results indicate that, under in vitro conditions, Cish - / - CD8 + T cells proliferated more rapidly and displayed enhanced effector functions compared to their WT counterparts. These preliminary results are promising, however more detailed analysis of the proliferation-inducing conditions will provide insights into Cish - / - CD8 + A deeper understanding of the enhanced phenotype documented in T cells.

[0476] Example 25 Increased levels of IL-15 in the tumor microenvironment induce increased levels of Cish in tumor-infiltrating NK cells

[0477] The present inventors determined that IL-15 rapidly induced Cish expression in cultured NK cells and induced CIS protein expression 1 hour after IL-15 stimulation. To visualize Cish expression in vivo, the Cish-lacZ reporter gene (Cish LacZ / + ) mouse strain. IL-15 + / + or IL-15 - / - Mice (stromal IL-15 status + or -) were lethally irradiated and treated with Cish LacZ / + Bone marrow reconstitution. Ten weeks later, these chimeric mice were subjected to injection of 1×10 5 The mice were either challenged with E0771 breast cancer cells or left unchallenged. One week later, the mice were sacrificed, the breast tumors were harvested and excised, and the tumor-resident NK cells were stained for β-galactosidase (Cish expression) and analyzed by flow cytometry. It was observed that the presence of stromal IL-15 significantly increased Cish expression in NK cells by approximately 2-fold ( Fig.28). NK cells infiltrating breast tumors in which IL-15 was present in the stroma showed increased Cish expression, and this was most pronounced in NK cells infiltrating breast tumors from mice whose stroma lacked IL-15. In both cases, NK cell Cish levels were greatest in tumor-resident NK cells compared to mammary fat pad NK cells, suggesting that IL-15 levels are higher in the EO771 tumor microenvironment. Given that this tumor is tightly controlled by NK cells and a model that is extremely responsive to CIS loss of function, our data suggest that elevated IL-15 levels in tumors and increased Cish expression in tumor-resident NK cells are predictors of tumor types that are likely to respond to small molecule CIS inhibitors.

[0478] Example 26 Human Cish - / - Evaluation (prediction) of NK cell targeting of melanoma metastasis in vivo

[0479] To evaluate people Cish - / - How NK cells precisely reproduce mouse Cish - / - To investigate the role of NK cells in tumor growth and metastasis in vivo, we performed adoptive cell transfer experiments in lymphoid mice (NOD / SCID / γC; NSG). For the adoptive transfer model, NSG mice were injected intravenously with 5×10 6 In vitro expanded human Cish + / + or the same gene Cish - / - Human NK cells or PBS. Then 8 h later, the mice were injected with 1×106 BRAF mutation patient-derived melanoma cells, which were maintained as a cell line in our laboratory. 6 In vitro amplified Cish + / + or Cish - / - Mice were treated with NK cells or PBS delivered intravenously. Mice were sacrificed on day 18 after tumor injection and lung perfusion was performed. Lungs and livers were then collected and metastases were counted.

[0480] It will be appreciated by those skilled in the art that many changes and / or modifications may be made to the present invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. Therefore, the embodiments of the present invention are considered in all aspects to be illustrative and not restrictive.

[0481] This patent application claims priority to AU 2015905220 filed on December 16, 2016, the entire contents of which are incorporated herein by reference.

[0482] All publications cited herein are hereby incorporated by reference in their entirety. Where reference is made to a URL or other such identifier or address, it should be understood that such identifiers may change, specific information on the Internet is constantly changing, but equivalent information may be obtained by searching the Internet. Citation of such information confirms its availability and public dissemination.

[0483] Any discussion of documents, acts, materials, devices, articles or the like which has been included in this specification is solely for the purpose of providing a background to the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this patent application.

[0484] Table 3. Summary of phosphorylation and ubiquitination sites detected in CIS

[0485]

[0486]

[0487] References

[0488] Alexander et al. (1999) Cell 98:597-608.

[0489] Allard et al. (2013) Clin Cancer Res 19:5626-5635.

[0490] Aman et al. (1999) J Biol Chem 274:30266-30272.

[0491] Babon et al. (2012) Immunity 36:239-250.

[0492] Babon et al. (2013) Methods Mol Biol 967:39-55.

[0493] Bohm et al. (1999) M. Med. Chem. Res. 9:445.

[0494] Borowsky (2011) Cold Spring Harb Perspect Biol, 3:a009670.

[0495] Bullock et al. (2006) Proc Natl Acad Sci USA 103:7637-7642.

[0496] Casalena et al.(2012)Methods Mol Biol,803:249-263.

[0497] Cerqueira et al.(2015)Arch Biochem Biophys 582:56-67.

[0498] Chan et al. (2014) Nat Immunol 15:431-438.

[0499] Chen et al. (2016) Nat Immunol 16:723-740.

[0500] Childs et al.(2013)Hematology Am Soc Hematol Educ Program 2013:234-246.

[0501] Constanfini et al.(2008)Cancer Biotherm Radiopharm 23:3-24.

[0502] Cox et al. (2014)Mol Cell Proteomics 13:2513-2526.

[0503] Croker et al. (2003) Nat Immunol 4:540-545.

[0504] Davies et al. (2002) Nature 417:949-954.

[0505] De Coupade et al. (2005), Biochem J, 390:407-418.

[0506] De Esch et al.(2001)J.Med. Chem.44:1666-1674.

[0507] Delconte et al. (2016) Nat Immunol 17:816-824.

[0508] Deshayes et al. (2008) Adv Drug Deliv Rev 60:537-47.

[0509] Ewing et al.(2001)J.Comput Aid.Mol.Design,15:411.

[0510] Ferrari de Andrade et al.(2014)Cancer Res 74:7298-7308.

[0511] Fioris et al.(2011)Molecular Informatics 31:12-20.

[0512] Giamann et al.(2006)4:555-563.

[0513] Gilfillan et al.(2008)The J Exp Med 205:2965-2973.

[0514] Good(2001)Current Opinion in Drug Disc.Devel.5:301.

[0515] Grabowska et al.(2014)Cancer Metastasis Rev 33:377-397.

[0516] Hoek et al(2015)PLOS One,10:e0118528.

[0517] Howl et al.(2007),Biochem Soc Trans 35:767-769.

[0518] Jang et al.(2012)Ann Clin Lab Sci 42:42-49.

[0519] Jensik et al.(2015)Mol Cell Endocrinol 401:130-141.

[0520] Johnstone et al.(2015)Dis Model Mech 8:237-251.

[0521] Keilhauer et al.(2015)Mol Cell Proteomics 14:120-135.

[0522] Kershaw et al.(2013)Nat Struct Mol Biol 20:469-476.

[0523] Koppelhus et al.(2008)Bioconj Chem 19:1526-34.

[0524] Kolesnik and Nicholson(2013)Methods Mol Biol 967:235-248.

[0525] Kopsidas et al.(2007)BMC Biotechnology 7:18-29.

[0526] Kuenemann et al.(2015)Prog.Biophys.Mol.Biol 119:20-32.

[0527] Larkin et al.(2015)N Engl J Med 373:23-34.

[0528] Lee et al.(2008)Blood 111:885-893.

[0529] Li and Wu(2009)Methods Mol Biol 570:67-76.

[0530] Linossi et al.(2013)PLoS One 8,e70536,doi:10.1371 / journal.pone.0070536.

[0531] Male et al.(2013),Future Medicine,Oct.2013,118-133.

[0532] Martinet et al.(2015),Cell Rep.,11(1):85-97.

[0533] Matsumoto et al.(1997)Blood 89:3148-3154.

[0534] Mills et al.(2001)J Comp.Aided Mol Des 15:81-96.

[0535] Mlecnik et al.(2014)Sci Transl Med 6:228-237.

[0536] Narni-Mancinelli et al.(2011)Proc Natl Acad Sci USA 108:18324-18329.

[0537] Needleman and Wunsch(1970)J.Mol.Biol.,48:444-453.

[0538] Nicholson et al.(1995)Blood 86:3698-3704.

[0539] Ng et al.(2003)Nucleic Acids Research 31:3812-3814.

[0540] Palmet et al.(2015)The Journal of Experimental Medicine 212:2095-2113.

[0541] Perkin et al.(1995)J Comp.Aided.Mol.Des.9:479-490.

[0542] Postow et al.(2015)N Engl J Med 372:2006-2017.

[0543] Rautela et al.(2005)Cancer Immunol Res 3:1207-1217.

[0544] Rossi et al.(2014)Cell Death and Disease,5:e1203.

[0545] Ruggeri et al.(2016)Blood 128(23):2616-2623.

[0546] Sathe et al.(2014)Nat Commun 5:4539.

[0547] Schirle et al.(2012)in Kinase Inhibitors Vol.795 Methods in MolecularBiology(ed Bernhard Kuster)Ch.11,161-177(Humana Press).

[0548] Shihab et al.(2013)Human Mutation 34:57-65.

[0549] Sim et al.(2012)Nucleic Acids Research 40(Web Server Issue):W452-457.

[0550] Stagg et al.(2011a)Cancer Res 71:2892-2900.

[0551] Stagg et al.(2011b)Proc Natl Acad Sci USA 108:7142-7147.

[0552] Swarn et al.(2007)J Immunol 178:7540-7549.

[0553] Von Ahsen et al.(2005)Chembiochem 6:481-490.

[0554] Walker et al.(2011)Pigment Cell Melanoma Res 24:1158-1176.

[0555] Walzer et al.(2007)Proc Natl Acad Sci USA 104:3384-3389.

[0556] Westermaier et al.(2015)Methods,71:44057.

[0557] Whiteside(2002)Biotechniques 33:S4-S15.

[0558] Wisniewski et al.(2009)Nat Methods 6:359-362.

[0559] Wu(2013)J Mol Genet Med,7:85.

[0560] Yao et al. (2005) Methods Mol Biol 298:91-103.

[0561] Yang et al. (2013) Nat Immunol 14:732-740.

[0562] Yoshimura et al. (2015) Embo J 14:2816-2826.

[0563] Zetsche et al. (2015) Cell 163: 1-3

[0564] Zhang et al. (1999) Proc Natl Acad Sci USA 96:2071-2076.

[0565] Zhang et al. (2015) J.Chem.Inf.Model 54:324-337.

[0566] Zhu et al. (2009) J Biomolecular Screening 14:1157-1164. Sequence Listing <110> Walter and Eliza Hall Institute of Medical Research <120> Inhibition of cytokine-induced SH2 protein in NK cells <130> P20137343WPD <150> AU 2015905220 <151> 2015-12-16 <160> 38 <170> PatentIn version 3.5 <210> 1 <211> 16 <212> PRT <213> Homo sapiens <220> <221> MISC_FEATURE <222> (8) <223> Phosphorylation of tyrosine <400> 1 Ala Ile Glu Thr Asp Lys Glu Tyr Tyr Thr Val Lys Asp Asp Arg Asp 1 5 10 15 <210> 2 <211> 5 <212> PRT <213> Homo sapiens <220> <221> X <222> (3) <223> [F2PMP] 2-phosphotyrosyl mimetic 4-(Phosphonodifluoromethyl)phenylalanine moiety <400> 2 Lys Glu Xaa Thr Val 1 5 <210> 3 <211> 12 <212> PRT <213> Homo sapiens <220> <221> MISC_FEATURE <222> (4) <223> Phosphorylation residues <400> 3 Cys Gln Val Tyr Phe Thr Tyr Asp Pro Tyr Ser Glu 1 5 10 <210> 4 <211> 12 <212> PRT <213> Homo sapiens <220> <221> MISC_FEATURE <222> (4) <223> Phosphorylation of tyrosine <400> 4 Tyr Asp Pro Tyr Ser Glu Glu Asp Pro Asp Glu Gly 1 5 10 <210> 5 <211> 12 <212> PRT <213> Homo sapiens <220> <221> MISC_FEATURE <222> (4)..(4) <223> Phosphorylated tyrosine <400> 5 Asp Asp Ala Tyr Cys Thr Phe Pro Ser Arg Asp Asp 1 5 10 <210> 6 <211> 258 <212> PRT <213> Homo sapiens <400> 6 Met Val Leu Cys Val Gln Gly Pro Arg Pro Leu Leu Ala Val Glu Arg 1 5 10 15 Thr Gly Gln Arg Pro Leu Trp Ala Pro Ser Leu Glu Leu Pro Lys Pro 20 25 30 Val Met Gln Pro Leu Pro Ala Gly Ala Phe Leu Glu Glu Val Ala Glu 35 40 45 Gly Thr Pro Ala Gln Thr Glu Ser Glu Pro Lys Val Leu Asp Pro Glu 50 55 60 Glu Asp Leu Leu Cys Ile Ala Lys Thr Phe Ser Tyr Leu Arg Glu Ser 65 70 75 80 Gly Trp Tyr Trp Gly Ser Ile Thr Ala Ser Glu Ala Arg Gln His Leu 85 90 95 Gln Lys Met Pro Glu Gly Thr Phe Leu Val Arg Asp Ser Thr His Pro 100 105 110 Ser Tyr Leu Phe Thr Leu Ser Val Lys Thr Thr Arg Gly Pro Thr Asn 115 120 125 Val Arg Ile Glu Tyr Ala Asp Ser Ser Phe Arg Leu Asp Ser Asn Cys 130 135 140 Leu Ser Arg Pro Arg Ile Leu Ala Phe Pro Asp Val Val Ser Leu Val 145 150 155 160 Gln His Tyr Val Ala Ser Cys Thr Ala Asp Thr Arg Ser Asp Ser Pro 165 170 175 Asp Pro Ala Pro Thr Pro Ala Leu Pro Met Pro Lys Glu Asp Ala Pro 180 185 190 Ser Asp Pro Ala Leu Pro Ala Pro Pro Pro Ala Thr Ala Val His Leu 195 200 205 Lys Leu Val Gln Pro Phe Val Arg Arg Ser Ser Ala Arg Ser Leu Gln 210 215 220 His Leu Cys Arg Leu Val Ile Asn Arg Leu Val Ala Asp Val Asp Cys 225 230 235 240 Leu Pro Leu Pro Arg Arg Met Ala Asp Tyr Leu Arg Gln Tyr Pro Phe 245 250 255 Leo Gln <210> 7 <211> 164 <212> PRT <213> Homo sapiens <400> 7 Asp Leu Leu Cys Ile Ala Lys Thr Phe Ser Tyr Leu Arg Glu Ser Gly 1 5 10 15 Trp Tyr Trp Gly Ser Ile Thr Ala Ser Glu Ala Arg Gln His Leu Gln 20 25 30 Lys Met Pro Glu Gly Thr Phe Leu Val Arg Asp Ser Thr His Pro Ser 35 40 45 Tyr Leu Phe Thr Leu Ser Val Lys Thr Thr Arg Gly Pro Thr Asn Val 50 55 60 Arg Ile Glu Tyr Ala Asp Ser Ser Phe Arg Leu Asp Ser Asn Cys Leu 65 70 75 80 Ser Arg Pro Arg Ile Leu Ala Phe Pro Asp Val Val Ser Leu Val Gln 85 90 95 His Tyr Val Ala Ser Cys Thr Ala Asp Thr Arg Ser Ala Thr Ala Val 100 105 110 His Leu Lys Leu Val Gln Pro Phe Val Arg Arg Ser Ser Ala Arg Ser 115 120 125 Leu Gln His Leu Cys Arg Leu Val Ile Asn Arg Leu Val Ala Asp Val 130 135 140 Asp Cys Leu Pro Leu Pro Arg Arg Met Ala Asp Tyr Leu Arg Gln Tyr 145 150 155 160 Pro Phe Gln Leu <210> 8 <211> 41 <212> PRT <213> Homo sapiens <400> 8 Ser Ser Ala Arg Ser Leu Gln His Leu Cys Arg Leu Val Ile Asn Arg 1 5 10 15 Leu Val Ala Asp Val Asp Cys Leu Pro Leu Pro Arg Arg Met Ala Asp 20 25 30 Tyr Leu Arg Gln Tyr Pro Phe Gln Leu 35 40 <210> 9 <211> 257 <212> PRT <213> Mus musculus <400> 9 Met Val Leu Cys Val Gln Gly Ser Cys Pro Leu Leu Ala Val Glu Gln 1 5 10 15 Ile Gly Arg Arg Pro Leu Trp Ala Gln Ser Leu Glu Leu Pro Gly Pro 20 25 30 Ala Met Gln Pro Leu Pro Thr Gly Ala Phe Pro Glu Glu Val Thr Glu 35 40 45 Glu Thr Pro Val Gln Ala Glu Asn Glu Pro Lys Val Leu Asp Pro Glu 50 55 60 Gly Asp Leu Leu Cys Ile Ala Lys Thr Phe Ser Tyr Leu Arg Glu Ser 65 70 75 80 Gly Trp Tyr Trp Gly Ser Ile Thr Ala Ser Glu Ala Arg Gln His Leu 85 90 95 Gln Lys Met Pro Glu Gly Thr Phe Leu Val Arg Asp Ser Thr His Pro 100 105 110 Ser Tyr Leu Phe Thr Leu Ser Val Lys Thr Thr Arg Gly Pro Thr Asn 115 120 125 Val Arg Ile Glu Tyr Ala Asp Ser Ser Phe Arg Leu Asp Ser Asn Cys 130 135 140 Leu Ser Arg Pro Arg Ile Leu Ala Phe Pro Asp Val Val Ser Leu Val 145 150 155 160 Gln His Tyr Val Ala Ser Cys Ala Ala Asp Thr Arg Ser Asp Ser Pro 165 170 175 Asp Pro Ala Pro Thr Pro Ala Leu Pro Met Ser Lys Gln Asp Ala Pro 180 185 190 Ser Asp Ser Val Leu Pro Ile Pro Val Ala Thr Ala Val His Leu Lys 195 200 205 Leu Val Gln Pro Phe Val Arg Arg Ser Ser Ala Arg Ser Leu Gln His 210 215 220 Leu Cys Arg Leu Val Ile Asn Arg Leu Val Ala Asp Val Asp Cys Leu 225 230 235 240 Pro Leu Pro Arg Arg Met Ala Asp Tyr Leu Arg Gln Tyr Pro Phe Gln 245 250 255 Leu <210> 10 <211> 257 <212> PRT <213> Brown rat <400> 10 Met Val Leu Cys Val Gln Gly Ser Cys Pro Leu Leu Val Val Glu Gln 1 5 10 15 Ile Gly Gln Arg Pro Leu Trp Ala Gln Ser Leu Glu Leu Pro Gly Pro 20 25 30 Ala Met Gln Pro Leu Pro Thr Gly Ala Phe Pro Glu Glu Val Thr Glu 35 40 45 Glu Thr Pro Val Gln Ser Glu Asn Glu Pro Lys Val Leu Asp Pro Glu 50 55 60 Gly Asp Leu Leu Cys Ile Ala Lys Thr Phe Ser Tyr Leu Arg Glu Ser 65 70 75 80 Gly Trp Tyr Trp Gly Ser Ile Thr Ala Ser Glu Ala Arg Gln His Leu 85 90 95 Gln Lys Met Pro Glu Gly Thr Phe Leu Val Arg Asp Ser Thr His Pro 100 105 110 Ser Tyr Leu Phe Thr Leu Ser Val Lys Thr Thr Arg Gly Pro Thr Asn 115 120 125 Val Arg Ile Glu Tyr Ala Asp Ser Ser Phe Arg Leu Asp Ser Asn Cys 130 135 140 Leu Ser Arg Pro Arg Ile Leu Ala Phe Pro Asp Val Val Ser Leu Val 145 150 155 160 Gln His Tyr Val Ala Ser Cys Thr Ala Asp Thr Arg Ser Asp Ser Pro 165 170 175 Asp Pro Ala Pro Thr Pro Ala Leu Pro Val Pro Lys Pro Asp Ala Pro 180 185 190 Gly Asp Pro Val Leu Pro Ile Pro Val Ala Thr Ala Val His Leu Lys 195 200 205 Leu Val Gln Pro Phe Val Arg Arg Ser Ser Ala Arg Ser Leu Gln His 210 215 220 Leu Cys Arg Leu Val Ile Asn Arg Leu Val Thr Asp Val Asp Cys Leu 225 230 235 240 Pro Leu Pro Arg Arg Met Ala Asp Tyr Leu Arg Gln Tyr Pro Phe Gln 245 250 255 Lion <210> 11 <211> 1154 <212> PRT <213> Homo sapiens <400> 11 Met Gln Tyr Leu Asn Ile Lys Glu Asp Cys Asn Ala Met Ala Phe Cys 1 5 10 15 Ala Lys Met Arg Ser Ser Lys Lys Thr Glu Val Asn Leu Glu Ala Pro 20 25 30 Glu Pro Gly Val Glu Val Ile Phe Tyr Leu Ser Asp Arg Glu Pro Leu 35 40 45 Arg Leu Gly Ser Gly Glu Tyr Thr Ala Glu Glu Leu Cys Ile Arg Ala 50 55 60 Ala Gln Ala Cys Arg Ile Ser Pro Leu Cys His Asn Leu Phe Ala Leu 65 70 75 80 Tyr Asp Glu Asn Thr Lys Leu Trp Tyr Ala Pro Asn Arg Thr Ile Thr 85 90 95 Val Asp Asp Lys Met Ser Leu Arg Leu His Tyr Arg Met Arg Phe Tyr 100 105 110 Phe Thr Asn Trp His Gly Thr Asn Asp Asn Glu Gln Ser Val Trp Arg 115 120 125 His Ser Pro Lys Lys Gln Lys Asn Gly Tyr Glu Lys Lys Lys Ile Pro 130 135 140 Asp Ala Thr Pro Leu Leu Asp Ala Ser Ser Leu Glu Tyr Leu Phe Ala 145 150 155 160 Gln Gly Gln Tyr Asp Leu Val Lys Cys Leu Ala Pro Ile Arg Asp Pro 165 170 175 Lys Thr Glu Gln Asp Gly His Asp Ile Glu Asn Glu Cys Leu Gly Met 180 185 190 Ala Val Leu Ala Ile Ser His Tyr Ala Met Met Lys Lys Met Gln Leu 195 200 205 Pro Glu Leu Pro Lys Asp Ile Ser Tyr Lys Arg Tyr Ile Pro Glu Thr 210 215 220 Leu Asn Lys Ser Ile Arg Gln Arg Asn Leu Leu Thr Arg Met Arg Ile 225 230 235 240 Asn Asn Val Phe Lys Asp Phe Leu Lys Glu Phe Asn Asn Lys Thr Ile 245 250 255 Cys Asp Ser Ser Val Ser Thr His Asp Leu Lys Val Lys Tyr Leu Ala 260 265 270 Thr Leu Glu Thr Leu Thr Lys His Tyr Gly Ala Glu Ile Phe Glu Thr 275 280 285 Ser Met Leu Leu Ile Ser Ser Glu Asn Glu Met Asn Trp Phe His Ser 290 295 300 Asn Asp Gly Gly Asn Val Leu Tyr Tyr Glu Val Met Val Thr Gly Asn 305 310 315 320 Leu Gly Ile Gln Trp Arg His Lys Pro Asn Val Val Ser Val Glu Lys 325 330 335 Glu Lys Asn Lys Leu Lys Arg Lys Lys Leu Glu Asn Lys His Lys Lys 340 345 350 Asp Glu Glu Lys Asn Lys Ile Arg Glu Glu Trp Asn Asn Phe Ser Tyr 355 360 365 Phe Pro Glu Ile Thr His Ile Val Ile Lys Glu Ser Val Val Ser Ile 370 375 380 Asn Lys Gln Asp Asn Lys Lys Met Glu Leu Lys Leu Ser Ser His Glu 385 390 395 400 Glu Ala Leu Ser Phe Val Ser Leu Val Asp Gly Tyr Phe Arg Leu Thr 405 410 415 Ala Asp Ala His His Tyr Leu Cys Thr Asp Val Ala Pro Pro Leu Ile 420 425 430 Val His Asn Ile Gln Asn Gly Cys His Gly Pro Ile Cys Thr Glu Tyr 435 440 445 Ala Ile Asn Lys Leu Arg Gln Glu Gly Ser Glu Glu Gly Met Tyr Val 450 455 460 Leu Arg Trp Ser Cys Thr Asp Phe Asp Asn Ile Leu Met Thr Val Thr 465 470 475 480 Cys Phe Glu Lys Ser Glu Gln Val Gln Gly Ala Gln Lys Gln Phe Lys 485 490 495 Asn Phe Gln Ile Glu Val Gln Lys Gly Arg Tyr Ser Leu His Gly Ser 500 505 510 Asp Arg Ser Phe Pro Ser Leu Gly Asp Leu Met Ser His Leu Lys Lys 515 520 525 Gln Ile Leu Arg Thr Asp Asn Ile Ser Phe Met Leu Lys Arg Cys Cys 530 535 540 Gln Pro Lys Pro Arg Glu Ile Ser Asn Leu Leu Val Ala Thr Lys Lys 545 550 555 560 Ala Gln Glu Trp Gln Pro Val Tyr Pro Met Ser Gln Leu Ser Phe Asp 565 570 575 Arg Ile Leu Lys Lys Asp Leu Val Gln Gly Glu His Leu Gly Arg Gly 580 585 590 Thr Arg Thr His Ile Tyr Ser Gly Thr Leu Met Asp Tyr Lys Asp Asp 595 600 605 Glu Gly Thr Ser Glu Glu Lys Lys Ile Lys Val Ile Leu Lys Val Leu 610 615 620 Asp Pro Ser His Arg Asp Ile Ser Leu Ala Phe Phe Glu Ala Ala Ser 625 630 635 640 Met Met Arg Gln Val Ser His Lys His Ile Val Tyr Leu Tyr Gly Val 645 650 655 Cys Val Arg Asp Val Glu Asn Ile Met Val Glu Glu Phe Val Glu Gly 660 665 670 Gly Pro Leu Asp Leu Phe Met His Arg Lys Ser Asp Val Leu Thr Thr 675 680 685 Pro Trp Lys Phe Lys Val Ala Lys Gln Leu Ala Ser Ala Leu Ser Tyr 690 695 700 Leu Glu Asp Lys Asp Leu Val His Gly Asn Val Cys Thr Lys Asn Leu 705 710 715 720 Leu Leu Ala Arg Glu Gly Ile Asp Ser Glu Cys Gly Pro Phe Ile Lys 725 730 735 Leu Ser Asp Pro Gly Ile Pro Ile Thr Val Leu Ser Arg Gln Glu Cys 740 745 750 Ile Glu Arg Ile Pro Trp Ile Ala Pro Glu Cys Val Glu Asp Ser Lys 755 760 765 Asn Leu Ser Val Ala Ala Asp Lys Trp Ser Phe Gly Thr Thr Leu Trp 770 775 780 Glu Ile Cys Tyr Asn Gly Glu Ile Pro Leu Lys Asp Lys Thr Leu Ile 785 790 795 800 Glu Lys Glu Arg Phe Tyr Glu Ser Arg Cys Arg Pro Val Thr Pro Ser 805 810 815 Cys Lys Glu Leu Ala Asp Leu Met Thr Arg Cys Met Asn Tyr Asp Pro 820 825 830 Asn Gln Arg Pro Phe Phe Arg Ala Ile Met Arg Asp Ile Asn Lys Leu 835 840 845 Glu Glu Gln Asn Pro Asp Ile Val Ser Glu Lys Lys Pro Ala Thr Glu 850 855 860 Val Asp Pro Thr His Phe Glu Lys Arg Phe Leu Lys Arg Ile Arg Asp 865 870 875 880 Leu Gly Glu Gly His Phe Gly Lys Val Glu Leu Cys Arg Tyr Asp Pro 885 890 895 Glu Gly Asp Asn Thr Gly Glu Gln Val Ala Val Lys Ser Leu Lys Pro 900 905 910 Glu Ser Gly Gly Asn His Ile Ala Asp Leu Lys Lys Glu Ile Glu Ile 915 920 925 Leu Arg Asn Leu Tyr His Glu Asn Ile Val Lys Tyr Lys Gly Ile Cys 930 935 940 Thr Glu Asp Gly Gly Asn Gly Ile Lys Leu Ile Met Glu Phe Leu Pro 945 950 955 960 Ser Gly Ser Leu Lys Glu Tyr Leu Pro Lys Asn Lys Asn Lys Ile Asn 965 970 975 Leu Lys Gln Gln Leu Lys Tyr Ala Val Gln Ile Cys Lys Gly Met Asp 980 985 990 Tyr Leu Gly Ser Arg Gln Tyr Val His Arg Asp Leu Ala Ala Arg Asn 995 1000 1005 Val Leu Val Glu Ser Glu His Gln Val Lys Ile Gly Asp Phe Gly 1010 1015 1020 Leu Thr Lys Ala Ile Glu Thr Asp Lys Glu Tyr Tyr Thr Val Lys 1025 1030 1035 Asp Asp Arg Asp Ser Pro Val Phe Trp Tyr Ala Pro Glu Cys Leu 1040 1045 1050 Met Gln Ser Lys Phe Tyr Ile Ala Ser Asp Val Trp Ser Phe Gly 1055 1060 1065 Val Thr Leu His Glu Leu Leu Thr Tyr Cys Asp Ser Asp Ser Ser 1070 1075 1080 Pro Met Ala Leu Phe Leu Lys Met Ile Gly Pro Thr His Gly Gln 1085 1090 1095 Met Thr Val Thr Arg Leu Val Asn Thr Leu Lys Glu Gly Lys Arg 1100 1105 1110 Leu Pro Cys Pro Pro Asn Cys Pro Asp Glu Val Tyr Gln Leu Met 1115 1120 1125 Arg Lys Cys Trp Glu Phe Gln Pro Ser Asn Arg Thr Ser Phe Gln 1130 1135 1140 Asn Leu Ile Glu Gly Phe Glu Ala Leu Leu Lys 1145 1150 <210> 12 <211> 1124 <212> PRT <213> Homo sapiens <400> 12 Met Ala Pro Pro Ser Glu Glu Thr Pro Leu Ile Pro Gln Arg Ser Cys 1 5 10 15 Ser Leu Leu Ser Thr Glu Ala Gly Ala Leu His Val Leu Leu Pro Ala 20 25 30 Arg Gly Pro Gly Pro Pro Gln Arg Leu Ser Phe Ser Phe Gly Asp His 35 40 45 Leu Ala Glu Asp Leu Cys Val Gln Ala Ala Lys Ala Ser Gly Ile Leu 50 55 60 Pro Val Tyr His Ser Leu Phe Ala Leu Ala Thr Glu Asp Leu Ser Cys 65 70 75 80 Trp Phe Pro Pro Ser His Ile Phe Ser Val Glu Asp Ala Ser Thr Gln 85 90 95 Val Leu Leu Tyr Arg Ile Arg Phe Tyr Phe Pro Asn Trp Phe Gly Leu 100 105 110 Glu Lys Cys His Arg Phe Gly Leu Arg Lys Asp Leu Ala Ser Ala Ile 115 120 125 Leu Asp Leu Pro Val Leu Glu His Leu Phe Ala Gln His Arg Ser Asp 130 135 140 Leu Val Ser Gly Arg Leu Pro Val Gly Leu Ser Leu Lys Glu Gln Gly 145 150 155 160 Glu Cys Leu Ser Leu Ala Val Leu Asp Leu Ala Arg Met Ala Arg Glu 165 170 175 Gln Ala Gln Arg Pro Gly Glu Leu Leu Lys Thr Val Ser Tyr Lys Ala 180 185 190 Cys Leu Pro Pro Ser Leu Arg Asp Leu Ile Gln Gly Leu Ser Phe Val 195 200 205 Thr Arg Arg Arg Ile Arg Arg Thr Val Arg Arg Ala Leu Arg Arg Val 210 215 220 Ala Ala Cys Gln Ala Asp Arg His Ser Leu Met Ala Lys Tyr Ile Met 225 230 235 240 Asp Leu Glu Arg Leu Asp Pro Ala Gly Ala Ala Glu Thr Phe His Val 245 250 255 Gly Leu Pro Gly Ala Leu Gly Gly His Asp Gly Leu Gly Leu Leu Arg 260 265 270 Val Ala Gly Asp Gly Gly Ile Ala Trp Thr Gln Gly Glu Gln Glu Val 275 280 285 Leu Gln Pro Phe Cys Asp Phe Pro Glu Ile Val Asp Ile Ser Ile Lys 290 295 300 Gln Ala Pro Arg Val Gly Pro Ala Gly Glu His Arg Leu Val Thr Val 305 310 315 320 Thr Arg Thr Asp Asn Gln Ile Leu Glu Ala Glu Phe Pro Gly Leu Pro 325 330 335 Glu Ala Leu Ser Phe Val Ala Leu Val Asp Gly Tyr Phe Arg Leu Thr 340 345 350 Thr Asp Ser Gln His Phe Phe Cys Lys Glu Val Ala Pro Pro Arg Leu 355 360 365 Leu Glu Glu Val Ala Glu Gln Cys His Gly Pro Ile Thr Leu Asp Phe 370 375 380 Ala Ile Asn Lys Leu Lys Thr Gly Gly Ser Arg Pro Gly Ser Tyr Val 385 390 395 400 Leu Arg Arg Ser Pro Gln Asp Phe Asp Ser Phe Leu Leu Thr Val Cys 405 410 415 Val Gln Asn Pro Leu Gly Pro Asp Tyr Lys Gly Cys Leu Ile Arg Arg 420 425 430 Ser Pro Thr Gly Thr Phe Leu Leu Val Gly Leu Ser Arg Pro His Ser 435 440 445 Ser Leu Arg Glu Leu Leu Ala Thr Cys Trp Asp Gly Gly Leu His Val 450 455 460 Asp Gly Val Ala Val Thr Leu Thr Ser Cys Cys Ile Pro Arg Pro Lys 465 470 475 480 Glu Lys Ser Asn Leu Ile Val Val Gln Arg Gly His Ser Pro Pro Thr 485 490 495 Ser Ser Leu Val Gln Pro Gln Ser Gln Tyr Gln Leu Ser Gln Met Thr 500 505 510 Phe His Lys Ile Pro Ala Asp Ser Leu Glu Trp His Glu Asn Leu Gly 515 520 525 His Gly Ser Phe Thr Lys Ile Tyr Arg Gly Cys Arg His Glu Val Val 530 535 540 Asp Gly Glu Ala Arg Lys Thr Glu Val Leu Leu Lys Val Met Asp Ala 545 550 555 560 Lys His Lys Asn Cys Met Glu Ser Phe Leu Glu Ala Ala Ser Leu Met 565 570 575 Ser Gln Val Ser Tyr Arg His Leu Val Leu Leu His Gly Val Cys Met 580 585 590 Ala Gly Asp Ser Thr Met Val Gln Glu Phe Val His Leu Gly Ala Ile 595 600 605 Asp Met Tyr Leu Arg Lys Arg Gly His Leu Val Pro Ala Ser Trp Lys 610 615 620 Leu Gln Val Val Lys Gln Leu Ala Tyr Ala Leu Asn Tyr Leu Glu Asp 625 630 635 640 Lys Gly Leu Pro His Gly Asn Val Ser Ala Arg Lys Val Leu Leu Ala 645 650 655 Arg Glu Gly Ala Asp Gly Ser Pro Pro Phe Ile Lys Leu Ser Asp Pro 660 665 670 Gly Val Ser Pro Ala Val Leu Ser Leu Glu Met Leu Thr Asp Arg Ile 675 680 685 Pro Trp Val Ala Pro Glu Cys Leu Arg Glu Ala Gln Thr Leu Ser Leu 690 695 700 Glu Ala Asp Lys Trp Gly Phe Gly Ala Thr Val Trp Glu Val Phe Ser 705 710 715 720 Gly Val Thr Met Pro Ile Ser Ala Leu Asp Pro Ala Lys Lys Leu Gln 725 730 735 Phe Tyr Glu Asp Arg Gln Gln Leu Pro Ala Pro Lys Trp Thr Glu Leu 740 745 750 Ala Leu Leu Ile Gln Gln Cys Met Ala Tyr Glu Pro Val Gln Arg Pro 755 760 765 Ser Phe Arg Ala Val Ile Arg Asp Leu Asn Ser Leu Ile Ser Ser Asp 770 775 780 Tyr Glu Leu Leu Ser Asp Pro Thr Pro Gly Ala Leu Ala Pro Arg Asp 785 790 795 800 Gly Leu Trp Asn Gly Ala Gln Leu Tyr Ala Cys Gln Asp Pro Thr Ile 805 810 815 Phe Glu Glu Arg His Leu Lys Tyr Ile Ser Gln Leu Gly Lys Gly Asn 820 825 830 Phe Gly Ser Val Glu Leu Cys Arg Tyr Asp Pro Leu Gly Asp Asn Thr 835 840 845 Gly Ala Leu Val Ala Val Lys Gln Leu Gln His Ser Gly Pro Asp Gln 850 855 860 Gln Arg Asp Phe Gln Arg Glu Ile Gln Ile Leu Lys Ala Leu His Ser 865 870 875 880 Asp Phe Ile Val Lys Tyr Arg Gly Val Ser Tyr Gly Pro Gly Arg Gln 885 890 895 Ser Leu Arg Leu Val Met Glu Tyr Leu Pro Ser Gly Cys Leu Arg Asp 900 905 910 Phe Leu Gln Arg His Arg Ala Arg Leu Asp Ala Ser Arg Leu Leu Leu 915 920 925 Tyr Ser Ser Gln Ile Cys Lys Gly Met Glu Tyr Leu Gly Ser Arg Arg 930 935 940 Cys Val His Arg Asp Leu Ala Ala Arg Asn Ile Leu Val Glu Ser Glu 945 950 955 960 Ala His Val Lys Ile Ala Asp Phe Gly Leu Ala Lys Leu Leu Pro Leu 965 970 975 Asp Lys Asp Tyr Tyr Val Val Arg Glu Pro Gly Gln Ser Pro Ile Phe 980 985 990 Trp Tyr Ala Pro Glu Ser Leu Ser Asp Asn Ile Phe Ser Arg Gln Ser 995 1000 1005 Asp Val Trp Ser Phe Gly Val Val Leu Tyr Glu Leu Phe Thr Tyr 1010 1015 1020 Cys Asp Lys Ser Cys Ser Pro Ser Ala Glu Phe Leu Arg Met Met 1025 1030 1035 Gly Cys Glu Arg Asp Val Pro Ala Leu Cys Arg Leu Leu Glu Leu 1040 1045 1050 Leu Glu Glu Gly Gln Arg Leu Pro Ala Pro Pro Ala Cys Pro Ala 1055 1060 1065 Glu Val His Glu Leu Met Lys Leu Cys Trp Ala Pro Ser Pro Gln 1070 1075 1080 Asp Arg Pro Ser Phe Ser Ala Leu Gly Pro Gln Leu Asp Met Leu 1085 1090 1095 Trp Ser Gly Ser Arg Gly Cys Glu Thr His Ala Phe Thr Ala His 1100 1105 1110 Pro Glu Gly Lys His His Ser Leu Ser Phe Ser 1115 1120 <210> 13 <211> 551 <212> PRT <213> Homo sapiens <400> 13 Met Ala Ala Pro Ala Leu Ser Trp Arg Leu Pro Leu Leu Ile Leu Leu 1 5 10 15 Leu Pro Leu Ala Thr Ser Trp Ala Ser Ala Ala Val Asn Gly Thr Ser 20 25 30 Gln Phe Thr Cys Phe Tyr Asn Ser Arg Ala Asn Ile Ser Cys Val Trp 35 40 45 Ser Gln Asp Gly Ala Leu Gln Asp Thr Ser Cys Gln Val His Ala Trp 50 55 60 Pro Asp Arg Arg Arg Trp Asn Gln Thr Cys Glu Leu Leu Pro Val Ser 65 70 75 80 Gln Ala Ser Trp Ala Cys Asn Leu Ile Leu Gly Ala Pro Asp Ser Gln 85 90 95 Lys Leu Thr Thr Val Asp Ile Val Thr Leu Arg Val Leu Cys Arg Glu 100 105 110 Gly Val Arg Trp Arg Val Met Ala Ile Gln Asp Phe Lys Pro Phe Glu 115 120 125 Asn Leu Arg Leu Met Ala Pro Ile Ser Leu Gln Val Val His Val Glu 130 135 140 Thr His Arg Cys Asn Ile Ser Trp Glu Ile Ser Gln Ala Ser His Tyr 145 150 155 160 Phe Glu Arg His Leu Glu Phe Glu Ala Arg Thr Leu Ser Pro Gly His 165 170 175 Thr Trp Glu Glu Ala Pro Leu Leu Thr Leu Lys Gln Lys Gln Glu Trp 180 185 190 Ile Cys Leu Glu Thr Leu Thr Pro Asp Thr Gln Tyr Glu Phe Gln Val 195 200 205 Arg Val Lys Pro Leu Gln Gly Glu Phe Thr Thr Trp Ser Pro Trp Ser 210 215 220 Gln Pro Leu Ala Phe Arg Thr Lys Pro Ala Ala Leu Gly Lys Asp Thr 225 230 235 240 Ile Pro Trp Leu Gly His Leu Leu Val Gly Leu Ser Gly Ala Phe Gly 245 250 255 Phe Ile Ile Leu Val Tyr Leu Leu Ile Asn Cys Arg Asn Thr Gly Pro 260 265 270 Trp Leu Lys Lys Val Leu Lys Cys Asn Thr Pro Asp Pro Ser Lys Phe 275 280 285 Phe Ser Gln Leu Ser Ser Glu His Gly Gly Asp Val Gln Lys Trp Leu 290 295 300 Ser Ser Pro Phe Pro Ser Ser Ser Phe Ser Pro Gly Gly Leu Ala Pro 305 310 315 320 Glu Ile Ser Pro Leu Glu Val Leu Glu Arg Asp Lys Val Thr Gln Leu 325 330 335 Leu Leu Gln Gln Asp Lys Val Pro Glu Pro Ala Ser Leu Ser Ser Asn 340 345 350 His Ser Leu Thr Ser Cys Phe Thr Asn Gln Gly Tyr Phe Phe Phe His 355 360 365 Leu Pro Asp Ala Leu Glu Ile Glu Ala Cys Gln Val Tyr Phe Thr Tyr 370 375 380 Asp Pro Tyr Ser Glu Glu Asp Pro Asp Glu Gly Val Ala Gly Ala Pro 385 390 395 400 Thr Gly Ser Ser Pro Gln Pro Leu Gln Pro Leu Ser Gly Glu Asp Asp 405 410 415 Ala Tyr Cys Thr Phe Pro Ser Arg Asp Asp Leu Leu Leu Phe Ser Pro 420 425 430 Ser Leu Leu Gly Gly Pro Ser Pro Pro Ser Thr Ala Pro Gly Gly Ser 435 440 445 Gly Ala Gly Glu Glu Arg Met Pro Pro Ser Leu Gln Glu Arg Val Pro 450 455 460 Arg Asp Trp Asp Pro Gln Pro Leu Gly Pro Pro Thr Pro Gly Val Pro 465 470 475 480 Asp Leu Val Asp Phe Gln Pro Pro Pro Glu Leu Val Leu Arg Glu Ala 485 490 495 Gly Glu Glu Val Pro Asp Ala Gly Pro Arg Glu Gly Val Ser Phe Pro 500 505 510 Trp Ser Arg Pro Pro Gly Gln Gly Glu Phe Arg Ala Leu Asn Ala Arg 515 520 525 Leu Pro Leu Asn Thr Asp Ala Tyr Leu Ser Leu Gln Glu Leu Gln Gly 530 535 540 Gln Asp Pro Thr His Leu Val 545 550 <210> 14 <211> 118 <212> PRT <213> Homo sapiens <400> 14 Met Asp Val Phe Leu Met Ile Arg Arg His Lys Thr Thr Ile Phe Thr 1 5 10 15 Asp Ala Lys Glu Ser Ser Thr Val Phe Glu Leu Lys Arg Ile Val Glu 20 25 30 Gly Ile Leu Lys Arg Pro Pro Asp Glu Gln Arg Leu Tyr Lys Asp Asp 35 40 45 Gln Leu Leu Asp Asp Gly Lys Thr Leu Gly Glu Cys Gly Phe Thr Ser 50 55 60 Gln Thr Ala Arg Pro Gln Ala Pro Ala Thr Val Gly Leu Ala Phe Arg 65 70 75 80 Ala Asp Asp Thr Phe Glu Ala Leu Cys Ile Glu Pro Phe Ser Ser Pro 85 90 95 Pro Glu Leu Pro Asp Val Met Lys Pro Gln Asp Ser Gly Ser Ser Ala 100 105 110 Asn Glu Gln Ala Val Gln 115 <210> 15 <211> 112 <212> PRT <213> Homo sapiens <400> 15 Met Asp Gly Glu Glu Lys Thr Tyr Gly Gly Cys Glu Gly Pro Asp Ala 1 5 10 15 Met Tyr Val Lys Leu Ile Ser Ser Asp Gly His Glu Phe Ile Val Lys 20 25 30 Arg Glu His Ala Leu Thr Ser Gly Thr Ile Lys Ala Met Leu Ser Gly 35 40 45 Pro Gly Gln Phe Ala Glu Asn Glu Thr Asn Glu Val Asn Phe Arg Glu 50 55 60 Ile Pro Ser His Val Leu Ser Lys Val Cys Met Tyr Phe Thr Tyr Lys 65 70 75 80 Val Arg Tyr Thr Asn Ser Ser Thr Glu Ile Pro Glu Phe Pro Ile Ala 85 90 95 Pro Glu Ile Ala Leu Glu Leu Leu Met Ala Ala Asn Phe Leu Asp Cys 100 105 110 <210> 16 <211> 780 <212> PRT <213> Homo sapiens <400> 16 Met Ala Thr Ser Asn Leu Leu Lys Asn Lys Gly Ser Leu Gln Phe Glu 1 5 10 15 Asp Lys Trp Asp Phe Met Arg Pro Ile Val Leu Lys Leu Leu Arg Gln 20 25 30 Glu Ser Val Thr Lys Gln Gln Trp Phe Asp Leu Phe Ser Asp Val His 35 40 45 Ala Val Cys Leu Trp Asp Asp Lys Gly Pro Ala Lys Ile His Gln Ala 50 55 60 Leu Lys Glu Asp Ile Leu Glu Phe Ile Lys Gln Ala Gln Ala Arg Val 65 70 75 80 Leu Ser His Gln Asp Asp Thr Ala Leu Leu Lys Ala Tyr Ile Val Glu 85 90 95 Trp Arg Lys Phe Phe Thr Gln Cys Asp Ile Leu Pro Lys Pro Phe Cys 100 105 110 Gln Leu Glu Ile Thr Leu Met Gly Lys Gln Gly Ser Asn Lys Lys Ser 115 120 125 Asn Val Glu Asp Ser Ile Val Arg Lys Leu Met Leu Asp Thr Trp Asn 130 135 140 Glu Ser Ile Phe Ser Asn Ile Lys Asn Arg Leu Gln Asp Ser Ala Met 145 150 155 160 Lys Leu Val His Ala Glu Arg Leu Gly Glu Ala Phe Asp Ser Gln Leu 165 170 175 Val Ile Gly Val Arg Glu Ser Tyr Val Asn Leu Cys Ser Asn Pro Glu 180 185 190 Asp Lys Leu Gln Ile Tyr Arg Asp Asn Phe Glu Lys Ala Tyr Leu Asp 195 200 205 Ser Thr Glu Arg Phe Tyr Arg Thr Gln Ala Pro Ser Tyr Leu Gln Gln 210 215 220 Asn Gly Val Gln Asn Tyr Met Lys Tyr Ala Asp Ala Lys Leu Lys Glu 225 230 235 240 Glu Glu Lys Arg Ala Leu Arg Tyr Leu Glu Thr Arg Arg Glu Cys Asn 245 250 255 Ser Val Glu Ala Leu Met Glu Cys Cys Val Asn Ala Leu Val Thr Ser 260 265 270 Phe Lys Glu Thr Ile Leu Ala Glu Cys Gln Gly Met Ile Lys Arg Asn 275 280 285 Glu Thr Glu Lys Leu His Leu Met Phe Ser Leu Met Asp Lys Val Pro 290 295 300 Asn Gly Ile Glu Pro Met Leu Lys Asp Leu Glu Glu His Ile Ile Ser 305 310 315 320 Ala Gly Leu Ala Asp Met Val Ala Ala Ala Ala Glu Thr Ile Thr Thr Asp 325 330 335 Ser Glu Lys Tyr Val Glu Gln Leu Leu Thr Leu Phe Asn Arg Phe Ser 340 345 350 Lys Leu Val Lys Glu Ala Phe Gln Asp Asp Pro Arg Phe Leu Thr Ala 355 360 365 Arg Asp Lys Ala Tyr Lys Ala Val Val Asn Asp Ala Thr Ile Phe Lys 370 375 380 Leu Glu Leu Pro Leu Lys Gln Lys Gly Val Gly Leu Lys Thr Gln Pro 385 390 395 400 Glu Ser Lys Cys Pro Glu Leu Leu Ala Asn Tyr Cys Asp Met Leu Leu 405 410 415 Arg Lys Thr Pro Leu Ser Lys Lys Leu Thr Ser Glu Glu Ile Glu Ala 420 425 430 Lys Leu Lys Glu Val Leu Leu Val Leu Lys Tyr Val Gln Asn Lys Asp 435 440 445 Val Phe Met Arg Tyr His Lys Ala His Leu Thr Arg Arg Leu Ile Leu 450 455 460 Asp Ile Ser Ala Asp Ser Glu Ile Glu Glu Asn Met Val Glu Trp Leu 465 470 475 480 Arg Glu Val Gly Met Pro Ala Asp Tyr Val Asn Lys Leu Ala Arg Met 485 490 495 Phe Gln Asp Ile Lys Val Ser Glu Asp Leu Asn Gln Ala Phe Lys Glu 500 505 510 Met His Lys Asn Asn Lys Leu Ala Leu Pro Ala Asp Ser Val Asn Ile 515 520 525 Lys Ile Leu Asn Ala Gly Ala Trp Ser Arg Ser Ser Glu Lys Val Phe 530 535 540 Val Ser Leu Pro Thr Glu Leu Glu Asp Leu Ile Pro Glu Val Glu Glu 545 550 555 560 Phe Tyr Lys Lys Asn His Ser Gly Arg Lys Leu His Trp His His Leu 565 570 575 Met Ser Asn Gly Ile Ile Thr Phe Lys Asn Glu Val Gly Gln Tyr Asp 580 585 590 Leu Glu Val Thr Thr Phe Gln Leu Ala Val Leu Phe Ala Trp Asn Gln 595 600 605 Arg Pro Arg Glu Lys Ile Ser Phe Glu Asn Leu Lys Leu Ala Thr Glu 610 615 620 Leu Pro Asp Ala Glu Leu Arg Arg Thr Leu Trp Ser Leu Val Ala Phe 625 630 635 640 Pro Lys Leu Lys Arg Gln Val Leu Leu Tyr Glu Pro Gln Val Asn Ser 645 650 655 Pro Lys Asp Phe Thr Glu Gly Thr Leu Phe Ser Val Asn Gln Glu Phe 660 665 670 Serum Leu Ile Lys Asn Ala Lys Val Gln Lys Arg Gly Lys Ile Asn Leu 675 680 685 Ile Gly Arg Leu Gln Leu Thr Thr Glu Arg Met Arg Glu Glu Glu Asn 690 695 700 Glu Gly Ile Val Gln Leu Arg Ile Leu Arg Thr Gln Glu Ala Ile Ile 705 710 715 720 Gln Ile Met Lys Met Arg Lys Lys Ile Ser Asn Ala Gln Leu Gln Thr 725 730 735 Glu Leu Val Glu Ile Leu Lys Asn Met Phe Leu Pro Gln Lys Lys Met 740 745 750 Ile Lys Glu Gln Ile Glu Trp Leu Ile Glu His Lys Tyr Ile Arg Arg 755 760 765 Asp Glu Ser Asp Ile Asn Thr Phe Ile Tyr Met Ala 770 775 780 <210> 17 <211> 301 <212> PRT <213> Homo sapiens <400> 17 Asp Ile Val Ser Glu Lys Lys Pro Ala Thr Glu Val Asp Pro Thr His 1 5 10 15 Phe Glu Lys Arg Phe Leu Lys Arg Ile Arg Asp Leu Gly Glu Gly His 20 25 30 Phe Gly Lys Val Glu Leu Cys Arg Tyr Asp Pro Glu Gly Asp Asn Thr 35 40 45 Gly Glu Gln Val Ala Val Lys Ser Leu Lys Pro Glu Ser Gly Gly Asn 50 55 60 His Ile Ala Asp Leu Lys Lys Glu Ile Glu Ile Leu Arg Asn Leu Tyr 65 70 75 80 His Glu Asn Ile Val Lys Tyr Lys Gly Ile Cys Thr Glu Asp Gly Gly 85 90 95 Asn Gly Ile Lys Leu Ile Met Glu Phe Leu Pro Ser Gly Ser Leu Lys 100 105 110 Glu Tyr Leu Pro Lys Asn Lys Asn Lys Ile Asn Leu Lys Gln Gln Leu 115 120 125 Lys Tyr Ala Val Gln Ile Cys Lys Gly Met Asp Tyr Leu Gly Ser Arg 130 135 140 Gln Tyr Val His Arg Asp Leu Ala Ala Arg Asn Val Leu Val Glu Ser 145 150 155 160 Glu His Gln Val Lys Ile Gly Asp Phe Gly Leu Thr Lys Ala Ile Glu 165 170 175 Thr Asp Lys Glu Tyr Tyr Thr Val Lys Asp Asp Arg Asp Ser Pro Val 180 185 190 Phe Trp Tyr Ala Pro Glu Cys Leu Met Gln Ser Lys Phe Tyr Ile Ala 195 200 205 Ser Asp Val Trp Ser Phe Gly Val Thr Leu His Glu Leu Leu Thr Tyr 210 215 220 Cys Asp Ser Asp Ser Ser Pro Met Ala Leu Phe Leu Lys Met Ile Gly 225 230 235 240 Pro Thr His Gly Gln Met Thr Val Thr Arg Leu Val Asn Thr Leu Lys 245 250 255 Glu Gly Lys Arg Leu Pro Cys Pro Pro Asn Cys Pro Asp Glu Val Tyr 260 265 270 Gln Leu Met Arg Lys Cys Trp Glu Phe Gln Pro Ser Asn Arg Thr Ser 275 280 285 Phe Gln Asn Leu Ile Glu Gly Phe Glu Ala Leu Leu Lys 290 295 300 <210> 18 <211> 18 <212> PRT <213> Homo sapiens <400> 18 Arg Arg Ala Lys Ala Ala Asp Gly Tyr Val Lys Pro Gln Ile Lys Gln 1 5 10 15 Val Val <210> 19 <211> 16 <212> PRT <213> Homo sapiens <400> 19 Ala Ile Glu Thr Asp Lys Glu Tyr Tyr Thr Val Lys Asp Asp Arg Asp 1 5 10 15 <210> 20 <211> 16 <212> PRT <213> Homo sapiens <220> <221> MISC_FEATURE <222> (8)..(8) <223> Phosphorylated tyrosine <400> 20 Leu Leu Pro Leu Asp Lys Asp Tyr Tyr Val Val Arg Glu Pro Gly Gln 1 5 10 15 <210> 21 <211> 12 <212> PRT <213> Homo sapiens <220> <221> MISC_FEATURE <222> (4) <223> Phosphorylation of tyrosine <400> twenty one Asn Gln Gly Tyr Phe Phe Phe His Leu Pro Asp Ala 1 5 10 <210> twenty two <211> 12 <212> PRT <213> Homo sapiens <220> <221> MISC_FEATURE <222> (4) <223> Phosphorylation of tyrosine <400> twenty two Tyr Phe Thr Tyr Asp Pro Tyr Ser Glu Glu Asp Pro 1 5 10 <210> twenty three <211> 12 <212> PRT <213> Homo sapiens <220> <221> MISC_FEATURE <222> (4) <223> Phosphorylation of tyrosine <400> twenty three Gln Asp Asp Tyr Cys Ala Phe Pro Pro Arg Asp Asp 1 5 10 <210> twenty four <211> 12 <212> PRT <213> Homo sapiens <220> <221> MISC_FEATURE <222> (4) <223> Phosphorylation of tyrosine <400> twenty four Thr Asp Ala Tyr Leu Ser Leu Gln Glu Leu Gln Gly 1 5 10 <210> 25 <211> 11 <212> PRT <213> Homo sapiens <220> <221> MISC_FEATURE <222> (5) <223> Phosphorylation of tyrosine <400> 25 Leu Val Thr Glu Tyr Gln Gly Asn Phe Ser Ala 1 5 10 <210> 26 <211> 11 <212> PRT <213> Homo sapiens <220> <221> MISC_FEATURE <222> (5) <223> Phosphorylation of tyrosine <400> 26 Leu Gln Pro Asp Tyr Ser Glu Arg Phe Cys His 1 5 10 <210> 27 <211> 11 <212> PRT <213> Homo sapiens <220> <221> MISC_FEATURE <222> (5) <223> Phosphorylation of tyrosine <400> 27 Ile His Ser Pro Tyr Trp Pro Pro Pro Cys Tyr 1 5 10 <210> 28 <211> 11 <212> PRT <213> Homo sapiens <220> <221> MISC_FEATURE <222> (5) <223> Phosphorylation of tyrosine <400> 28 Pro Pro Pro Cys Tyr Ser Leu Lys Pro Glu Ala 1 5 10 <210> 29 <211> 38 <212> PRT <213> Homo sapiens <220> <221> MISC_FEATURE <222> (6) <223> Phosphorylation of Serine <220> <221> MISC_FEATURE <222> (8) <223> Phosphorylation of Serine <220> <221> MISC_FEATURE <222> (14)..(14) <223> Phosphorylated Threonine <220> <221> MISC_FEATURE <222> (21)..(21) <223> Ubiquitinated lysine <400> 29 Ala Ala Asp Thr Arg Ser Asp Ser Pro Asp Pro Ala Pro Thr Pro Ala 1 5 10 15 Leu Pro Met Ser Lys Gln Asp Ala Pro Ser Asp Ser Val Leu Pro Ile 20 25 30 Pro Val Ala Thr Ala Val 35 <210> 30 <211> 16 <212> PRT <213> Homo sapiens <400> 30 Ser Asp Ser Pro Asp Pro Ala Pro Thr Pro Ala Leu Pro Met Ser Lys 1 5 10 15 <210> 31 <211> 40 <212> PRT <213> Homo sapiens <400> 31 Arg Pro Leu Trp Ala Gln Ser Leu Glu Leu Pro Gly Pro Ala Met Gln 1 5 10 15 Pro Leu Pro Thr Gly Ala Phe Pro Glu Glu Val Thr Glu Glu Thr Pro 20 25 30 Val Gln Ala Glu Asn Glu Pro Lys 35 40 <210> 32 <211> 43 <212> PRT <213> Homo sapiens <400> 32 Ser Asp Ser Pro Asp Pro Ala Pro Thr Pro Ala Leu Pro Met Ser Lys 1 5 10 15 Gln Asp Ala Pro Ser Asp Ser Val Leu Pro Ile Pro Val Ala Thr Ala 20 25 30 Val His Leu Lys Leu Val Gln Pro Phe Val Arg 35 40 <210> 33 <211> 32 <212> PRT <213> Homo sapiens <400> 33 Gln Asp Ala Pro Ser Asp Ser Val Leu Pro Ile Pro Val Ala Thr Ala 1 5 10 15 Val His Leu Lys Leu Val Gln Pro Phe Val Arg Arg Ser Ser Ala Arg 20 25 30 <210> 34 <211> 19 <212> PRT <213> Homo sapiens <400> 34 Val Leu Asp Pro Glu Gly Asp Leu Leu Cys Ile Ala Lys Thr Phe Ser 1 5 10 15 Tyr Leu Arg <210> 35 <211> 14 <212> PRT <213> Homo sapiens <400> 35 Gln His Leu Gln Lys Met Pro Glu Gly Thr Phe Leu Val Arg 1 5 10 <210> 36 <211> 23 <212> PRT <213> Homo sapiens <400> 36 Asp Ser Thr His Pro Ser Tyr Leu Phe Thr Leu Ser Val Lys Thr Thr 1 5 10 15 Arg Gly Pro Thr Asn Val Arg 20 <210> 37 <211> 36 <212> PRT <213> Homo sapiens <400> 37 Ser Asp Ser Pro Asp Pro Ala Pro Thr Pro Ala Leu Pro Met Ser Lys 1 5 10 15 Gln Asp Ala Pro Ser Asp Ser Val Leu Pro Ile Pro Val Ala Thr Ala 20 25 30 Val His Leu Lys 35 <210> 38 <211> 27 <212> PRT <213> Homo sapiens <400> 38 Gln Asp Ala Pro Ser Asp Ser Val Leu Pro Ile Pro Val Ala Thr Ala 1 5 10 15 Val His Leu Lys Leu Val Gln Pro Phe Val Arg 20 25

Claims

1. Use of CIS-suppressive NK cells in the preparation of a drug for preventing or treating cancer, wherein the CIS-suppressive NK cells are NK cells that have been genetically modified to have reduced CIS expression.

2. The use according to claim 1, wherein the CIS suppressor NK cells are autologous.

3. The use according to claim 1, wherein the CIS suppressor NK cells are allogeneic.

4. The use according to claim 1, wherein the CIS suppressor NK cells are Cish - / - .

5. The use according to any one of claims 1 to 4, wherein the cancer is selected from the group consisting of metastatic melanoma, metastatic prostate cancer, metastatic breast cancer, triple-negative breast cancer, bladder cancer, brain cancer, esophageal cancer, liver cancer, head and neck cancer, squamous cell lung cancer, non-small cell lung cancer, Merkel cell carcinoma, sarcoma, hepatocellular carcinoma, multiple myeloma, pancreatic cancer, colorectal cancer, cervical cancer, gastric cancer, kidney cancer, metastatic renal cell carcinoma, leukemia, ovarian cancer and malignant glioma.

6. The use according to claim 5, wherein the cancer is selected from the group consisting of metastatic melanoma, metastatic prostate cancer, metastatic breast cancer, triple-negative breast cancer, sarcoma and leukemia.

7. The use according to any one of claims 1 to 4, wherein the cancer comprises a tumor.